{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:32:15Z","timestamp":1791855135071,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd015064","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000}}],"reference-count":1021,"publisher":"Wiley","issue":"8","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015064.pub2","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T07:21:45Z","timestamp":1722928905000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Topical anti-inflammatory treatments for eczema: network meta-analysis"],"prefix":"10.1002","volume":"2024","author":[{"given":"Stephanie J","family":"Lax","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology; University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Van Vogt","sequence":"additional","affiliation":[{"name":"Imperial Clinical Trials Unit; Imperial College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Candy","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology; University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd","family":"Steele","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Royal Free London; London UK"},{"name":"Wellcome Sanger Institute; Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Reynolds","sequence":"additional","affiliation":[{"name":"School of Public Health, Physiotherapy and Sports Science; University College Dublin; Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Stuart","sequence":"additional","affiliation":[{"name":"Primary Care and Population Sciences, Faculty of Medicine; University of Southampton; Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roses","family":"Parker","sequence":"additional","affiliation":[{"name":"The Cochrane Collaboration; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Axon","sequence":"additional","affiliation":[{"name":"Cochrane Methods Support Unit; Cochrane; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Roberts","sequence":"additional","affiliation":[{"name":"Nottingham Support Group for Carers of Children with Eczema; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Doyle","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology; University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek K","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Medicine, and Department of Health Research Methods, Evidence & Impact; McMaster University; Hamilton, Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Futamura","sequence":"additional","affiliation":[{"name":"Department of Pediatrics; National Hospital Organization Nagoya Medical Center; Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Santer","sequence":"additional","affiliation":[{"name":"Primary Care and Population Sciences, Faculty of Medicine; University of Southampton; Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hywel C","family":"Williams","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology; University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzie","family":"Cro","sequence":"additional","affiliation":[{"name":"Imperial Clinical Trials Unit; Imperial College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron M","family":"Drucker","sequence":"additional","affiliation":[{"name":"Department of Medicine; University of Toronto; Toronto Canada"},{"name":"Research and Innovation Institute and Department of Medicine; Women's College Hospital; Toronto Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Boyle","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Section of Inflammation and Repair; Imperial College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"10.1002\/14651858.CD015064.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ctim.2017.10.003","article-title":"A new topical treatment of atopic dermatitis in pediatric patients based on Ficus carica L. (Fig): a randomized, placebo-controlled clinical trial","volume":"35","author":"Abbasi","year":"2017","journal-title":"Complementary Therapies in Medicine"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0002|cit2","unstructured":"Fig fruit extract cream and hydrocortisone ointment in atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=IRCT2014101419529N1"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0003|cit3","first-page":"72","article-title":"Hydrocortisone butyrate 0.1% lipocream in pediatric patients with atopic dermatitis","volume":"8","author":"Abramovits","year":"2010","journal-title":"Skinmed"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0004|cit4","first-page":"302","article-title":"An open clinical trial comparing (paired comparisons) desoximetasone with betamethasone 17-valerate","volume":"32","author":"Adam","year":"1978","journal-title":"Medical Journal of Malaysia"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2133.1981.tb00042.x","article-title":"Halogenation and topical corticosteroids: a comparison between the 17-butyrate esters of hydrocortisone and clobetasone in ointment bases","volume":"104","author":"Allenby","year":"1981","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2133.1973.tb15456.x","article-title":"Controlled trial of the treatment of atopic eczema with a urea-hydrocortisone preparation versus betamethasone 17-valerat","volume":"88","author":"Almeyda","year":"1973","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2133.1974.tb12948.x","article-title":"Double-blind controlled study of treatment of atopic eczema with a preparation of hydrocortisone in a new drug delivery system versus betamethasone 17-valerate","volume":"91","author":"Almeyda","year":"1974","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0008|cit8","first-page":"474-81","article-title":"Usefulness of HF-264 ointment in the treatment of acute eczema, contact dermatitis and atopic dermatitis. Results of paired comparative study by the double blind technique","volume":"43","year":"1981","journal-title":"Nishinihon Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2230.2010.03948.x","article-title":"Effects of tacrolimus ointment on toll-like receptors in atopic dermatitis","volume":"36","author":"Antiga","year":"2011","journal-title":"Clinical and Experimental Dermatology"},{"issue":"11","key":"10.1002\/14651858.CD015064.pub2-BIB0010|cit10","first-page":"573","article-title":"Clinical evaluation of suprofen ointment in atopic patients: paired comparative studies with ufenamate ointment","volume":"15","author":"Asada","year":"1987","journal-title":"Yakuri to Chiryo"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1600-0625.2008.00756.x","article-title":"Skin physiological parameters confirm the therapeutic efficacy of pimecrolimus cream 1% in patients with mild-to-moderate atopic dermatitis","volume":"18","author":"Aschoff","year":"2009","journal-title":"Experimental Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0012|cit12","unstructured":"Elidel-study: Elidel in patients with atopic dermatitis clinicaltrials.gov\/ct2\/show\/NCT00180141"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0013|cit13","first-page":"459","article-title":"Halcinonide: a new potent topical anti-inflammatory drug","volume":"14","author":"Bagatell","year":"1974","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0014|cit14","first-page":"46","article-title":"A multicenter comparison of alclometasone dipropionate cream 0.05% and hydrocortisone cream 1.0% in the treatment of atopic dermatitis","volume":"33","author":"Bagatell","year":"1983","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000321711","article-title":"Clinical and cytological effects of pimecrolimus cream 1% after resolution of active atopic dermatitis lesions by topical corticosteroids: a randomized controlled trial","volume":"222","author":"Bangert","year":"2011","journal-title":"Dermatology (Basel, Switzerland)"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0016|cit16","unstructured":"A multicenter, 5-week, randomized, double-blind, placebo controlled, parallel group study exploring the effects of pimecrolimus cream 1% (twice daily application) vs. placebo control (twice daily application) on the molecular and cellular profile of adults https:\/\/www.novctrd.com\/ctrdweb\/trialresult\/trialresults\/pdf?trialResultId=2168"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0017|cit17","unstructured":"Effects of pimecrolimus cream 1% on the molecular and cellular profile of adult male patients with atopic dermatitis clinicaltrials.gov\/show\/NCT00117377"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD015064.pub2-BIB0018|cit18","first-page":"182","article-title":"Pimecrolimus cream 1% is effective, well tolerated and safe in infants\/children with atopic eczema of the face","volume":"17","author":"Barba","year":"2003","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0019|cit19","first-page":"655","article-title":"Clinical evaluation of a new halcinonide-antifungal combination","volume":"20","author":"Barba-Rubio","year":"1976","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1398-9995.2006.01269.x","article-title":"Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis","volume":"62","author":"Bieber","year":"2007","journal-title":"Allergy"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0021|cit21","unstructured":"Double-blind, randomized, reference-controlled, multicenter, parallel-group study to compare the efficacy and safety of Advantan ointment once daily with Protopic 0.03% ointment twice daily over max. 3 weeks in 250 children and adolescents with atopic dermatitis - Advantan vs. Protopic in children trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2004-002099-40-DE"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0022|cit22","first-page":"796","article-title":"Clinical study of clocortolone pivalate in the treatment of eczema\/atopic dermatitis","volume":"21","author":"Binder","year":"1977","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1001\/archdermatol.2010.34","article-title":"Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial","volume":"146","author":"Bissonnette","year":"2010","journal-title":"Archives of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0024|cit24","first-page":"S58","article-title":"Safety and efficacy of a non-steroidal anti-inflammatory agent (WBI-1001) as a novel topical treatment for psoriasis and atopic dermatitis","volume":"129","author":"Bissonnette","year":"2009","journal-title":"Journal of Investigative Dermatology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0025|cit25","first-page":"AB9","article-title":"A substituted trans-stilbene derivative as a novel topical treatment for atopic dermatitis: results from a randomized, placebo-controlled clinical trial","volume":"62","author":"Bissonnette","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0026|cit26","unstructured":"Phase IIa study of WBI-1001 cream for atopic dermatitis clinicaltrials.gov\/show\/NCT00837551"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1365-2133.2011.10775.x","article-title":"Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial","volume":"166","author":"Bissonnette","year":"2012","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0028|cit28","unstructured":"Non-steroid, atopic dermatitis phase IIb 12-week trial; topical WBI-1001 cream clinicaltrials.gov\/show\/NCT01098734"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0030|cit30","unstructured":"Tofacitinib ointment for atopic dermatitis (atopic eczema) clinicaltrials.gov\/show\/NCT02001181"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"811-20","DOI":"10.1002\/jcph.1360","article-title":"Systemic tofacitinib concentrations in adult patients with atopic dermatitis treated with 2% tofacitinib ointment and application to pediatric study planning","volume":"59","author":"Purohit","year":"2019","journal-title":"Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0032|cit32","first-page":"e104","article-title":"Pruritus response and skin biomarkers of atopic dermatitis with crisaborole vs. vehicle in patients with mild-to-moderate atopic dermatitis","volume":"183","author":"Bissonnette","year":"2020","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1274-89","DOI":"10.1016\/j.jaci.2019.06.047","article-title":"Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial","volume":"144","author":"Bissonnette","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"S2","key":"10.1002\/14651858.CD015064.pub2-BIB0034|cit34","first-page":"49-50","article-title":"Early improvement in pruritus and reduction in clinical signs in a phase 2a mechanism of action study of crisaborole in mild to moderate atopic dermatitis","volume":"27","author":"Bissonnette","year":"2018","journal-title":"Experimental Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0035|cit35","first-page":"85","article-title":"Changes in skin biomarkers following crisaborole treatment correlate with clinical improvement in atopic dermatitis","volume":"12","author":"Guttman-Yassky","year":"2020","journal-title":"Journal of the Dermatology Nurses' Association"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.jid.2019.03.641","article-title":"Improvement in skin inflammation and barrier function biomarkers with crisaborole treatment in atopic dermatitis (AD)","volume":"139","author":"Guttman-Yassky","year":"2019","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jaad.2023.02.064","article-title":"Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome towards nonlesional and normal skin","volume":"89","author":"Kim","year":"2023","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0038|cit38","unstructured":"Crisaborole ointment 2% skin biomarker biopsy study in atopic dermatitis clinicaltrials.gov\/ct2\/show\/NCT03233529"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1185\/03007997509113676","article-title":"Double-blind comparison between two new topical corticosteroids, halcinonide 0.1% and clobetasol propionate cream 0.05%","volume":"3","author":"Bleeker","year":"1975","journal-title":"Current Medical Research and Opinion"},{"issue":"4 Pt 1","key":"10.1002\/14651858.CD015064.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0091-6749(98)70281-7","article-title":"A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children","volume":"102","author":"Boguniewicz","year":"1998","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0041|cit41","first-page":"AB83","article-title":"Steroid-sparing potential of pimecrolimus cream 1% in the long-term management of severe atopic eczema in adults","volume":"54","author":"Brautigam","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0042|cit42","first-page":"330","article-title":"Clobetasol propionate 0.05% lotion in the treatment of moderate to severe atopic dermatitis: a randomized evaluation versus clobetasol propionate emollient cream","volume":"4","author":"Breneman","year":"2005","journal-title":"Journal of Drugs in Dermatology"},{"issue":"Suppl 1 Pt 2","key":"10.1002\/14651858.CD015064.pub2-BIB0043|cit43","first-page":"1S409","article-title":"Clobetasol propionate 0.5% is equivalent as lotion or emollient cream in atopic dermatitis","volume":"129","author":"Breneman","year":"2002","journal-title":"Annales de Dermatologie et de Venereologie"},{"issue":"12","key":"10.1002\/14651858.CD015064.pub2-BIB0044|cit44","first-page":"360","article-title":"Modern corticosteroid in a modern base. Hydrocortisone buteprate (HBP) in a new base in the treatment of atopic dermatitis","volume":"19","author":"Busch-Heidger","year":"1993","journal-title":"Aktuelle Dermatologie"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/009127006100100604","article-title":"Fluocinolone acetonide, a new topical corticosteroid: clinical and pharmacologic evaluation","volume":"1","author":"Cahn","year":"1961","journal-title":"Journal of New Drugs"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/009127006100100604","article-title":"Fluocinolone acetonide, a new topical corticosteroid: clinical and pharmacologic evaluation","volume":"1","author":"Cahn","year":"1961","journal-title":"Journal of New Drugs"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/CM9.0000000000002489","article-title":"A multi-center, double-blind, randomized, placebo- and positive- controlled phase II clinical study of benvitimod for the treatment of atopic dermatitis","volume":"136","author":"Cai","year":"2023","journal-title":"Chinese Medical Journal"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0048|cit48","unstructured":"Multi-centre, randomised, double-blind, placebo- and comparator-controlled trial on benvitimod cream in patients with atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR-IIR-17012153"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2133.2006.07609.x","article-title":"The comparative effects of tacrolimus and hydrocortisone in adult atopic dermatitis: an immunohistochemical study","volume":"156","author":"Caproni","year":"2007","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0050|cit50","unstructured":"Confirmatory study in pediatric patients with atopic dermatitis https:\/\/www.novctrd.com\/ctrdweb\/trialresult\/trialresults\/pdf?trialResultId=1997"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0051|cit51","first-page":"34","article-title":"Pimecrolimus cream 1% for the treatment of atopic dermatitis in Chinese children and adults: multicenter, randomized, double-blind, parallel-group, vehicle-controlled trial","volume":"40","author":"Liu","year":"2007","journal-title":"Chinese Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0052|cit52","unstructured":"A 4-week, randomized, multicenter, double-blind, vehicle-controlled, parallel-group clinical trial to evaluate the efficacy and safety of pimecrolimus cream 1% in the short-term treatment of patients with mild to moderate atopic dermatitis (eczema) www.novctrd.com\/ctrdweb\/trialresult\/trialresults\/pdf?trialResultId=1936"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1046\/j.1365-4362.2001.01161.x","article-title":"Azone enhances clinical effectiveness of an optimized formulation of triamcinolone acetonide in atopic dermatitis","volume":"40","author":"Cato","year":"2001","journal-title":"International Journal of Dermatology"},{"issue":"1337","key":"10.1002\/14651858.CD015064.pub2-BIB0054|cit54","first-page":"713","article-title":"Treatment of atopic dermatitis","volume":"223","author":"Chapman","year":"1979","journal-title":"Practitioner"},{"issue":"2 Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1016\/j.jaad.2005.04.061","article-title":"Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis","volume":"53","author":"Chapman","year":"2005","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2 Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1016\/j.jaad.2005.04.061","article-title":"Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis","volume":"53","author":"Chapman","year":"2005","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0057|cit57","first-page":"739","article-title":"Atopic dermatitis: treatment with topical betamethasone dipropionate","volume":"16","author":"Charney","year":"1975","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0058|cit58","first-page":"97","article-title":"Methods of clinical trial of a local corticoid","volume":"28","author":"Craps","year":"1972","journal-title":"Archives Belges de Dermatologie et de Syphiligraphie"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0059|cit59","first-page":"13","article-title":"Procedures for the clinical investigation of a topical corticosteroid","volume":"53","author":"Craps","year":"1973","journal-title":"Acta Dermato-Venereologica, Supplementum"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0060|cit60","first-page":"595","article-title":"Clinical evaluation of tralonide ointment, a new topical steroid","volume":"9","author":"Cullen","year":"1971","journal-title":"Current Therapeutic Research: Clinical and Experimental"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0061|cit61","first-page":"595","article-title":"Clinical evaluation of tralonide ointment, a new topical steroid","volume":"9","author":"Cullen","year":"1971","journal-title":"Current Therapeutic Research: Clinical and Experimental"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/030006057400200112","article-title":"A comparison of metosyn and betnovate in the treatment of eczema and psoriasis","volume":"2","author":"Cunliffe","year":"1974","journal-title":"Journal of International Medical Research"},{"issue":"7","key":"10.1002\/14651858.CD015064.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/09546634.2019.1708240","article-title":"Comparing the effects of proactive treatment with tacrolimus ointment and mometasone furoate on the epidermal barrier structure and ceramide levels of patients with atopic dermatitis","volume":"32","author":"Dahnhardt","year":"2021","journal-title":"Journal of Dermatological Treatment"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0064|cit64","first-page":"466","article-title":"Clinical evaluation of bendazac (AF-983). A non-steroid topical anti-inflammatory agent","volume":"50","author":"De Gregorio","year":"1970","journal-title":"Acta Dermato-Venereologica"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0065|cit65","first-page":"466","article-title":"Clinical evaluation of bendazac (AF-983). A non-steroid topical anti-inflammatory agent","volume":"50","author":"De Gregorio","year":"1970","journal-title":"Acta Dermato-Venereologica"},{"issue":"9","key":"10.1002\/14651858.CD015064.pub2-BIB0066|cit66","first-page":"545","article-title":"An investigator-blinded evaluation of fluocinonide 0.1% cream in the treatment of atopic dermatitis and psoriasis vulgaris","volume":"20","author":"Del Rosso","year":"2007","journal-title":"Cosmetic Dermatology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0067|cit67","first-page":"AB46","article-title":"Daily application of fluocinonide 0.1% cream for the treatment of atopic dermatitis","volume":"62","author":"Del Rosso","year":"2010","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD015064.pub2-BIB0068|cit68","first-page":"24","article-title":"Daily application of fluocinonide 0.1% cream for the treatment of atopic dermatitis","volume":"2","author":"Del Rosso","year":"2009","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1001\/archderm.1989.01670160118034","article-title":"Double-blind randomized placebo-controlled trial of local cyclosporine in atopic dermatitis letter","volume":"125","author":"De Prost","year":"1989","journal-title":"Archives of Dermatology"},{"issue":"Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0070|cit70","first-page":"136","article-title":"Randomised double-blind placebo-controlled trial of local cyclosporin in atopic dermatitis","volume":"144","author":"De Prost","year":"1989","journal-title":"Acta Dermato-Venereologica"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2340\/0001555571452454","article-title":"Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis","volume":"71","author":"De Rie","year":"1991","journal-title":"Acta Dermato-Venereologica"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000367696","article-title":"Clinical efficacy and tolerability of a novel selective corticosteroid in atopic dermatitis - two randomised controlled trials","volume":"28","author":"Dolle","year":"2015","journal-title":"Skin Pharmacology and Physiology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0073|cit73","unstructured":"A randomised, double-blind, placebo-controlled study of topical GW870086X formulation in subjects with moderate or severe atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2010-022280-35-DE"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0074|cit74","unstructured":"A study to test the effect of 2 different doses of topical GW870086X on atopic dermatitis also including a postive control and a placebo clinicaltrials.gov\/ct2\/show\/NCT01299610"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0075|cit75","unstructured":"A study assessing GW870086's potential to cause skin thinning https:\/\/clinicaltrials.gov\/show\/NCT01381445"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1365-2133.2009.09143.x","article-title":"Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial","volume":"161","author":"Doss","year":"2009","journal-title":"British Journal of Dermatology"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD015064.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1399-3038.2009.00895.x","article-title":"Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment","volume":"21","author":"Doss","year":"2010","journal-title":"Pediatric Allergy and Immunology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0078|cit78","first-page":"50","article-title":"The impact of tacrolimus ointment on health-related quality of life of Chinese adult and pediatric patients with atopic dermatitis [Chinese]","volume":"35","author":"Dou","year":"2006","journal-title":"Journal of Clinical Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0079|cit79","first-page":"50","article-title":"The impact of tacrolimus ointment on health-related quality of life of Chinese adult and pediatric patients with atopic dermatitis [Chinese]","volume":"35","author":"Dou","year":"2006","journal-title":"Journal of Clinical Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jaad.2005.06.013","article-title":"Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison","volume":"53","author":"Draelos","year":"2005","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0081|cit81","first-page":"769","article-title":"Alclometasone dipropionate in atopic dermatitis: a clinical study","volume":"33","author":"Duke","year":"1983","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"96-102","DOI":"10.1111\/j.1365-2133.2004.05696.x","article-title":"Validation of the eczema area and severity index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme","volume":"150","author":"Barbier","year":"2004","journal-title":"British Journal of Dermatology"},{"issue":"S2","key":"10.1002\/14651858.CD015064.pub2-BIB0083|cit83","first-page":"110","article-title":"Pimecrolimus (ElidelA, SDZ ASM 981) cream 1% is safe in the long term management of atopic eczema","volume":"15","author":"Boguniewicz","year":"2001","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0084|cit84","first-page":"348","article-title":"Pimecrolimus (SDZ ASM 981) cream 1% provides significant and rapid relief of pruritus in pediatric patients with moderate to severe atopic dermatitis","volume":"119","author":"Boguniewicz","year":"2002","journal-title":"Journal of Investigative Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1067\/mjd.2002.122187","article-title":"Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents","volume":"46","author":"Eichenfield","year":"2002","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-4632.2004.02234.x","article-title":"Use of pimecrolimus cream 1% (Elidel) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome","volume":"44","author":"Eichenfield","year":"2005","journal-title":"International Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1525-1470.2008.00671.x","article-title":"Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis","volume":"25","author":"Langley","year":"2008","journal-title":"Pediatric Dermatology"},{"issue":"Suppl 1 Pt 2","key":"10.1002\/14651858.CD015064.pub2-BIB0088|cit88","first-page":"1S417","article-title":"Pimecrolimus (SDZ ASM 981) cream is effective in patients aged 3 months to 17 years with atopic dermatitis","volume":"129","author":"Lucky","year":"2002","journal-title":"Annales de Dermatologie et de Venereologie"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0089|cit89","first-page":"348","article-title":"Efficacy and local tolerability of pimecrolimus cream 1% in the treatment of atopic dermatitis in the face\/neck region of pediatric subjects","volume":"119","author":"Pariser","year":"2002","journal-title":"Journal of Investigative Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1542\/peds.110.6.1133","article-title":"The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis","volume":"110","author":"Whalley","year":"2002","journal-title":"Pediatrics"},{"issue":"S2","key":"10.1002\/14651858.CD015064.pub2-BIB0091|cit91","first-page":"112","article-title":"The benefit of pimecrolimus (ElidelA, SDZ ASM 981) on quality of life in the treatment of mild-to-moderate paediatric atopic eczema","volume":"15","author":"Whalley","year":"2001","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1067\/mjd.2002.122187","article-title":"Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents","volume":"46","author":"Eichenfield","year":"2002","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jaad.2005.10.063","article-title":"Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age","volume":"54","author":"Eichenfield","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jaad.2005.10.063","article-title":"Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from 3 months of age","volume":"54","author":"Eichenfield","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0095|cit95","first-page":"97","article-title":"Double-blind paired comparison clinical trial of halcinonide and hydrocortisone","volume":"22","author":"El-Hefnawi","year":"1978","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"7","key":"10.1002\/14651858.CD015064.pub2-BIB0096|cit96","first-page":"735","article-title":"A bilateral comparison study of pimecrolimus cream 1% and a topical medical device cream in the treatment of patients with atopic dermatitis","volume":"10","author":"Emer","year":"2011","journal-title":"Journal of Drugs in Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0097|cit97","unstructured":"Pimecrolimus cream 1% (Elidel\u00ae) and medicated device cream (EletoneTM) in the treatment and maintenance of atopic dermatitis clinicaltrials.gov\/show\/NCT01177566"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0098|cit98","unstructured":"A 12 week multicenter study consisting of a 6 week double blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the safety and efficacy of Elidel Cream 1% in mild to moderate head and neck atopic dermatitis of patients intolerant of topical corticosteroids trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2004-001036-23-IT"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0099|cit99","unstructured":"A 4-week, randomized, multicenter, parallel-group, placebo-controlled study to investigate the effect of Elidel (pimecrolimus) cream 1% on the Quality of Life (QoL) of patients with moderate facial Atopic Eczema (AE), in whom previous treatment, including appropriate use of topical corticosteroids (TCS), has been unsatisfactory trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2004-002688-25-GB"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0100|cit100","unstructured":"A 12 week multicenter study consisting of a 6 week double blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the efficacy and safety of Elidel\u00ae Cream 1% in mild to moderate facial atopic dermatitis of patients (2 to 11 years of age, inclusive) intolerant of, or dependent on, topical corticosteroids trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2005-001650-25-DE"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0101|cit101","unstructured":"A placebo-controlled, multicentre, double-blinded, intra-individual comparison to gain evidence of the safety, tolerability and efficacy of prednicarbat cream and ointment in patients with active atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2009-012028-98-DE"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0102|cit102","unstructured":"A phase 2, proof of concept and dose finding study, investigating treatment efficacy of LEO 29102 cream (2.5 mg\/g, 1.0 mg\/g, 0.3 mg\/g, 0.1 mg\/g, 0.03 mg\/g), LEO 29102 cream vehicle, and Elidel (Pimecrolimus) cream 10 mg\/g, after cutaneous administration twice daily for 4 weeks. An international, multi-centre, prospective, randomised, double-blind, 7 arm, vehicle-controlled, parallel group study trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2009-013792-22-FI"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0103|cit103","unstructured":"Double-blind, randomized, vehicle-controlled, multicenter, multinational, parallel-group study of the efficacy and safety of mapracorat ointment in concentrations of 0.01%, 0.03% and 0.1% over max. 4 weeks in subjects with Atopic Dermatitis (AD) - efficacy and safety of different concentrations of mapracorat in AD trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2010-024279-14-CZ"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0104|cit104","unstructured":"Comparison of defined skin parameters in two comparable lesional skin areas after topical treatment with Soventol HydroCort 0.5 % Cremogel or placebo trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2011-001175-38-DE"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0105|cit105","unstructured":"Study into the safety and efficacy of eczema cream clobetasone butyrate trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2015-004899-30-Outside-EU\/EEA"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0106|cit106","first-page":"309","article-title":"Comparative clinical trial with 1% hydrocortisone and 0.1% hydrocortisone butyrate cream in non-infected eczema","volume":"57","author":"Fadrhoncova","year":"1982","journal-title":"Cesko-Slovenska Dermatologie"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/030006057600400403","article-title":"A comparative clinical evaluation of a new topical steroid 'halcinonide' and hydrocortisone in steroid-responsive dermatoses","volume":"4","author":"Fattah","year":"1976","journal-title":"Journal of International Medical Research"},{"issue":"8","key":"10.1002\/14651858.CD015064.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1365-4362.1979.tb04686.x","article-title":"Multicenter trial of fluocinonide in an emollient cream base","volume":"18","author":"Fisher","year":"1979","journal-title":"International Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0109|cit109","first-page":"65","article-title":"Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%","volume":"79","author":"Fowler","year":"2007","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0110|cit110","first-page":"AB59","article-title":"Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid based emollient foam in the treatment of patients with atopic dermatitis","volume":"64","author":"Frankel","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0111|cit111","first-page":"666","article-title":"Bilateral comparison study of pimecrolimus cream 1% and a ceramide-hyaluronic acid emollient foam in the treatment of patients with atopic dermatitis","volume":"10","author":"Frankel","year":"2011","journal-title":"Journal of Drugs in Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0112|cit112","unstructured":"Bilateral comparison study of Elidel 1% and hylatopic plus emollient foam for the treatment of subjects with atopic dermatitis clinicaltrials.gov\/show\/NCT01202149"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0113|cit113","first-page":"AB3","article-title":"A new treatment for atopic dermatitis: a randomized double-blind placebo-controlled study","volume":"54","author":"Freeman","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"11","key":"10.1002\/14651858.CD015064.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1640-51","DOI":"10.1111\/1346-8138.16120","article-title":"A phase 2b, randomized, double-blind, multicenter, vehicle-controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild-to-moderate atopic dermatitis","volume":"48","author":"Fujita","year":"2021","journal-title":"Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0115|cit115","unstructured":"Study to assess efficacy and safety of two regimens of crisaborole ointment 2% in Japanese participants aged \u2265 2 years with mild to moderate atopic dermatitis clinicaltrials.gov\/show\/NCT03954158"},{"issue":"7","key":"10.1002\/14651858.CD015064.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"577-85","DOI":"10.1111\/1346-8138.12534","article-title":"Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial","volume":"41","author":"Furue","year":"2014","journal-title":"Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"466-70","DOI":"10.1080\/09546634.2018.1530439","article-title":"Pharmacokinetic disposition of topical phosphodiesterase-4 inhibitor E6005 in patients with atopic dermatitis","volume":"30","author":"Kitahara","year":"2019","journal-title":"Journal of Dermatological Treatment"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0118|cit118","unstructured":"A phase 2 study of E6005 in patients with atopic dermatitis clinicaltrials.gov\/show\/NCT01461941"},{"issue":"7","key":"10.1002\/14651858.CD015064.pub2-BIB0119|cit119","first-page":"554","article-title":"Treatment of the atopic dermatitis with a water-in-oil emulsion with or without the addition of hydrocortisone - results of a controlled double-blind randomized study using clinical evaluation and bioengineering methods","volume":"71","author":"Gehring","year":"1996","journal-title":"Zeitschrift fur Hautkrankheiten"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0120|cit120","first-page":"307","article-title":"Double blind comparison of diflucortolone valerate and betamethasone valerate","volume":"113","author":"Gelmetti","year":"1978","journal-title":"Giornale Italiano di Dermatologia\/Minerva Dermatologica"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/archderm.1973.01620210038010","article-title":"A clinical evaluation of 0.05% desonide cream. A new nonfluorinated topical corticosteroid","volume":"107","author":"Gentry","year":"1973","journal-title":"Archives of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1111\/all.15690","article-title":"Effects of topical corticosteroid versus tacrolimus on insulin sensitivity and bone homeostasis in adults with atopic dermatitis: a randomized controlled study","volume":"78","author":"Gether","year":"2023","journal-title":"Allergy"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0123|cit123","unstructured":"The effects of topical corticosteroid use on insulin sensitivity and bone turnover clinicaltrials.gov\/show\/NCT04114097"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0124|cit124","first-page":"585","article-title":"A multicentric trial of a new steroid, betamethasone benzoate, in common dermatological disorders","volume":"16","author":"Ghatikar","year":"1974","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"12","key":"10.1002\/14651858.CD015064.pub2-BIB0125|cit125","first-page":"597","article-title":"Hydrocortisone-17-butyrate (0.1 percent) versus hydrocortisone acetate (1 percent) in atopic dermatitis. Controlled double-blind study of 20 children","volume":"33","author":"Giannetti","year":"1981","journal-title":"Minerva Pediatrica"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0126|cit126","first-page":"341","article-title":"The therapeutic efficacy of mometasone furoate cream 0.1% applied once daily vs clobetasol propionate cream 0.05% applied twice daily in chronic eczema","volume":"40","author":"Goh","year":"1999","journal-title":"Singapore Medical Journal"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0127|cit127","first-page":"S15","article-title":"The safety and efficacy of roflumilast cream 0.15% and 0.05% in patients with atopic dermatitis: randomized, double-blind, phase 2 proof of concept study","volume":"14","author":"Gooderham","year":"2021","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"5S1","key":"10.1002\/14651858.CD015064.pub2-BIB0128|cit128","first-page":"S15-S16","article-title":"The safety and efficacy of roflumilast cream 0.15% and 0.05% in atopic dermatitis: phase II proof-of-concept study","volume":"14","author":"Gooderham","year":"2021","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0129|cit129","first-page":"e69","article-title":"The safety and efficacy of roflumilast cream 0.15% and 0.05% in atopic dermatitis: phase II proof-of-concept study","volume":"184","author":"Gooderham","year":"2021","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0130|cit130","unstructured":"Safety and efficacy of ARQ-151 cream in adolescents and adults with atopic dermatitis clinicaltrials.gov\/show\/NCT03916081"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s40257-023-00780-w","article-title":"Once-daily crisaborole ointment, 2%, as a long-term maintenance treatment in patients aged >= 3 months with mild-to-moderate atopic dermatitis: a 52-week clinical study","volume":"24","author":"Eichenfield","year":"2023","journal-title":"American Journal of Clinical Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"ljac140.004","DOI":"10.1093\/bjd\/ljac140.004","article-title":"288 Once-daily crisaborole as a long-term maintenance treatment in patients with mild-to-moderate atopic dermatitis: a 52-week clinical trial","volume":"188","author":"Gower","year":"2023","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0133|cit133","first-page":"791","article-title":"Once-daily crisaborole as a long-term maintenance treatment in participants with mild-to-moderate atopic dermatitis: a 52-week clinical trial","volume":"39","author":"Gower","year":"2022","journal-title":"Pediatric Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0134|cit134","unstructured":"A study to evaluate long-term maintenance treatment with once daily crisaborole ointment 2% in pediatric and adult participants with mild-to-moderate atopic dermatitis clinicaltrials.gov\/show\/NCT04040192"},{"issue":"8","key":"10.1002\/14651858.CD015064.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/j.1651-2227.2007.00363.x","article-title":"Short-term growth in children with eczema during treatment with topical mometasone furoate and tacrolimus","volume":"96","author":"Gradman","year":"2007","journal-title":"Acta Paediatrica"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0136|cit136","unstructured":"Short term growth in children with atopic dermatitis clinicaltrials.gov\/show\/NCT00236106"},{"issue":"Suppl 59","key":"10.1002\/14651858.CD015064.pub2-BIB0137|cit137","first-page":"46","article-title":"Randomised comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream in atopic dermatitis","volume":"145","author":"Griffiths","year":"2001","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2133.2002.04894.x","article-title":"Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis","volume":"147","author":"Griffiths","year":"2002","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.jid.2016.02.582","article-title":"A model to evaluate intra-patient differential effects of topical agents in atopic dermatitis","volume":"136","author":"Guttman-Yassky","year":"2016","journal-title":"Journal of Investigative Dermatology (Conference: 2016 Annual Meeting of the Society for Investigative Dermatology)"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2017.01.027","article-title":"Molecular signatures order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitis","volume":"140","author":"Guttman-Yassky","year":"2017","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.jid.2019.03.662","article-title":"Topical nitric oxide releasing therapy with 2% SB414 cream downregulated major gene expressions in patients with atopic dermatitis","volume":"139","author":"Guttman-Yassky","year":"2019","journal-title":"Journal of Investigative Dermatology"},{"issue":"S2","key":"10.1002\/14651858.CD015064.pub2-BIB0142|cit142","first-page":"14","article-title":"A topical nitric oxide-releasing cream SB414: results of a phase 1b double-blind, randomized, vehicle-controlled study in patients with mild-to-moderate atopic dermatitis","volume":"27","author":"Maeda-Chubachi","year":"2018","journal-title":"Experimental Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0143|cit143","first-page":"37-8","article-title":"Topical DS107 for the treatment of mild-to-moderate atopic dermatitis: results from ADVANTAGE, an 8 week phase 2b randomized, double-blind, vehicle-controlled study","volume":"27","author":"Hamza","year":"2018","journal-title":"Experimental Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0144|cit144","unstructured":"Safety and efficacy study of topically applied DS107 cream in mild to moderate atopic dermatitis patients clinicaltrials.gov\/show\/NCT02925793"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0145|cit145","first-page":"261","article-title":"A randomized double blind study of ointment containing diflucortolone valerate and hydrocortisone acetate","volume":"51","author":"Handa","year":"1985","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4103\/ijpd.ijpd_158_21","article-title":"Comparing the effectiveness of topical fluticasone 0.05% cream versus topical tacrolimus 0.1% ointment in pediatric atopic dermatitis: a randomized controlled trial","volume":"23","author":"Handa","year":"2022","journal-title":"Indian Journal of Paediatric Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11882-001-0040-4","article-title":"Tacrolimus ointment: advancing the treatment of atopic dermatitis","volume":"1","author":"Beltrani","year":"2001","journal-title":"Current Allergy and Asthma Reports"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1067\/mjd.2001.109814","article-title":"The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis","volume":"44","author":"Drake","year":"2001","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1067\/mjd.2002.124603","article-title":"Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections","volume":"47","author":"Ling","year":"2002","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1067\/mjd.2001.109810","article-title":"Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy","volume":"44","author":"Hanifin","year":"2001","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/09546630310004324","article-title":"Safe treatment of head\/neck AD with tacrolimus ointment","volume":"14","author":"Kang","year":"2003","journal-title":"Journal of Dermatological Treatment"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1067\/mjd.2001.109813","article-title":"A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients","volume":"44","author":"Paller","year":"2001","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1067\/mjd.2001.109817","article-title":"Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety","volume":"44","author":"Soter","year":"2001","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1067\/mjd.2001.109813","article-title":"A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients","volume":"Vol. 44","author":"Paller","year":"2001","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"s47","DOI":"10.1067\/mjd.2001.109813","article-title":"A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients","volume":"Vol. 44","author":"Paller","year":"2001","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0156|cit156","first-page":"S55","article-title":"A long-term study of safety and allergic comorbidity development in a randomized trial of pimecrolimus cream in infants with atopic dermatitis","volume":"130","author":"Hanifin","year":"2010","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0157|cit157","unstructured":"Protocol 271-12-205: a Phase 2 multi-center, randomized, double-blind, vehicle-controlled, three-arm, parallel group study to assess the safety, tolerability, and efficacy of topical OPA-15406 ointment, in subjects with mild\/moderate atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2013-003899-12-PL"},{"issue":"7","key":"10.1002\/14651858.CD015064.pub2-BIB0158|cit158","first-page":"886","article-title":"To report efficacy results from an 8-week phase 2 study treating adolescents and adults with mild to moderate atopic dermatitis treated with 0.3% and 1% OPA-15406 ointment","volume":"95","author":"Hanifin","year":"2015","journal-title":"Acta Dermato-Venereologica"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaad.2016.04.001","article-title":"OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): a phase-II randomized, double-blind, placebo-controlled study","volume":"75","author":"Hanifin","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0160|cit160","unstructured":"A study to evaluate the effectiveness and safety of a topical OPA-15406 ointment to treat subjects with atopic dermatitis clinicaltrials.gov\/show\/NCT02068352"},{"issue":"39","key":"10.1002\/14651858.CD015064.pub2-BIB0161|cit161","first-page":"1240","article-title":"Therapy of eczema. Once daily use of diflorasone diacetate in comparison to thrice daily use of betamethasone-17-valerate","volume":"72","author":"Harder","year":"1983","journal-title":"Schweizerische Rundschau fur Medizin Praxis"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0162|cit162","first-page":"344","article-title":"Comparative study of clobetasone butyrate cream (Eumovate) and hydrocortisone cream in children with eczema","volume":"48","author":"Haribhakti","year":"1982","journal-title":"Indian Journal of Dermatology, Venereology and Leprology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0163|cit163","first-page":"357","article-title":"Desoximetasone 0.25% and tacrolimus 0.1% ointments versus tacrolimus alone in the treatment of atopic dermatitis","volume":"78","author":"Hebert","year":"2006","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0164|cit164","first-page":"175","article-title":"Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis","volume":"6","author":"Hebert","year":"2007","journal-title":"Journal of Drugs in Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0165|cit165","first-page":"175","article-title":"Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis","volume":"6","author":"Hebert","year":"2007","journal-title":"Journal of Drugs in Dermatology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0166|cit166","first-page":"AB84","article-title":"A phase 3 double-blind, randomized, vehicle-controlled study of desonide foam in pediatric and adolescent patients with mild to moderate atopic dermatitis","volume":"54","author":"Friedlander","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"334-40","DOI":"10.1016\/j.jaad.2008.04.019","article-title":"Desonide foam 0.05%: safety in children as young as 3 months","volume":"59","author":"Hebert","year":"2008","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"334-40","DOI":"10.1016\/j.jaad.2008.04.019","article-title":"Desonide foam 0.05%: safety in children as young as 3 months","volume":"59","author":"Hebert","year":"2008","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"334-40","DOI":"10.1016\/j.jaad.2008.04.019","article-title":"Desonide foam 0.05%: safety in children as young as 3 months","volume":"59","author":"Hebert","year":"2008","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-4632.2004.02234.x","article-title":"Use of pimecrolimus cream 1% (Elidel) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome","volume":"44","author":"Eichenfield","year":"2005","journal-title":"International Journal of Dermatology"},{"issue":"Suppl s2","key":"10.1002\/14651858.CD015064.pub2-BIB0171|cit171","first-page":"110","article-title":"Pimecrolimus (Elidel\u00ae, SDZ ASM 981) cream 1% is effective and safe in infants aged 3-23 months with atopic eczema","volume":"15","author":"Ho","year":"2001","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0172|cit172","first-page":"532","article-title":"SDZ ASM 981 cream 1% is efficacious and safe in infants aged 3-23 months with atopic dermatitis","volume":"117","author":"Ho","year":"2001","journal-title":"Journal of Investigative Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mpd.2003.65","article-title":"Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants","volume":"142","author":"Ho","year":"2003","journal-title":"Journal of Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1542\/peds.110.6.1133","article-title":"The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis","volume":"110","author":"Whalley","year":"2002","journal-title":"Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2133.2008.08928.x","article-title":"The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial","volume":"160","author":"Hoeger","year":"2009","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0176|cit176","unstructured":"Efficacy and safety of pimecrolimus cream 1% in patients (2 to 11 years old) with mild to moderate facial atopic dermatitis clinicaltrials.gov\/show\/NCT00130364"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0177|cit177","first-page":"A42","article-title":"Pimecrolimus selectively targets T cells in skin lesions of patients with atopic dermatitis","volume":"124","author":"Hoetzenecker","year":"2005","journal-title":"Journal of Investigative Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"1276-83","DOI":"10.1016\/j.jaci.2005.02.011","article-title":"Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis","volume":"115","author":"Hoetzenecker","year":"2005","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"11","key":"10.1002\/14651858.CD015064.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"905-10","DOI":"10.1136\/adc.2006.094276","article-title":"Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children","volume":"91","author":"Hofman","year":"2006","journal-title":"Archives of Disease in Childhood"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0180|cit180","first-page":"411","article-title":"Tacrolimus ointment application does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children","volume":"19","author":"Hofman","year":"2005","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0181|cit181","first-page":"A48","article-title":"Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children","volume":"47","author":"Murrell","year":"2006","journal-title":"Australasian Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1081-1206(10)60859-9","article-title":"Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics","volume":"98","author":"Hung","year":"2007","journal-title":"Annals of Allergy, Asthma & Immunology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0183|cit183","first-page":"721","article-title":"Evaluation of diflucortolone valerianate, a new corticosteroid for topical use in dermatoses with acute and chronic course. Comparison with fluocortolone caproate","volume":"8","author":"Innocenti","year":"1977","journal-title":"Chronica Dermatologica"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0184|cit184","unstructured":"Efficacy of topical azathioprine-betamethasone cream with betamethasone cream in cutaneous eczema trialsearch.who.int\/Trial2.aspx?TrialID=IRCT2014092519292N1"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"228","DOI":"10.4103\/2277-9175.166651","article-title":"Efficacy of topical azathioprine and betamethasone versus betamethasone-only emollient cream in 2-18 years old patients with moderate-to-severe atopic dermatitis: a randomized controlled trial","volume":"4","author":"Iraji","year":"2015","journal-title":"Advanced Biomedical Research"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0186|cit186","unstructured":"A multi-center, randomized, double-blind, vehicle-controlled, parallel-group comparison trial to assess the efficacy and safety of OPA-15406 ointment in patients with atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-JapicCTI-163372"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0187|cit187","unstructured":"Pimecrolimus and epidermal barrier function: role for pimecrolimus in restoring skin barrier function and normalizing epidermal lipid content and differentiation in atopic epidermis: a randomized, intra-patient, double-blind (right\/left arm) study in adults with atopic dermatitis treated with 1% pimecrolimus cream and 0.1% triamcinolone acetonide cream as treatment control twice daily for 3 weeks trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2007-003106-99-DE"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jaci.2009.03.032","article-title":"Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis","volume":"123","author":"Jensen","year":"2009","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"3 Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0189|cit189","first-page":"R19-28","article-title":"Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis","volume":"124","author":"Jensen","year":"2009","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0190|cit190","unstructured":"Pimecrolimus and epidermal barrier function clinicaltrials.gov\/show\/NCT01132079"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0191|cit191","doi-asserted-by":"crossref","first-page":"AB3","DOI":"10.1016\/j.jaad.2006.10.061","article-title":"Substantial improvement of the skin barrier in atopic dermatitis after treatment with pimecrolimus but not with betamethasone","volume":"56","author":"Proksch","year":"2007","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0192|cit192","first-page":"196","article-title":"Pimecrolimus cream treatment repairs skin barrier structure more effectively than triamcinolone acetonide (TCA) cream treatment in atopic dermatitis","volume":"19","author":"Jensen","year":"2010","journal-title":"Experimental Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2340\/00015555-1533","article-title":"Effects of pimecrolimus compared with triamcinolone acetonide cream on skin barrier structure in atopic dermatitis: a randomized, double-blind, right-left arm trial","volume":"93","author":"Jensen","year":"2013","journal-title":"Acta Dermato-Venereologica"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0194|cit194","first-page":"701-6","article-title":"Topical corticosteroids but not calcineurin inhibitors induced atrophy after four weeks","volume":"29","author":"Jirakova","year":"2015","journal-title":"Journal of Biological Regulators and Homeostatic Agents"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0190-9622(95)90014-4","article-title":"Multicenter trial for long-term safety and efficacy comparison of 0.05% desonide and 1% hydrocortisone ointments in the treatment of atopic dermatitis in pediatric patients","volume":"33","author":"Jorizzo","year":"1995","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD015064.pub2-BIB0196|cit196","first-page":"34","article-title":"Study of calcipotriol betamethasone ointment in the treatment of patients with refractory chronic eczema","volume":"6","author":"Ju","year":"2013","journal-title":"Asian Journal of Pharmaceutical and Clinical Research"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0197|cit197","first-page":"681","article-title":"Tacrolimus ointment for adults with moderate to severe atopic dermatitis: a dose escalation study","volume":"110","author":"Kang","year":"1998","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/archderm.1978.01640130024007","article-title":"Topical use of caffeine with hydrocortisone in the treatment of atopic dermatitis","volume":"114","author":"Kaplan","year":"1978","journal-title":"Archives of Dermatology"},{"issue":"Suppl s2","key":"10.1002\/14651858.CD015064.pub2-BIB0199|cit199","first-page":"111","article-title":"Pimecrolimus (Elidel, SDZ ASM 981) cream 1%: a new approach to long-term management of atopic eczema in infants","volume":"15","author":"Kapp","year":"2001","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"Suppl 1 Pt 2","key":"10.1002\/14651858.CD015064.pub2-BIB0200|cit200","first-page":"1S412","article-title":"Pimecrolimus (SDZ ASM 981) cream: a new treatment strategy for the long-term management of atopic dermatitis in infants","volume":"129","author":"Kapp","year":"2002","journal-title":"Annales de Dermatologie et de Venereologie"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1067\/mai.2002.126500","article-title":"Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug","volume":"110","author":"Kapp","year":"2002","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0202|cit202","first-page":"350","article-title":"Treatment with pimecrolimus cream 1% is corticosteroid sparing in infants with atopic dermatitis","volume":"119","author":"Kapp","year":"2002","journal-title":"Journal of Investigative Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0203|cit203","first-page":"350","article-title":"Pimecrolimus cream 1% provides long-term disease management in children with severe atopic dermatitis","volume":"119","author":"Kaufmann","year":"2002","journal-title":"Journal of Investigative Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000080855","article-title":"Influence of pimecrolimus cream 1% on different morphological signs of eczema in infants with atopic dermatitis","volume":"209","author":"Breuer","year":"2004","journal-title":"Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0205|cit205","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.jaci.2004.08.015","article-title":"Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants","volume":"114","author":"Kaufmann","year":"2004","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1399-3038.2005.00306.x","article-title":"Treatment of infants with atopic eczema with pimecrolimus cream 1% improves parents' quality of life: a multicenter, randomized trial","volume":"16","author":"Staab","year":"2005","journal-title":"Pediatric Allergy and Immunology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD015064.pub2-BIB0207|cit207","first-page":"P2.37","article-title":"Pimecrolimus cream 1% is effective in the treatment of atopic eczema in infants, irrespective of clinical score","volume":"17","author":"Thaci","year":"2003","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1398-9995.2005.00977.x","article-title":"Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial","volume":"61","author":"Kaufmann","year":"2006","journal-title":"Allergy"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD015064.pub2-BIB0209|cit209","first-page":"183","article-title":"Comparison of pimecrolimus cream 1% and tacrolimus ointment 0.03% in paediatric patients with atopic eczema","volume":"17","author":"Kempers","year":"2003","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jaad.2004.01.051","article-title":"A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis","volume":"51","author":"Kempers","year":"2004","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0211|cit211","first-page":"634","article-title":"The efficacy and safety of pimecrolimus in children less than 2 years old: a randomised, controlled clinical trial","volume":"67","author":"Kim","year":"2012","journal-title":"Allergy"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaad.2008.04.020","article-title":"Clobetasol propionate emulsion formulation foam 0.05%: review of phase II open-label and phase III randomized controlled trials in steroid-responsive dermatoses in adults and adolescents","volume":"59","author":"Kimball","year":"2008","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/09546630310013388","article-title":"Acute and maintenance treatment of atopic dermatitis in children - two comparative studies with fluticasone propionate (0.05%) cream","volume":"14","author":"Kirkup","year":"2003","journal-title":"Journal of Dermatological Treatment"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/09546630310013388","article-title":"Acute and maintenance treatment of atopic dermatitis in children - two comparative studies with fluticasone propionate (0.05%) cream","volume":"14","author":"Kirkup","year":"2003","journal-title":"Journal of Dermatological Treatment"},{"issue":"7","key":"10.1002\/14651858.CD015064.pub2-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"948","DOI":"10.2340\/00015555-2395","article-title":"Efficacy of a cream containing ceramides and magnesium in the treatment of mild to moderate atopic dermatitis: a randomized, double-blind, emollient- and hydrocortisone-controlled trial","volume":"96","author":"Koppes","year":"2016","journal-title":"Acta Dermato-Venereologica"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0216|cit216","first-page":"AB88","article-title":"Tacrolimus pharmacokinetics in adult and pediatric atopic dermatitis patients following topical application of tacrolimus ointment","volume":"54","author":"Krueger","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0217|cit217","first-page":"185","article-title":"Pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adult and pediatric patients with moderate to severe atopic dermatitis","volume":"6","author":"Krueger","year":"2007","journal-title":"Journal of Drugs in Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0218|cit218","first-page":"223","article-title":"Alclometasone dipropionate 0.05% vs hydrocortisone 1.0%: potential to induce cutaneous atrophy in children","volume":"9","author":"Kuokkanen","year":"1987","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0219|cit219","unstructured":"A phase 2b, multicenter, randomized, double-blind, vehicle controlled, parallel group dose ranging study to assess efficacy, safety, tolerability and pharmacokinetics of PF-06700841 cream in participants with mild or moderate atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2018-003050-24-PL"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0220|cit220","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bjd.21826","article-title":"Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study","volume":"187","author":"Landis","year":"2022","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0221|cit221","unstructured":"Dose ranging study to assess efficacy, safety, tolerability and pharmacokinetics of PF-06700841 topical cream in participants with mild or moderate atopic dermatitis clinicaltrials.gov\/show\/NCT03903822"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/030006058301100512","article-title":"Clinical comparison of alclometasone dipropionate cream 0.05% with hydrocortisone butyrate cream 0.1% in the treatment of atopic dermatitis in children","volume":"11","author":"Lassus","year":"1983","journal-title":"Journal of International Medical Research"},{"issue":"8","key":"10.1002\/14651858.CD015064.pub2-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-4362.1984.tb04214.x","article-title":"Alclometasone dipropionate cream 0.05% versus clobetasone butyrate cream 0.05%. A controlled clinical comparison in the treatment of atopic dermatitis in children","volume":"23","author":"Lassus","year":"1984","journal-title":"International Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/09546639509086850","article-title":"Prednicarbate 0.25% ointment in the treatment of atopic dermatitis: a vehicle-controlled double-blind study","volume":"6","author":"Lawlor","year":"1995","journal-title":"Journal of Dermatological Treatment"},{"issue":"6-7","key":"10.1002\/14651858.CD015064.pub2-BIB0225|cit225","first-page":"590","article-title":"Comparative study of efficacy and effect on plasma cortisol levels of micronized desonide cream 0.1 p. 100 versus betamethasone dipropionate cream 0.05 p. 100 in the treatment of childhood atopic dermatitis","volume":"127","author":"Lebrun-Vignes","year":"2000","journal-title":"Annales de Dermatologie et de Venereologie"},{"issue":"8","key":"10.1002\/14651858.CD015064.pub2-BIB0226|cit226","doi-asserted-by":"crossref","first-page":"604-6","DOI":"10.1046\/j.1365-4362.1999.00759.x","article-title":"A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone","volume":"38","author":"Lebwohl","year":"1999","journal-title":"International Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"7408","DOI":"10.1038\/srep07408","article-title":"Functional interpretation of metabolomics data as a new method for predicting long-term side effects: treatment of atopic dermatitis in infants","volume":"4","author":"Lee","year":"2014","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2133.1974.tb06429.x","article-title":"Halcinonide in the treatment of corticosteroid responsive dermatoses","volume":"90","author":"Leibsohn","year":"1974","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jaci.2004.05.037","article-title":"Effect of pimecrolimus cream 1% on skin condition and sleep disturbance in children with atopic dermatitis","volume":"114","author":"Leo","year":"2004","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"S334","DOI":"10.1016\/j.jaci.2004.01.711","article-title":"The effect of elidel 1% cream on skin condition and sleep parameters in children with mild to moderate atopic dermatitis (AD)","volume":"113","author":"Leo","year":"2004","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0231|cit231","unstructured":"An exploratory, randomized, double-blind, vehicle-controlled, multicenter, parallel dose study investigating the use of pimecrolimus cream 1% in mild to moderate atopic dermatitis patients who demonstrate a clinical insensitivity to topical glucocorticoid www.novctrd.com\/ctrdweb\/trialresult\/trialresults\/pdf?trialResultId=1453"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2133.2009.09145.x","article-title":"Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial","volume":"161","author":"Leung","year":"2009","journal-title":"British Journal of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD015064.pub2-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/milmed\/139.9.728","article-title":"Double blind trial of a new topical corticosteroid in a US naval hospital","volume":"139","author":"Levy","year":"1974","journal-title":"Military Medicine"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.jaci.2004.12.424","article-title":"Tacrolimus cream 0.03% is safe and effective in the treatment of mild to moderate atopic dermatitis in adults","volume":"115","author":"Levy","year":"2005","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"7","key":"10.1002\/14651858.CD015064.pub2-BIB0235|cit235","first-page":"402-5","article-title":"A multi-center, randomized, double-blind, parallel, vehicle controlled study on the moderate to severe eczema patients with the treatment of clobetasone butyrate cream","volume":"43","author":"Liu","year":"2014","journal-title":"Journal of Clinical Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0236|cit236","first-page":"151","article-title":"Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis","volume":"59","author":"Lucky","year":"1997","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"19","key":"10.1002\/14651858.CD015064.pub2-BIB0237|cit237","first-page":"1062","article-title":"Treatment of Besnier's prurigo with calmuril-hydrocortisone 1% cream and triamcinolone acetonide 0,1% cream. A controlled clinical study","volume":"137","author":"Ludvigsen","year":"1975","journal-title":"Ugeskrift for Laeger"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0238|cit238","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1046\/j.1365-2133.2001.04134.x","article-title":"SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis","volume":"144","author":"Luger","year":"2001","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0239|cit239","doi-asserted-by":"crossref","first-page":"S198","DOI":"10.1016\/S0926-9959(98)95293-X","article-title":"SDZ ASM 981: a emerging new standard for the treatment of atopic dermatitis","volume":"11","author":"Van Leent","year":"1998","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/09546630410033781","article-title":"Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis","volume":"15","author":"Luger","year":"2004","journal-title":"Journal of Dermatological Treatment"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0241|cit241","first-page":"671","article-title":"Short-term topical corticosteroid therapy (halcinonide ointment) in the management of atopic dermatitis","volume":"30","author":"Lupton","year":"1982","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0242|cit242","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000251113","article-title":"An evaluation of betamethasone dipropionate (Diprosone) versus Locacorten 0.02% cream","volume":"153","author":"Mali","year":"1976","journal-title":"Dermatologica"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1046\/j.1365-4362.1998.00394.x","article-title":"Clobetasol propionate emollient 0.05% in the treatment of atopic dermatitis","volume":"37","author":"Maloney","year":"1998","journal-title":"International Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000250502","article-title":"Study of the effects of hydrocortisone and hydrocortisone 17-butyrate ointments on plasma ACTH levels and synacthen responses in children with eczema","volume":"160","author":"Marten","year":"1980","journal-title":"Dermatologica"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0245|cit245","first-page":"266","article-title":"Hydrocortisone butyrate 0.1% lotion in the treatment of atopic dermatitis in pediatric subjects","volume":"7","author":"Matheson","year":"2008","journal-title":"Journal of Drugs in Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0246|cit246","first-page":"75","article-title":"The treatment of infantile eczema with fluocinolone acetonide cream","volume":"52","author":"Meenan","year":"1963","journal-title":"Journal of the Irish Medical Association"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000078462","article-title":"Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis","volume":"208","author":"Meurer","year":"2004","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD015064.pub2-BIB0248|cit248","first-page":"132","article-title":"Pimecrolimus cream 1% provides rapid reduction of pruritus in adults with moderate atopic eczema","volume":"16","author":"Meurer","year":"2002","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0249|cit249","first-page":"350","article-title":"Pimecrolimus cream 1% provides significant and rapid relief of pruritus and improves disease control and quality of life in atopic dermatitis in adults","volume":"119","author":"Meurer","year":"2002","journal-title":"Journal of Investigative Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000065863","article-title":"Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study","volume":"205","author":"Meurer","year":"2002","journal-title":"Dermatology (Basel, Switzerland)"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0251|cit251","first-page":"IC1244","article-title":"Pimecrolimus (SDZ ASM 981) cream improves disease control and quality of life in the long-term management of atopic dermatitis in adults","volume":"129","author":"Meurer","year":"2002","journal-title":"Annales de Dermatologie et de Venereologie"},{"issue":"Suppl S1","key":"10.1002\/14651858.CD015064.pub2-BIB0252|cit252","first-page":"96","article-title":"Sparing corticosteroids in adults with atopic eczema","volume":"16","author":"Meurer","year":"2002","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0253|cit253","unstructured":"A 16-week, randomized, multi-center, parallel-group, pimecrolimus-blinded, controlled study (4-week treatment period followed by 12-week observational period) to evaluate the safety of concomitant use of ASM 981 (pimecrolimus) cream 1% (BID) plus topical corticosteroid (BID) for the treatment of severe atopic dermatitis in patients 2 to 17 years of age trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2005-000839-17-DE"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0254|cit254","first-page":"AB69","article-title":"Concomitant use of topical corticosteroids and pimecrolimus cream 1% in the treatment of severe pediatric atopic dermatitis has a safety profile comparable to topical corticosteroids alone","volume":"60","author":"Eichenfield","year":"2009","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3109\/09546630903410158","article-title":"Addition of pimecrolimus cream 1% to a topical corticosteroid treatment regimen in paediatric patients with severe atopic dermatitis: a randomized, double-blind trial","volume":"21","author":"Meurer","year":"2010","journal-title":"Journal of Dermatological Treatment"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0256|cit256","first-page":"269","article-title":"Alclometasone dipropionate ointment 0.05% versus hydrocortisone ointment 1.0% in children with eczema","volume":"12","author":"Mobacken","year":"1986","journal-title":"Acta Therapeutica"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5603\/FD.a2020.0003","article-title":"Efficacy and safety of 0.1% tacrolimus ointment versus 0.05% clobetasone butyrate ointment in childhood atopic dermatitis","volume":"6","author":"Das","year":"2020","journal-title":"Forum Dermatologicum"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0258|cit258","first-page":"85","article-title":"Efficacy and safety of 0.1% tacrolimus ointment versus 0.05% clobetasone butyrate ointment in childhood atopic dermatitis","volume":"12","author":"Mowla","year":"2020","journal-title":"Journal of the Dermatology Nurses' Association"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"e2020094","DOI":"10.5826\/dpc.1004a94","article-title":"An open-label prospective study to compare the efficacy and safety of topical fluticasone versus tacrolimus in the proactive treatment of atopic dermatitis","volume":"10","author":"Mudaliyar","year":"2020","journal-title":"Dermatology Practical & Conceptual"},{"issue":"5574","key":"10.1002\/14651858.CD015064.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/bmj.4.5574.275","article-title":"Comparison of betamethasone 17-valerate ointment with fluocortolone and fluocortolone caproate ointment","volume":"4","author":"Munro","year":"1967","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/bmj.3.5984.626","article-title":"Clobetasone butyrate, a new topical corticosteroid: clinical activity and effects on pituitary-adrenal axis function and model of epidermal atrophy","volume":"3","author":"Munro","year":"1975","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0262|cit262","unstructured":"A 12 week multicenter study consisting of a 6 week double blind, randomized, vehicle controlled, parallel group phase, followed by a 6 week open label phase, to assess the safety and efficacy of pimecrolimus cream 1% in mild to moderate head and neck atopic dermatitis of patients intolerant of topical corticosteroid www.novctrd.com\/ctrdweb\/trialresult\/trialresults\/pdf?trialResultId=2214"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1365-2133.2007.08192.x","article-title":"A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids","volume":"157","author":"Murrell","year":"2007","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0264|cit264","unstructured":"Safety and efficacy of pimecrolimus cream 1% in mild to moderate head and neck atopic dermatitis (AD) patients clinicaltrials.gov\/show\/NCT00121316"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0265|cit265","first-page":"46","article-title":"Randomized vehicle-controlled trial of pimecrolimus cream 1 % in adult patients with mild to moderate head and neck atopic dermatitis intolerant of, or dependent on TCS","volume":"126","author":"Weise-Riccardi","year":"2006","journal-title":"Journal of Investigative Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0266|cit266","first-page":"43","article-title":"Randomized vehicle-controlled trial of pimecrolimus cream 1% in adult patients with mild to moderate head and neck atopic dermatitis intolerant of, or dependent on, topical corticosteroids","volume":"155","author":"Weise-Riccardi","year":"2006","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0267|cit267","first-page":"62","article-title":"FK506 (Tacrolimus) ointment for atopic dermatitis-results of a double-blind, optimal dose finding study in a multicenter trial Japanese FK506 ointment study group","volume":"38","author":"Nakagawa","year":"1997","journal-title":"Australasian Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0268|cit268","first-page":"683","article-title":"Comparative study of FK506 (Tacrolimus) ointment vs alclometasone dipropionate ointment in atopic dermatitis (face and neck lesions)","volume":"110","author":"Nakagawa","year":"1998","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0269|cit269","unstructured":"Phase II clinical study of JTE-052 - dose finding study in patients with atopic dermatitis www.clinicaltrials.jp\/cti-user\/trial\/ShowDirect.jsp?japicId=JapicCTI-152887"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/bjd.16014","article-title":"Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study","volume":"178","author":"Nakagawa","year":"2018","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/1346-8138.14322","article-title":"Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis","volume":"45","author":"Nakagawa","year":"2018","journal-title":"Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0272|cit272","unstructured":"A phase II study of JTE-052 ointment in pediatric patients with atopic dermatitis www.clinicaltrials.jp\/cti-user\/trial\/ShowDirect.jsp?japicId=JapicCTI-173553"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0273|cit273","first-page":"AB53","article-title":"Efficacy and safety of topical delgocitinib (JTE-052), janus kinase inhibitor, in Japanese pediatric patients with atopic dermatitis: a phase II, randomized, double-blind, vehicle-controlled study","volume":"81","author":"Nakagawa","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"1575-83","DOI":"10.1016\/j.jaci.2019.08.004","article-title":"Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis","volume":"144","author":"Nakagawa","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0275|cit275","unstructured":"Phase III clinical study of JTE-052 - randomized controlled and long-term extension study in patients with atopic dermatitis www.clinicaltrials.jp\/cti-user\/trial\/ShowDirect.jsp?japicId=JapicCTI-173554"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"823-31 (Correct","DOI":"10.1016\/j.jaad.2019.12.015","article-title":"Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study","volume":"82","author":"Nakagawa","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0277|cit277","first-page":"AB199","article-title":"Efficacy and safety of topical delgocitinib (JTE-052), janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase III, randomized, double-blind, vehicle-controlled study","volume":"81","author":"Nakagawa","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0278|cit278","unstructured":"Phase III study of JTE-052 ointment in pediatric patients with atopic dermatitis www.clinicaltrials.jp\/cti-user\/trial\/ShowDirect.jsp?japicId=JapicCTI-184064"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0279|cit279","doi-asserted-by":"crossref","first-page":"854-62","DOI":"10.1016\/j.jaad.2021.06.014","article-title":"Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study","volume":"85","author":"Nakagawa","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"AB52","DOI":"10.1016\/j.jaad.2021.06.235","article-title":"Delgocitinib ointment in pediatric patients with atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study","volume":"85","author":"Nakagawa","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"11","key":"10.1002\/14651858.CD015064.pub2-BIB0281|cit281","first-page":"525","article-title":"A comparative clinical trial of desoxymethasone in the treatment of eczematous conditions","volume":"27","author":"Natarajan","year":"1974","journal-title":"Indian Practitioner"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0282|cit282","unstructured":"Study of pimecrolimus treatment for atopic dermatitis of African American children clinicaltrials.gov\/show\/NCT00810862"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0283|cit283","unstructured":"Topical application of AS101 for the treatment of atopic dermatitis clinicaltrials.gov\/ct2\/show\/NCT00927212"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0284|cit284","unstructured":"CT 327 in the treatment of atopic dermatitis clinicaltrials.gov\/show\/NCT00996008"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0285|cit285","unstructured":"LEO 29102 cream in the treatment of atopic dermatitis clinicaltrials.gov\/show\/NCT01037881"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0286|cit286","unstructured":"Study of 0416 ointment in the treatment of atopic dermatitis clinicaltrials.gov\/show\/NCT01053247"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0287|cit287","unstructured":"Study of 0417 ointment in the treatment of atopic dermatitis clinicaltrials.gov\/show\/NCT01139450"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0288|cit288","unstructured":"A safety study to evaluate the use and effectiveness of a topical ointment to treat adults with atopic dermatitis clinicaltrials.gov\/show\/NCT01702181"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0289|cit289","unstructured":"A human study to investigate the positive and negative effects of ointments containing roflumilast in patients suffering from a chronic inflammatory skin rash trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2012-003000-12-DE"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0290|cit290","unstructured":"Topical roflumilast in adults with atopic dermatitis clinicaltrials.gov\/show\/NCT01856764"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0291|cit291","unstructured":"Double-blind, trial to evaluate the safety and efficacy of MRX-6 cream 2% clinicaltrials.gov\/show\/NCT02031445"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0292|cit292","first-page":"S46","article-title":"Long-term safety of crisaborole in children and adults with mild-to-moderate atopic dermatitis","volume":"1","author":"Eichenfield","year":"2016","journal-title":"Pediatric Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0293|cit293","first-page":"S32-S33","article-title":"Long-term safety of crisaborole ointment in children, adolescents, and adults with mild to moderate atopic dermatitis (abstract)","volume":"34","author":"Eichenfield","year":"2017","journal-title":"Pediatric Dermatology (Conference: 13th World Congress of Pediatric Dermatology, United States)"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0294|cit294","doi-asserted-by":"crossref","first-page":"1030-7","DOI":"10.1111\/pde.14328","article-title":"Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild-to-moderate atopic dermatitis","volume":"37","author":"Eichenfield","year":"2020","journal-title":"Pediatric Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0295|cit295","doi-asserted-by":"crossref","first-page":"AB86","DOI":"10.1016\/j.jaad.2017.04.348","article-title":"Crisaborole ointment improves global atopic dermatitis severity: pooled results from two phase 3 clinical trials","volume":"76","author":"Fowler","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"S1","key":"10.1002\/14651858.CD015064.pub2-BIB0296|cit296","first-page":"S33","article-title":"Crisaborole ointment improves global atopic dermatitis severity: pooled results from two phase 3 clinical trials","volume":"34","author":"Fowler","year":"2017","journal-title":"Pediatric Dermatology"},{"issue":"10 Supplement 2","key":"10.1002\/14651858.CD015064.pub2-BIB0297|cit297","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.jid.2017.07.099","article-title":"Crisaborole ointment improves global atopic dermatitis severity: pooled results from two phase 3 clinical trials","volume":"137","author":"Fowler","year":"2017","journal-title":"Journal of Investigative Dermatology (Conference: 47th Annual Meeting of the European Society for Dermatological Research, ESDR 2017. Austria)"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0298|cit298","first-page":"1430","article-title":"Impact of crisaborole on sleep outcomes in pediatric patients with mild-to-moderate atopic dermatitis and their families","volume":"38","author":"Fowler","year":"2021","journal-title":"Pediatric Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0299|cit299","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s13555-023-00899-y","article-title":"Impact of crisaborole on sleep outcomes in pediatric patients with mild-to-moderate atopic dermatitis","volume":"13","author":"Fowler","year":"2023","journal-title":"Dermatology and Therapy"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0300|cit300","first-page":"262","article-title":"Improvements in sleep outcomes for crisaborole-treated pediatric patients with mild-to-moderate atopic dermatitis and their families","volume":"149","author":"Fowler","year":"2022","journal-title":"Pediatrics (2021 National Conference and Exhibition Abstract)"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD015064.pub2-BIB0301|cit301","first-page":"66","article-title":"Crisaborole ointment improves global atopic dermatitis severity: pooled results from two phase 3 clinical trials","volume":"59","author":"Fowler","year":"2018","journal-title":"Australasian Journal of Dermatology (Conference: 51st Annual Scientific Meeting of the Australasian College of Dermatologists. Australia)"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0302|cit302","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1542\/peds.141.1MA3.251","article-title":"A novel nonsteroidal, topical anti-inflammatory, phosphodiesterase 4 inhibitor, crisaborole ointment, reduced pruritus and signs of atopic dermatitis in 2 phase 3 studies in children and adults","volume":"141","author":"Hebert","year":"2018","journal-title":"Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0303|cit303","first-page":"e110","article-title":"Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis with and without comorbid allergies or asthma","volume":"185","author":"Lio","year":"2021","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0304|cit304","doi-asserted-by":"crossref","first-page":"AB97","DOI":"10.1016\/j.jaad.2021.06.406","article-title":"26304 Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis with and without comorbid allergies or asthma","volume":"85","author":"Lio","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0305|cit305","unstructured":"Safety and efficacy of AN2728 topical ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis clinicaltrials.gov\/show\/NCT02118766"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0306|cit306","unstructured":"Safety and efficacy of AN2728 topical ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis https:\/\/www.clinicaltrials.gov\/study\/NCT02118766"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0307|cit307","first-page":"AB86","article-title":"Crisaborole topical ointment, 2%: a novel, nonsteroidal, topical anti-inflammatory, phosphodiesterase 4 inhibitor: results from two phase 3 studies treating children and adult patients with mild to moderate atopic dermatitis","volume":"74","author":"Paller","year":"2016","journal-title":"Journal of the American Academy of Dermatology."},{"key":"10.1002\/14651858.CD015064.pub2-BIB0308|cit308","first-page":"e39-e40","article-title":"Crisaborole ointment improves global atopic dermatitis severity across patients with varying baseline characteristics: pooled results from two phase III trials (abstract)","volume":"179","author":"Paller","year":"2018","journal-title":"British Journal of Dermatology (Conference: 10th George Rajka International Symposium on Atopic Dermatitis. Netherlands)"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"e6.494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0310|cit310","first-page":"705","article-title":"Phase 3 studies treating children and adult patientswithmild tomoderate atopic dermatitis with crisaborole ointment, a novel, nonsteroidal, topical anti-inflammatory, phosphodiesterase 4 inhibitor","volume":"33","author":"Paller","year":"2016","journal-title":"Pediatric Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0311|cit311","first-page":"S10-11","article-title":"Results from two phase 3 studies in children and adults with mildto-moderate atopic dermatitis treated with crisaborole topical ointment, 2%, a novel nonsteroidal, topical anti-inflammatory, phosphodiesterase 4 inhibitor","volume":"9","author":"Paller","year":"2016","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0312|cit312","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1542\/peds.141.1MA3.275","article-title":"Phase 3 studies treating children and adult patients with mild to moderate atopic dermatitis with crisaborole ointment, a novel, nonsteroidal, topical antiinflammatory, phosphodiesterase 4 inhibitor","volume":"141","author":"Paller","year":"2018","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1542\/peds.142.1MA9.814","article-title":"Crisaborole ointment effect on global atopic dermatitis severity and early relief in pruritus: pooled results from two phase 3 clinical trials (abstract)","volume":"142","author":"Paller","year":"2018","journal-title":"Pediatrics"},{"issue":"13","key":"10.1002\/14651858.CD015064.pub2-BIB0314|cit314","doi-asserted-by":"crossref","first-page":"adv00170","DOI":"10.2340\/00015555-3489","article-title":"Evaluating the efficacy of crisaborole using the atopic dermatitis severity index and percentage of affected body surface area","volume":"100","author":"Silverberg","year":"2020","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0315|cit315","first-page":"28-9","article-title":"Crisaborole demonstrates improvement in quality of life in patients with mild to moderate atopic dermatitis","volume":"25","author":"Simpson","year":"2016","journal-title":"Experimental Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"605-19","DOI":"10.1007\/s13555-018-0263-0","article-title":"Crisaborole ointment improves quality of life of patients with mild to moderate atopic dermatitis and their families","volume":"8","author":"Simpson","year":"2018","journal-title":"Dermatology and Therapy"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"587-8","DOI":"10.1007\/s13555-021-00506-y","article-title":"Relationship among treatment, pruritus, Investigator\u2019s Static Global Assessment, and Quality of Life in patients with atopic dermatitis","volume":"11","author":"Simpson","year":"2021","journal-title":"Dermatology and Therapy"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0318|cit318","doi-asserted-by":"crossref","first-page":"AB28","DOI":"10.1016\/j.jaci.2020.12.141","article-title":"Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis with comorbid allergic rhinitis or asthma","volume":"147","author":"Spergel","year":"2021","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0319|cit319","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.anai.2020.08.158","article-title":"Efficacy of crisaborole in patients with mild-to-moderate atopic dermatitis with and without comorbid allergic rhinitis","volume":"125","author":"Spergel","year":"2020","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"9","key":"10.1002\/14651858.CD015064.pub2-BIB0320|cit320","doi-asserted-by":"crossref","first-page":"1742-6","DOI":"10.1111\/jdv.15712","article-title":"Examining the association between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole","volume":"33","author":"Stander","year":"2019","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0321|cit321","first-page":"e118","article-title":"Impact of crisaborole in patients with mild-to-moderate atopic dermatitis who received prior treatment","volume":"187","author":"Stein-Gold","year":"2022","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0322|cit322","doi-asserted-by":"crossref","first-page":"AB244","DOI":"10.1016\/j.jaad.2018.05.971","article-title":"Relationship between pruritus and quality of life in patients with atopic dermatitis treated with crisaborole","volume":"79","author":"St\u00e4nder","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0323|cit323","first-page":"e60","article-title":"Evaluating the severity of atopic dermatitis in children and adults: mapping of Investigator's Static Global Assessment to Eczema Area and Severity Index in phase III studies of crisaborole 2%","volume":"184","author":"Thyssen","year":"2021","journal-title":"British Journal of Dermatology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0324|cit324","doi-asserted-by":"crossref","first-page":"191.26","DOI":"10.4049\/jimmunol.196.Supp.191.26","article-title":"Two phase 3 study results of children and adults with mild-to-moderate atopic dermatitis treated with crisaborole topical ointment, 2%, a novel, nonsteroidal, topical, anti-inflammatory, phosphodiesterase 4 inhibitor","volume":"196","author":"Zane","year":"2016","journal-title":"Journal of Immunology (Baltimore, Md. : 1950)"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0325|cit325","doi-asserted-by":"crossref","first-page":"AB397","DOI":"10.1016\/j.jaci.2015.12.1230","article-title":"Efficacy and safety of crisaborole topical ointment, 2%, a novel, nonsteroidal, topical, anti-inflammatory, phosphodiesterase inhibitor in 2 phase 3 studies in children and adults with mild to-moderate atopic dermatitis","volume":"137","author":"Boguniewicz","year":"2016","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"S1","key":"10.1002\/14651858.CD015064.pub2-BIB0326|cit326","first-page":"S46","article-title":"Reduced pruritus and signs of atopic dermatitis in phase 3 trials with a nonsteroidal topical phosphodiesterase inhibitor, crisaborole","volume":"33","author":"Hebert","year":"2016","journal-title":"Pediatric Dermatology"},{"issue":"5 Suppl. 1","key":"10.1002\/14651858.CD015064.pub2-BIB0327|cit327","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jid.2016.02.309","article-title":"Reduced pruritus and signs of atopic dermatitis in phase 3 trials with a nonsteroidal topical phosphodiesterase inhibitor, crisaborole","volume":"136","author":"Hebert","year":"2016","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0328|cit328","unstructured":"Safety and efficacy of AN2728 topical ointment, 2% in children, adolescents, and adults (aged 2 years and older) with atopic dermatitis clinicaltrials.gov\/show\/NCT02118792"},{"issue":"4-A Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0329|cit329","first-page":"S99-S100","article-title":"Crisaborole topical ointment 2%, a novel, nonsteroidal, topical, anti-inflammatory, phosphodiesterase inhibitor, in 2 phase 3 studies in children and adults with mild-to-moderate atopic dermatitis","volume":"22","author":"Paller","year":"2016","journal-title":"Journal of Managed Care and Speciality Pharmacy"},{"issue":"S1","key":"10.1002\/14651858.CD015064.pub2-BIB0330|cit330","first-page":"S19","article-title":"Two phase 3 studies in atopic dermatitis with crisaborole, the novel, nonsteroidal topical phosphodiesterase 4 inhibitor","volume":"33","author":"Paller","year":"2016","journal-title":"Pediatric Dermatology"},{"issue":"9 Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0331|cit331","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.1016\/j.jid.2016.06.050","article-title":"A novel, nonsteroidal, topical, anti-inflammatory, phosphodiesterase inhibitor, crisaborole topical ointment, 2%, in two phase 3 studies in children and adults with mild to moderate atopic dermatitis","volume":"136","author":"Paller","year":"2016","journal-title":"Journal of Investigative Dermatology"},{"issue":"5 Suppl. 1","key":"10.1002\/14651858.CD015064.pub2-BIB0332|cit332","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.jid.2016.02.316","article-title":"Phase 3 studies in atopic dermatitis with the novel, nonsteroidal topical phosphodiesterase 4 inhibitor, crisaborole","volume":"136","author":"Paller","year":"2016","journal-title":"Journal of Investigative Dermatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0333|cit333","first-page":"S36","article-title":"Safety and efficacy of AN2728 topical ointment, 2% and 0.5% in adolescents with atopic dermatitis","volume":"134","author":"Stein-Gold","year":"2014","journal-title":"Journal of Investigative Dermatology"},{"issue":"5 Suppl. 1","key":"10.1002\/14651858.CD015064.pub2-BIB0334|cit334","first-page":"AB65","article-title":"Safety and efficacy of AN2728 topical ointment, 2% and 0.5%, in a phase II dose-ranging study of adolescents with mild to moderate atopic dermatitis","volume":"70","author":"Stein-Gold","year":"2014","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0335|cit335","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2340\/00015555-2893","article-title":"Early relief of pruritus in atopic dermatitis with crisaborole ointment, a non-steroidal, phosphodiesterase 4 inhibitor","volume":"98","author":"Yosipovitch","year":"2018","journal-title":"Acta Dermato-Venereologica"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0336|cit336","doi-asserted-by":"crossref","first-page":"191.27","DOI":"10.4049\/jimmunol.196.Supp.191.27","article-title":"Crisaborole topical ointment, 2%, a novel nonsteroidal, anti-inflammatory, topical, phosphodiesterase 4 inhibitor, reduced pruritus and signs of atopic dermatitis in 2 phase 3 studies in children and adults with mild-to-moderate atopic dermatitis","volume":"196","author":"Zane","year":"2016","journal-title":"Journal of Immunology (Baltimore, Md. : 1950)"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0337|cit337","unstructured":"A clinical trial to compare topical agents in adults with mild to moderate atopic dermatitis (AD) clinicaltrials.gov\/show\/NCT02376049"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0338|cit338","unstructured":"Clinical study to evaluate the efficacy and safety of desoximetasone (DSXS) with atopic dermatitis clinicaltrials.gov\/ct2\/show\/NCT02595073"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0339|cit339","unstructured":"Study of RVT-501 in adult and adolescent subjects with atopic dermatitis clinicaltrials.gov\/ct2\/show\/NCT02950922"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0340|cit340","unstructured":"8-week atopic dermatitis (AD) treatment study clinicaltrials.gov\/show\/NCT03386032"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0341|cit341","unstructured":"A phase 3b\/4 study of the efficacy, safety, and local tolerability of crisaborole ointment, 2% in pediatric and adult subjects (ages 2 years and older) with mild to moderate atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2018-001043-31-SE"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0342|cit342","unstructured":"A study of crisaborole ointment 2%; crisaborole vehicle; TCS and TCI in subjects aged \u2265 2 years, with mild-moderate AD clinicaltrials.gov\/show\/NCT03539601"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0343|cit343","unstructured":"ASPIRE: PROs & caregiver burden in children with atopic dermatitis clinicaltrials.gov\/show\/NCT03645057"},{"issue":"8","key":"10.1002\/14651858.CD015064.pub2-BIB0344|cit344","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.jid.2022.05.397","article-title":"388 Impact of crisaborole & tacrolimus 0.03% on patient-reported outcomes and caregiver burden in children with atopic dermatitis","volume":"142","author":"Wieser","year":"2022","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0345|cit345","unstructured":"Dose-ranging trial to evaluate delgocitinib cream 1, 3, 8, and 20 mg\/g compared to delgocitinib cream vehicle over an 8-week treatment period in adult subjects with atopic dermatitis clinicaltrials.gov\/show\/NCT03725722"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0346|cit346","doi-asserted-by":"crossref","first-page":"AB148","DOI":"10.1016\/j.jaad.2021.06.605","article-title":"Efficacy of ruxolitinib cream among patients with atopic dermatitis based on previous medication history: pooled results from two phase 3 studies","volume":"85","author":"Blauvelt","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0347|cit347","first-page":"e136-e137","article-title":"Long-term safety and disease control with ruxolitinib cream in patients with atopic dermatitis based on previous medication history: pooled results from two phase III studies","volume":"185","author":"Blauvelt","year":"2021","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0348|cit348","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/jdv.18571","article-title":"Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis","volume":"37","author":"Blauvelt","year":"2023","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0349|cit349","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jid.2021.02.335","article-title":"Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream","volume":"141","author":"Blauvelt","year":"2021","journal-title":"Journal of Investigative Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.jid.2021.02.347","article-title":"Ruxolitinib cream rapidly decreases skin pain in atopic dermatitis","volume":"141","author":"Blauvelt","year":"2021","journal-title":"Journal of Investigative Dermatology"},{"issue":"8 Supplement","key":"10.1002\/14651858.CD015064.pub2-BIB0351|cit351","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.jid.2022.05.315","article-title":"307 High-threshold responses to ruxolitinib cream in adolescents and adults with atopic dermatitis","volume":"142","author":"Blauvelt","year":"2022","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0352|cit352","first-page":"14","article-title":"Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: a pooled analysis from two randomized phase 3 studies","volume":"14","author":"Blauvelt","year":"2022","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"AB121","DOI":"10.1016\/j.jaad.2021.06.501","article-title":"Ruxolitinib cream rapidly decreases pruritus in atopic dermatitis: pooled results from two phase 3 studies","volume":"85","author":"Blauvelt","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0354|cit354","first-page":"20","article-title":"Impact of ruxolitinib cream on work productivity and activity impairment and associated indirect costs in patients with atopic dermatitis: pooled results from two phase III studies","volume":"20","author":"Bloudek","year":"2022","journal-title":"American Journal of Clinical Dermatology"},{"issue":"10","key":"10.1002\/14651858.CD015064.pub2-BIB0355|cit355","first-page":"S97","article-title":"Effects of ruxolitinib cream on work productivity and activity impairment in patients with atopic dermatitis: 52-week pooled results from two phase 3 studies","volume":"28","author":"Eichenfield","year":"2022","journal-title":"Journal of Managed Care and Speciality Pharmacy"},{"issue":"3 Supplement","key":"10.1002\/14651858.CD015064.pub2-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"AB202","DOI":"10.1016\/j.jaad.2022.06.841","article-title":"35163 Ruxolitinib cream provided progressive improvement in patients with atopic dermatitis who did not achieve Investigator's Global Assessment treatment success at week 8: pooled results from 2 phase 3 studies","volume":"87","author":"Eichenfield","year":"2022","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"AB179","DOI":"10.1016\/j.jaad.2021.06.728","article-title":"Effects of ruxolitinib cream on work productivity and activity impairment in patients with atopic dermatitis: pooled results from two phase 3 studies","volume":"85","author":"Eichenfield","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0358|cit358","first-page":"1433-4","article-title":"Long-term safety and disease control of ruxolitinib cream among adolescents with atopic dermatitis: results from two phase 3 studies","volume":"38","author":"Eichenfield","year":"2021","journal-title":"Pediatric Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"AB158","DOI":"10.1016\/j.jaad.2021.06.644","article-title":"27633 Efficacy and safety of ruxolitinib cream among adolescents with atopic dermatitis: pooled results from two phase 3 studies","volume":"85","author":"Eichenfield","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0360|cit360","first-page":"1424","article-title":"Efficacy and safety of ruxolitinib cream among adolescents with atopic dermatitis: pooled results from two phase 3 studies","volume":"38","author":"Eichenfield","year":"2021","journal-title":"Pediatric Dermatology"},{"issue":"8 Supplement","key":"10.1002\/14651858.CD015064.pub2-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jid.2022.05.283","article-title":"275 Effects of ruxolitinib cream on sleep and quality of life over 52 weeks in black patients with atopic dermatitis","volume":"142","author":"Eichenfield","year":"2022","journal-title":"Journal of Investigative Dermatology"},{"issue":"8 Supplement","key":"10.1002\/14651858.CD015064.pub2-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/j.jid.2022.05.295","article-title":"287 Effects of ruxolitinib cream on pruritus in black patients with atopic dermatitis","volume":"142","author":"Eichenfield","year":"2022","journal-title":"Journal of Investigative Dermatology"},{"issue":"3 Supplement","key":"10.1002\/14651858.CD015064.pub2-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"AB180","DOI":"10.1016\/j.jaad.2022.06.752","article-title":"34794 Long-term safety and disease control of ruxolitinib cream among Black or African American patients with atopic dermatitis: pooled results from 2 phase 3 studies","volume":"87","author":"Eichenfield","year":"2022","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD015064.pub2-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"B27","DOI":"10.1016\/j.jid.2022.05.1015","article-title":"LB991 Clinical serum biomarker profiling in TRuE-AD1 and TRuE-AD2 studies after 8 weeks of treatment with ruxolitinib cream","volume":"142","author":"Liu","year":"2022","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0365|cit365","unstructured":"Topical ruxolitinib evaluation in atopic dermatitis study 1 (TRuE AD1) - an efficacy and safety study of ruxolitinib cream in adolescents and adults with atopic dermatitis clinicaltrials.gov\/show\/NCT03745638"},{"issue":"10","key":"10.1002\/14651858.CD015064.pub2-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1016\/j.jid.2021.08.213","article-title":"208 Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies","volume":"141","author":"Papp","year":"2021","journal-title":"Journal of Investigative Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"AB160","DOI":"10.1016\/j.jaad.2021.06.653","article-title":"27716 Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by baseline clinical characteristics: pooled subgroup analysis from two randomized phase 3 studies","volume":"85","author":"Papp","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"AB149","DOI":"10.1016\/j.jaad.2021.06.609","article-title":"Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by baseline patient demographics: pooled subgroup analysis from two randomized phase 3 studies","volume":"85","author":"Papp","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0369|cit369","first-page":"e167","article-title":"Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: pooled results from two phase 3 studies","volume":"186","author":"Papp","year":"2022","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0370|cit370","first-page":"26","article-title":"Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies","volume":"26","author":"Papp","year":"2022","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0371|cit371","first-page":"1008","article-title":"Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies","volume":"5","author":"Papp","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0372|cit372","first-page":"e134-e135","article-title":"Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase III studies","volume":"185","author":"Papp","year":"2021","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0373|cit373","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0374|cit374","first-page":"e116-e117","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from two phase III randomized double-blind studies","volume":"183","author":"Papp","year":"2020","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0375|cit375","first-page":"e62-e63","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: pooled analysis of two phase III, randomized, double-blind studies","volume":"184","author":"Papp","year":"2021","journal-title":"British Journal of Dermatology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0376|cit376","first-page":"S12-S13","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: pooled analysis of two phase III, randomized, double-blind studies","volume":"14","author":"Papp","year":"2021","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0377|cit377","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/j.jid.2021.02.333","article-title":"Effects of ruxolitinib cream in patients with atopic dermatitis with head and\/or neck involvement","volume":"141","author":"Simpson","year":"2021","journal-title":"Journal of Investigative Dermatology"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0378|cit378","first-page":"S11","article-title":"Effects of ruxolitinib cream on pruritus and sleep in atopic dermatitis: 52-week pooled results from two Phase 3 studies","volume":"15","author":"Simpson","year":"2022","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"AB35","DOI":"10.1016\/j.jaci.2020.12.161","article-title":"Disease characteristics and burden in patients with atopic dermatitis: insights from two phase 3 studies of ruxolitnib cream","volume":"147","author":"Simpson","year":"2021","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0380|cit380","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jid.2021.02.351","article-title":"Efficacy of ruxolitinib cream in adults and adolescents with atopic comorbidities","volume":"141","author":"Simpson","year":"2021","journal-title":"Journal of Investigative Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0381|cit381","doi-asserted-by":"crossref","first-page":"AB178","DOI":"10.1016\/j.jaad.2021.06.727","article-title":"Patient-reported outcomes of ruxolitinib cream for the treatment of atopic dermatitis: pooled results from two phase 3 studies","volume":"85","author":"Simpson","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3 Supplement","key":"10.1002\/14651858.CD015064.pub2-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"AB53","DOI":"10.1016\/j.jaad.2022.06.247","article-title":"34587 Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by anatomic region: pooled analysis from two randomized phase 3 studies","volume":"87","author":"Simpson","year":"2022","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0383|cit383","first-page":"e166","article-title":"Effects of ruxolitinib cream on pruritus and sleep in atopic dermatitis: 52-week pooled results from two phase III studies","volume":"186","author":"Simpson","year":"2022","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0384|cit384","doi-asserted-by":"crossref","first-page":"AB121","DOI":"10.1016\/j.jaad.2021.06.502","article-title":"Effect of ruxolitinib cream on sleep disturbance and sleep impairment: pooled analysis from two randomized phase 3 studies","volume":"85","author":"Simpson","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"AB157","DOI":"10.1016\/j.jaad.2021.06.640","article-title":"Effects of ruxolitinib cream in patients with atopic dermatitis with baseline body surface area \u2265 10% and Eczema Area and Severity Index score \u2265 16: pooled results from two phase 3 studies","volume":"85","author":"Simpson","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0386|cit386","doi-asserted-by":"crossref","first-page":"AB50","DOI":"10.1016\/j.jaad.2021.06.226","article-title":"Efficacy of ruxolitinib cream in patients with atopic dermatitis who demonstrated partial responses: pooled analysis from two randomized phase 3 studies","volume":"85","author":"Simpson","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0387|cit387","first-page":"e135-e136","article-title":"Long-term safety and disease control with ruxolitinib cream in patients with more severe atopic dermatitis: pooled results from two phase III studies","volume":"185","author":"Simpson","year":"2021","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0388|cit388","first-page":"e122","article-title":"Effects of ruxolitinib cream on patient-reported quality of life in atopic dermatitis: 52-week pooled results from two phase III studies","volume":"187","author":"Simpson","year":"2022","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0389|cit389","first-page":"1424","article-title":"Efficacy of ruxolitinib cream on pruritus in adolescents with atopic dermatitis: pooled results from two phase 3 studies","volume":"38","author":"Szepietowski","year":"2021","journal-title":"Pediatric Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0390|cit390","unstructured":"Efficacy and safety study of ruxolitinib cream followed by a long term safety period in adolescents and adults with atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2018-003713-18-ES"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0391|cit391","unstructured":"TRuE AD2 - an efficacy and safety study of ruxolitinib cream in adolescents and adults with atopic dermatitis clinicaltrials.gov\/show\/NCT03745651"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0392|cit392","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/1346-8138.16792","article-title":"Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged \u2265 2 years with mild-to-moderate atopic dermatitis","volume":"50","author":"Ma","year":"2020","journal-title":"Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0393|cit393","unstructured":"Crisaborole for Asian subjects (\u2265 2 years of age) with mild to moderate atopic dermatitis clinicaltrials.gov\/show\/NCT04360187"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0394|cit394","unstructured":"A phase II study of HY209 gel for atopic dermatitis patients (Shaperon) clinicaltrials.gov\/show\/NCT04530643"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0395|cit395","unstructured":"A study of the efficacy, safety, tolerability and pharmacokinetics of PF07038124 ointment in participants with eczema or psoriasis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020-003977-23-PL"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0396|cit396","unstructured":"Study to assess efficacy, safety, tolerability and pharmacokinetics of PF-07038124 ointment in participants with atopic dermatitis or plaque psoriasis clinicaltrials.gov\/show\/NCT04664153"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0397|cit397","unstructured":"Trial of PDE4 inhibition with roflumilast for the management of atopic dermatitis clinicaltrials.gov\/show\/NCT04773587"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0398|cit398","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.jval.2023.03.209","article-title":"CO136 Efficacy and safety of roflumilast cream 0.15% in adults and children aged 6 and older with mild to moderate atopic dermatitis in two phase 3 Integument trials","volume":"26","author":"Simpson","year":"2023","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0399|cit399","unstructured":"A phase 3, 4-week, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-151 cream 0.15% administered daily in subjects with atopic dermatitis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2021-006884-67-PL"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0400|cit400","unstructured":"Trial of PDE4 inhibition with roflumilast for the management of atopic dermatitis (INTEGUMENT-II) clinicaltrials.gov\/show\/NCT04773600"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0401|cit401","first-page":"S15","article-title":"Tapinarof cream 1% once daily for the treatment of moderate to severe atopic dermatitis in children and adults: the pivotal phase 3 ADORING clinical program","volume":"15","author":"Eichenfield","year":"2022","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0402|cit402","first-page":"1452","article-title":"Tapinarof cream 1% once daily for the treatment of moderate to severe atopic dermatitis in children and adults: the pivotal phase 3 ADORING clinical program","volume":"38","author":"Eichenfield","year":"2021","journal-title":"Pediatric Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0403|cit403","first-page":"e136","article-title":"Tapinarof cream 1% once daily for the treatment of moderate-to-severe atopic dermatitis in children and adults: the pivotal phase III ADORING clinical program","volume":"186","author":"Eichenfield","year":"2022","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0404|cit404","first-page":"e127","article-title":"Tapinarof cream 1% once daily for the treatment of moderate-to-severe atopic dermatitis in children and adults: the pivotal phase III ADORING clinical programme","volume":"185","author":"Eichenfield","year":"2021","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0405|cit405","unstructured":"ADORING 1 study reveals promising results for tapinarof in atopic dermatitis https:\/\/www.dermatologytimes.com\/view\/adoring-1-study-reveals-promising-results-for-tapinarof-in-atopic-dermatitis (first received 18 July 2023)"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0406|cit406","unstructured":"Tapinarof for the treatment of atopic dermatitis in children and adults clinicaltrials.gov\/show\/NCT05014568"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0407|cit407","unstructured":"Dermavant Sciences New positive topline results of tapinarof cream for AD down to 2 years https:\/\/www.dermatologytimes.com\/view\/new-positive-topline-results-of-tapinarof-cream-for-ad-down-to-2-years (first received 18 July 2023)"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0408|cit408","unstructured":"Tapinarof for the treatment of atopic dermatitis in children and adults (DMVT-505-3102) clinicaltrials.gov\/show\/NCT05032859"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0409|cit409","unstructured":"A phase 1\/2 study of E6005 in pediatric subjects with atopic dermatitis clinicaltrials.gov\/show\/NCT02094235"},{"issue":"8","key":"10.1002\/14651858.CD015064.pub2-BIB0410|cit410","doi-asserted-by":"crossref","first-page":"881-7","DOI":"10.1111\/1346-8138.13231","article-title":"Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: results from a randomized, vehicle-controlled exploratory trial","volume":"43","author":"Nemoto","year":"2016","journal-title":"Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0411|cit411","first-page":"74","article-title":"Efficacy of two fluorinated topical steroids in the treatment of common eczemas, on a once a day treatment schedule","volume":"52","author":"Neumann","year":"1971","journal-title":"Acta Dermato-Venereologica Supplementum"},{"issue":"7","key":"10.1002\/14651858.CD015064.pub2-BIB0412|cit412","first-page":"548","article-title":"A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis","volume":"6","author":"Neumann","year":"2008","journal-title":"Journal of the German Society of Dermatology"},{"issue":"10","key":"10.1002\/14651858.CD015064.pub2-BIB0413|cit413","first-page":"1689","article-title":"Therapy of atopical eczema in children. Results of a controlled study with the topical corticosteroid preparations Mometason and Prednikarbat","volume":"22","author":"Nolting","year":"1991","journal-title":"Der Kinderarzt"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0414|cit414","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1365-2133.1989.tb01430.x","article-title":"The effect of combined topical steroids and habit-reversal treatment in patients with atopic dermatitis","volume":"121","author":"Noren","year":"1989","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0415|cit415","unstructured":"A study of E6005 in Japanese patients with atopic dermatitis https:\/\/clinicaltrials.gov\/show\/NCT01179880"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0416|cit416","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/09546634.2016.1157257","article-title":"Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: an investigator-blinded, vehicle-controlled study","volume":"27","author":"Ohba","year":"2016","journal-title":"Journal of Dermatological Treatment"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0417|cit417","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/09546634.2015.1093587","article-title":"Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis","volume":"27","author":"Ohba","year":"2016","journal-title":"Journal of Dermatological Treatment"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0418|cit418","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/1346-8138.15123","article-title":"Phase 1 study of crisaborole in Japanese healthy volunteers and patients with atopic dermatitis","volume":"47","author":"Ono","year":"2020","journal-title":"Journal of Dermatology"},{"issue":"10","key":"10.1002\/14651858.CD015064.pub2-BIB0419|cit419","first-page":"1145","article-title":"Pimecrolimus cream and tacrolimus ointment in the treatment of atopic dermatitis: a pilot study on patient preference","volume":"12","author":"Onumah","year":"2013","journal-title":"Journal of Drugs in Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0420|cit420","first-page":"P0242","article-title":"Tacrolimus ointment is effective and safe in Japanese atopic dermatitis children","volume":"129","author":"Ohtsuki","year":"2002","journal-title":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0421|cit421","first-page":"569","article-title":"Efficacy and safety of FK506 (tacrolimus) ointment in children with atopic dermatitis-phase III double-blinded comparison with vehicle ointment","volume":"19","author":"Otsuki","year":"2003","journal-title":"Journal of Clinical Therapeutics & Medicines (Rinsho Iyaku)"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0422|cit422","first-page":"301-6","article-title":"Double-blind studies on hydrocortisone 17-butyrate and halcinonide in the topical treatment of non-infectious eczematous dermatitis","volume":"36","author":"Pala","year":"1982","journal-title":"Annali Italiani di Dermatologia Clinica e Sperimentale"},{"issue":"12","key":"10.1002\/14651858.CD015064.pub2-BIB0423|cit423","first-page":"1153","article-title":"Adult patients with moderate atopic dermatitis: tacrolimus ointment versus pimecrolimus cream","volume":"7","author":"Abramovits","year":"2008","journal-title":"Journal of Drugs in Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0424|cit424","unstructured":"Comparison study between Protopic (tacrolimus ointment) and Elidel (pimecrolimus cream) in pediatric patients with mild atopic dermatitis clinicaltrials.gov\/show\/NCT00667160"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0425|cit425","first-page":"338","article-title":"Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in pediatric patients with atopic dermatitis (abstract)","volume":"21","author":"Paller","year":"2004","journal-title":"Pediatric Dermatology (10th World Congress on Pediatric Dermatology)"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0426|cit426","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jaad.2004.12.038","article-title":"Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies","volume":"52","author":"Paller","year":"2005","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0427|cit427","unstructured":"Comparison study between Protopic (tacrolimus ointment) and Elidel (pimecrolimus cream) in treating pediatric patients with atopic dermatitis clinicaltrials.gov\/show\/NCT00666159"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0428|cit428","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jaad.2004.12.038","article-title":"Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies","volume":"52","author":"Paller","year":"2005","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0429|cit429","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/09546630701287332","article-title":"Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis","volume":"18","author":"Abramovits","year":"2007","journal-title":"Journal of Dermatological Treatment"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0430|cit430","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2340\/00015555-0748","article-title":"Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids","volume":"90","author":"Kirsner","year":"2010","journal-title":"Acta Dermato-Venereologica"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0431|cit431","unstructured":"A comparison study between Protopic (tacrolimus) ointment and Elidel (pimecrolimus) cream in treating subjects with atopic dermatitis clinicaltrials.gov\/show\/NCT00666302"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0432|cit432","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jaad.2004.12.038","article-title":"Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies","volume":"52","author":"Paller","year":"2005","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0433|cit433","unstructured":"A dose-finding study of GSK2894512 cream in subjects with atopic dermatitis (AD) clinicaltrials.gov\/show\/NCT02564055"},{"issue":"4 Supplement 1","key":"10.1002\/14651858.CD015064.pub2-BIB0434|cit434","first-page":"AB140","article-title":"Treatment of atopic dermatitis with tapinarof cream: secondary outcomes from a phase 2b, randomized parallel-group study","volume":"81","author":"Paller","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0435|cit435","first-page":"e115-6","article-title":"Treatment of atopic dermatitis with tapinarof cream: secondary outcomes from a phase IIb randomized parallel-group study","volume":"183","author":"Paller","year":"2020","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0436|cit436","doi-asserted-by":"crossref","first-page":"632-8","DOI":"10.1016\/j.jaad.2020.05.135","article-title":"Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis","volume":"84","author":"Paller","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0437|cit437","first-page":"S16","article-title":"Patient-reported outcomes in subjects with atopic dermatitis treated with tapinarof cream: results from a Phase IIb, randomized, parallel-group study","volume":"12","author":"Paller","year":"2019","journal-title":"Journal of Clinical and Aesthetic Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0438|cit438","doi-asserted-by":"crossref","first-page":"e3.89-98","DOI":"10.1016\/j.jaad.2018.06.047","article-title":"A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis","volume":"80","author":"Peppers","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0439|cit439","first-page":"171","article-title":"Proof of efficacy of Kamillosan(R) cream in atopic eczema","volume":"5","author":"Patzelt-Wenczler","year":"2000","journal-title":"European Journal of Medical Research"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0440|cit440","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000255315","article-title":"Analysis of the results obtained in the treatment of atopic dermatitis with corticosteroid and neomycin containing ointments","volume":"120","author":"Polano","year":"1960","journal-title":"Dermatologica"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0441|cit441","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1440-0960.1969.tb01188.x","article-title":"Drug trial: a comparison between the topical efficacy of 1 percent hydrocortisone and 0.2 percent fluocortolone","volume":"10","author":"Portnoy","year":"1969","journal-title":"Australasian Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0442|cit442","first-page":"25","article-title":"Comparative evaluation of efficacy, tolerability and safety of 0.1% topical momethasone furoate and 0.05% desonide in the treatment of childhood atopic dermatitis","volume":"77","author":"Prado de Oliveira","year":"2002","journal-title":"Anais Brasileiros de Dermatologia"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0443|cit443","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1468-3083.1993.tb00040.x","article-title":"Mometasone furoate in the treatment of atopic dermatitis in children","volume":"2","author":"Rafanelli","year":"1993","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0444|cit444","first-page":"84","article-title":"Efficacy of topical tacrolimus in atopic dermatitis","volume":"18","author":"Rahman","year":"2008","journal-title":"Journal of Pakistan Association of Dermatologists"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0445|cit445","first-page":"457","article-title":"Topical tacrolimus versus hydrocortisone on atopic dermatitis in paediatric patients: a randomized controlled trial","volume":"24","author":"Rahman","year":"2015","journal-title":"Mymensingh Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0446|cit446","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/030006058601400206","article-title":"Hydrocortisone 17-butyrate (Locoid) 0.1% fatty cream versus desonide (Apolar) 0.1% ointment in the treatment of patients suffering from atopic dermatitis","volume":"14","author":"Rajka","year":"1986","journal-title":"Journal of International Medical Research"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0447|cit447","first-page":"298","article-title":"Treatment of resistant steroid-responsive dermatoses. A comparison of Diprolene and Neriforte","volume":"19","author":"Ramelet","year":"1982","journal-title":"Clinical Trials Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0448|cit448","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/0926-9959(96)00032-3","article-title":"The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate","volume":"7","author":"Ramsay","year":"1996","journal-title":"Journal of the European Academy of Dermatology and Venereology."},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0449|cit449","doi-asserted-by":"crossref","first-page":"572-82","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"4 Supplement 1","key":"10.1002\/14651858.CD015064.pub2-BIB0450|cit450","first-page":"AB198","article-title":"Effects of ruxolitinib cream on pruritus and quality of life in adult patients with atopic dermatitis: results from a phase 2, randomized, dose-ranging, vehicle-and active-controlled study","volume":"81","author":"Kim","year":"2019","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0451|cit451","doi-asserted-by":"crossref","first-page":"1305-13","DOI":"10.1016\/j.jaad.2020.02.009","article-title":"Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study","volume":"82","author":"Kim","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0452|cit452","unstructured":"A study to evaluate the safety and efficacy of INCB018424 phosphate cream applied topically to adults with atopic dermatitis clinicaltrials.gov\/show\/NCT03011892"},{"issue":"5 Supplement","key":"10.1002\/14651858.CD015064.pub2-BIB0453|cit453","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1016\/j.jid.2019.03.1074","article-title":"Ruxolitinib cream significantly modulates inflammatory profiles of atopic dermatitis patients","volume":"139","author":"Owens","year":"2019","journal-title":"Journal of Investigative Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0454|cit454","first-page":"e104","article-title":"Association between an itch-free state in atopic dermatitis treated with ruxolitinib cream and systemic inflammatory mediators","volume":"183","author":"Owens","year":"2020","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0455|cit455","first-page":"85","article-title":"12-week efficacy and safety data of ruxolitinib cream in adult patients with atopic dermatitis: results from a phase 2 study","volume":"12","author":"Raoof","year":"2020","journal-title":"Journal of the Dermatology Nurses' Association"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0456|cit456","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1067\/mai.2002.121832","article-title":"Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis","volume":"109","author":"Reitamo","year":"2002","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl s1","key":"10.1002\/14651858.CD015064.pub2-BIB0457|cit457","first-page":"137","article-title":"Tacrolimus ointment twice a day is more effective than once daily application or standard corticosteroid therapy in children with atopic dermatitis","volume":"16","author":"Bos","year":"2002","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0458|cit458","doi-asserted-by":"crossref","first-page":"554-62","DOI":"10.1046\/j.1365-2133.2004.05782.x","article-title":"0.03% tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial","volume":"150","author":"Reitamo","year":"2004","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 1 Pt 1","key":"10.1002\/14651858.CD015064.pub2-BIB0459|cit459","first-page":"1S247","article-title":"Tacrolimus ointment 0.03% (protopic) twice a day is more effective than once a day or conventional therapy in children with moderate to severe AD","volume":"129","author":"Reitamo","year":"2002","journal-title":"Annales de Dermatologie et de Venereologie"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0460|cit460","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2340\/00015555-0803","article-title":"One-year treatment with 0.1% tacrolimus ointment versus a corticosteroid regimen in adults with moderate to severe atopic dermatitis: a randomized, double-blind, comparative trial","volume":"90","author":"Mandelin","year":"2010","journal-title":"Acta Dermato-Venereologica"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0461|cit461","doi-asserted-by":"crossref","first-page":"A77","DOI":"10.1016\/S1098-3015(10)73447-1","article-title":"Changes in health related utility among adults with atopic dermatitis treated with tacrolimus ointment compared to a standard corticosteroid regimen","volume":"12","author":"Poole","year":"2009","journal-title":"Value in Health"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0462|cit462","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1468-3083.2009.03485.x","article-title":"Quality of life and health-related utility analysis of adults with moderate and severe atopic dermatitis treated with tacrolimus ointment vs. topical corticosteroids","volume":"24","author":"Poole","year":"2010","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0463|cit463","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1111\/j.1365-2133.2005.06592.x","article-title":"A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis","volume":"152","author":"Reitamo","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD015064.pub2-BIB0464|cit464","first-page":"308","article-title":"0.1% tacrolimus ointment twice daily is an effective treatment for adults with moderate or severe atopic dermatitis","volume":"17","author":"Reitamo","year":"2003","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD015064.pub2-BIB0465|cit465","first-page":"156","article-title":"Superior efficacy of 0.1% tacrolimus ointment in treating adults with moderate to severe atopic dermatitis","volume":"17","author":"Reitamo","year":"2003","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"Suppl s1","key":"10.1002\/14651858.CD015064.pub2-BIB0466|cit466","first-page":"5","article-title":"Efficacy and safety of tacrolimus ointment compared with hydrocortisone treatment in adults with moderate-to- severe atopic dermatitis","volume":"16","author":"Reitamo","year":"2002","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0467|cit467","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/archderm.1971.04000240056007","article-title":"Fluocinonide. Preliminary evaluation of a new topically applied corticosteroid","volume":"104","author":"Rosenberg","year":"1971","journal-title":"Archives of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0468|cit468","first-page":"P0252","article-title":"Efficacy and safety comparison of desonide 0.05% lotion versus fluocortolone 0.5% ointment in atopic dermatitis","volume":"129","author":"Rossi","year":"2002","journal-title":"Annales de Dermatologie et de Venereologie"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0469|cit469","first-page":"695","article-title":"Hydrocortisone valerate. Double-blind comparison with two other topical steroids","volume":"21","author":"Roth","year":"1978","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0470|cit470","first-page":"695","article-title":"Hydrocortisone valerate. Double-blind comparison with two other topical steroids","volume":"21","author":"Roth","year":"1978","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0471|cit471","first-page":"695","article-title":"Hydrocortisone valerate. Double-blind comparison with two other topical steroids","volume":"21","author":"Roth","year":"1978","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0472|cit472","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1067\/mai.2002.121831","article-title":"Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis","volume":"109","author":"Reitamo","year":"2002","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"Suppl 1 Pt 2","key":"10.1002\/14651858.CD015064.pub2-BIB0473|cit473","first-page":"1S421","article-title":"Tacrolimus ointment (protopic) shows superior efficacy and comparable safety in a short-term comparison versus corticosteroids in children with AD","volume":"129","author":"Rustin","year":"2002","journal-title":"Annales de Dermatologie et de Venereologie"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0474|cit474","first-page":"P2-42","article-title":"Tacrolimus ointment shows greater efficacy than corticosteroids in the short term treatment of atopic dermatitis in children","volume":"16","author":"Rustin","year":"2002","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0475|cit475","first-page":"233","article-title":"Improvement of atopic dermatitis with tacrolimus ointment (0.03, 0.1 and 0.3%) in a dose-response study with placebo","volume":"38","author":"Bieber","year":"1997","journal-title":"Australasian Journal of Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD015064.pub2-BIB0476|cit476","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJM199709183371203","article-title":"A short-term trial of tacrolimus ointment for atopic dermatitis","volume":"337","author":"Ruzicka","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0477|cit477","doi-asserted-by":"crossref","first-page":"205","DOI":"10.12793\/jkscpt.1997.5.2.205","article-title":"Comparison of the safety and efficacy of mometasone furoate cream 0.1% and fluocortin butylester cream 0.75% in the treatment of atopic dermatitis","volume":"5","author":"Ryu","year":"1997","journal-title":"Journal of Korean Society for Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0478|cit478","unstructured":"Study of OPA-15406 ointment in patients with atopic dermatitis clinicaltrials.gov\/show\/NCT02914548"},{"issue":"8","key":"10.1002\/14651858.CD015064.pub2-BIB0479|cit479","doi-asserted-by":"crossref","first-page":"672-9","DOI":"10.1111\/1346-8138.14979","article-title":"Efficacy and safety of topical OPA-15406, a new phosphodiesterase 4 inhibitor, in Japanese patients with atopic dermatitis for 8A weeks: a phase 2, randomized, double-blind, placebo-controlled study","volume":"46","author":"Saeki","year":"2019","journal-title":"Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0480|cit480","unstructured":"Phase 2 study of OPA-15406 ointment in pediatric patients with atopic dermatitis clinicaltrials.gov\/show\/NCT03018691"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0481|cit481","doi-asserted-by":"crossref","first-page":"17-24","DOI":"10.1111\/1346-8138.15137","article-title":"Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA- 15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2-14 years with atopic dermatitis","volume":"47","author":"Saeki","year":"2020","journal-title":"Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0482|cit482","unstructured":"Comparison trial of OPA-15406 ointment in pediatric patients with atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-JapicCTI-194700"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0483|cit483","unstructured":"Comparison trial of OPA-15406 ointment in pediatric patients with atopic dermatitis https:\/\/clinicaltrials.gov\/show\/NCT03911401"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0484|cit484","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjd.20655","article-title":"Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial","volume":"186","author":"Saeki","year":"2022","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0485|cit485","doi-asserted-by":"crossref","first-page":"AB67","DOI":"10.1016\/j.jaad.2021.06.292","article-title":"Difamilast a topical PDE4 inhibitor: phase 3 trials in Japanese adult and pediatric patients with atopic dermatitis","volume":"85","author":"Tanaka","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0486|cit486","unstructured":"Comparison trial of OPA-15406 ointment in adult patients with atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-JapicCTI-194678"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0487|cit487","unstructured":"Comparison trial of OPA-15406 ointment in adult patients with atopic dermatitis syndrome clinicaltrials.gov\/show\/NCT03908970"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0488|cit488","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaad.2021.10.027","article-title":"Difamilast ointment in adult patients with atopic dermatitis: a phase 3 randomized, double-blind, vehicle-controlled trial","volume":"86","author":"Saeki","year":"2022","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0489|cit489","doi-asserted-by":"crossref","first-page":"AB67","DOI":"10.1016\/j.jaad.2021.06.292","article-title":"Difamilast, a topical PDE4 inhibitor: phase 3 trials in Japanese adult and pediatric patients with atopic dermatitis","volume":"85","author":"Tanaka","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0490|cit490","first-page":"e47-e48","article-title":"Does early effective topical treatment of atopic dermatitis in toddlers with either corticosteroids or tacrolimus affect early sensitization?","volume":"179","author":"Ahola","year":"2018","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0491|cit491","first-page":"1","article-title":"Are infants and toddlers with moderate-to-severe atopic dermatitis undertreated? Experiences of a Finnish tertiary care hospital","volume":"101","author":"Antti","year":"2021","journal-title":"Acta Dermato-Venereologica"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0492|cit492","doi-asserted-by":"crossref","first-page":"550-6","DOI":"10.1111\/apa.15001","article-title":"Young children with moderate-to-severe atopic dermatitis can be treated safely and effectively with either topical tacrolimus or mild corticosteroids","volume":"109","author":"Perala","year":"2020","journal-title":"Acta Paediatrica"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0493|cit493","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/ced\/llad098","article-title":"Topical tacrolimus and corticosteroids in childhood moderate-to-severe atopic dermatitis with impact on airways: a long-term randomized open-label study","volume":"48","author":"Perala","year":"2023","journal-title":"Clinical and Experimental Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0494|cit494","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/ced.15024","article-title":"Safety of tacrolimus 0.03% and 0.1% ointments in young children with atopic dermatitis: a 36-month follow-up study","volume":"47","author":"Salava","year":"2022","journal-title":"Clinical and Experimental Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0495|cit495","first-page":"3","article-title":"First experiences with 1% pimecrolimus cream therapy in prevention of atopic eczema flares in children (Czechoslovakian)","volume":"79","author":"Salavec","year":"2004","journal-title":"Cesko-Slovenska Dermatologie"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0496|cit496","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1365-2133.1962.tb13464.x","article-title":"Fluocinolone acetonide. A new steroid preparation for topical use","volume":"74","author":"Samman","year":"1962","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0497|cit497","first-page":"84","article-title":"Evaluation of rebound phenomenon in children with atopic dermatitis treated with topical corticosteroids","volume":"35","author":"Sanabria-Silva","year":"1991","journal-title":"Dermatologia: Revista Mexicana"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0498|cit498","first-page":"5","article-title":"Betamethasone dipropionate in psoriasis and atopic dermatitis","volume":"40","author":"Savin","year":"1976","journal-title":"Connecticut Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0499|cit499","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1542\/peds.2004-2638","article-title":"Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study","volume":"116","author":"Schachner","year":"2005","journal-title":"Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0500|cit500","first-page":"230","article-title":"Comparative clinical trial of a new trihalogenated dermatocorticoid (halometasone) versus betamethasone dipropionate (German)","volume":"58","author":"Schuppli","year":"1983","journal-title":"Zeitschrift fur Hautkrankheiten"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0501|cit501","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0149-2918(97)80095-1","article-title":"Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis","volume":"19","author":"Sears","year":"1997","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0502|cit502","first-page":"89","article-title":"Comparative efficacy of hydrocortisone valerate 0.2 percent ointment in the treatment of atopic dermatitis","volume":"32","author":"Sefton","year":"1983","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0503|cit503","first-page":"282","article-title":"Clinical evaluation of hydrocortisone valerate 0.2% ointment","volume":"6","author":"Sefton","year":"1984","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0504|cit504","first-page":"89","article-title":"Comparative efficacy of hydrocortisone valerate 0.2 percent ointment in the treatment of atopic dermatitis","volume":"32","author":"Sefton","year":"1983","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0505|cit505","first-page":"282","article-title":"Clinical evaluation of hydrocortisone valerate 0.2% ointment","volume":"6","author":"Sefton","year":"1984","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0506|cit506","first-page":"89","article-title":"Comparative efficacy of hydrocortisone valerate 0.2 percent ointment in the treatment of atopic dermatitis","volume":"32","author":"Sefton","year":"1983","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0507|cit507","first-page":"282","article-title":"Clinical evaluation of hydrocortisone valerate 0.2% ointment","volume":"6","author":"Sefton","year":"1984","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0508|cit508","first-page":"89","article-title":"Comparative efficacy of hydrocortisone valerate 0.2 percent ointment in the treatment of atopic dermatitis","volume":"32","author":"Sefton","year":"1983","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0509|cit509","first-page":"282","article-title":"Clinical evaluation of hydrocortisone valerate 0.2% ointment","volume":"6","author":"Sefton","year":"1984","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0510|cit510","unstructured":"A 6-month, randomized, multicenter, parallel-group, double blind, vehicle-controlled study to evaluate the efficacy and safety of pimecrolimus cream 1% twice daily vs standard of care in the management of mild to severe atopic dermatitis in children 3 months to 11 years www.novctrd.com\/ctrdweb\/trialresult\/trialresults\/pdf?trialResultId=1463"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0511|cit511","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/09546630600647297","article-title":"Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis","volume":"17","author":"Siegfried","year":"2006","journal-title":"Journal of Dermatological Treatment"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0512|cit512","first-page":"S93","article-title":"Pimecrolimus cream 1% rapidly reduces the extent and severity of atopic dermatitis in infants and children, including head-and-neck involvement: post hoc analysis of a 6-month, randomized, vehicle-controlled trial","volume":"132","author":"Siegfried","year":"2012","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0513|cit513","unstructured":"A 26-week, randomized, multicenter, parallel-group, double-blind, vehicle-controlled study to evaluate the incidence of atopic dermatitis flares when pimecrolimus cream 1% is used at the first signs and\/or symptoms of atopic dermatitis and its safety and tolerability in adults 18 years of age and older https:\/\/www.novctrd.com\/ctrdweb\/trialresult\/trialresults\/pdf?trialResultId=1954"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0514|cit514","first-page":"2","article-title":"Effective management of atopic eczema with early intervention: results from a randomized vehicle-controlled trial of pimecrolimus cream 1% in children and adolescents","volume":"19","author":"Sigurgeirsson","year":"2005","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0515|cit515","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/j.1468-3083.2008.02785.x","article-title":"Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis","volume":"22","author":"Sigurgeirsson","year":"2008","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0516|cit516","first-page":"AB56","article-title":"A 5-year randomized study to investigate the safety of pimecrolimus cream 1% in the treatment of mild-to-moderate atopic dermatitis in infants: clinical safety","volume":"64","author":"Bishop","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0517|cit517","first-page":"679","article-title":"Efficacy and safety of pimecrolimus cream 1% in infants with mild-to-moderate atopic dermatitis: a randomized 5-year study","volume":"29","author":"Johnson","year":"2012","journal-title":"Pediatric Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0518|cit518","unstructured":"5-year safety study of pimecrolimus cream 1% in infants 3-12 months of age with mild to moderate atopic dermatitis clinicaltrials.gov\/show\/NCT00120523"},{"issue":"S96","key":"10.1002\/14651858.CD015064.pub2-BIB0519|cit519","first-page":"16","article-title":"Efficacy and safety of pimecrolimus cream 1% in infants with mild-to-moderate atopic dermatitis: a randomised 5-year study","volume":"67","author":"Nieto","year":"2012","journal-title":"Allergy"},{"issue":"2 Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0520|cit520","first-page":"AB58","article-title":"A 5-year randomized study to investigate the safety of pimecrolimus cream 1% in the treatment of mild-to-moderate atopic dermatitis in infants: immunologic parameters","volume":"64","author":"Poulin","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0521|cit521","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1542\/peds.2014-1990","article-title":"Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial","volume":"135","author":"Sigurgeirsson","year":"2015","journal-title":"Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0522|cit522","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bjd.15849","article-title":"A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal - author response","volume":"177","author":"Sigurgeirsson","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0523|cit523","first-page":"304","article-title":"Topical 0.03% tacrolimus ointment, 0.05% clobetasone butyrate cream alone and their combination in older children with atopic dermatitis - an open randomized comparative study","volume":"15","author":"Sikder Md","year":"2005","journal-title":"Journal of Pakistan Association of Dermatologists"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0524|cit524","first-page":"37","article-title":"Pimecrolimus cream 1% once-daily maintenance therapy for the prevention of relapse in mild to moderate atopic dermatitis in adults","volume":"153","author":"Smith","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD015064.pub2-BIB0525|cit525","first-page":"549-52","article-title":"Treatment of atopic dermatitis with topical corticosteroids in children. Efficacy and systemic effects of triamcinolone acetonide and alclometasone dipropionate","volume":"3","author":"Smitt","year":"1993","journal-title":"European Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0526|cit526","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2133.1974.tb06385.x","article-title":"The clinical evaluation of a new topical corticosteroid, clobetasol propionate. An international controlled trial","volume":"90","author":"Sparkes","year":"1974","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0527|cit527","unstructured":"Combination therapy for atopic dermatitis clinicaltrials.gov\/show\/NCT00119158"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0528|cit528","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1365-2133.2007.08001.x","article-title":"Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial","volume":"157","author":"Spergel","year":"2007","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0529|cit529","unstructured":"Safety and efficacy of pimecrolimus cream 1% in atopic disease modification clinicaltrials.gov\/show\/NCT00124709"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0530|cit530","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/pde.12867","article-title":"Study of the atopic march: development of atopic comorbidities","volume":"33","author":"Schneider","year":"2016","journal-title":"Pediatric Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0531|cit531","doi-asserted-by":"crossref","first-page":"e1530-8","DOI":"10.1542\/peds.2015-1444","article-title":"Food allergy in infants with atopic dermatitis: limitations of food-specific IgE measurements","volume":"136","author":"Spergel","year":"2015","journal-title":"Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0532|cit532","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1365-2133.1994.tb08556.x","article-title":"Local steroid therapy and bacterial skin flora in atopic dermatitis","volume":"131","author":"Stalder","year":"1994","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0533|cit533","unstructured":"Efficacy and safety of AN2728 topical ointment to treat adolescents with atopic dermatitis clinicaltrials.gov\/show\/NCT01602341"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0534|cit534","first-page":"16","article-title":"Safety and efficacy of AN2728 topical ointment, 2% and 0.5%, in a phase 2 dose-ranging study of adolescents with mild-to-moderate atopic dermatitis","volume":"54","author":"Stein-Gold","year":"2013","journal-title":"Australasian Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0535|cit535","first-page":"14","article-title":"Safety and efficacy of AN2728 topical ointment, 2% and 0.5%, in a phase 2 dose-ranging study of adolescents with mild-to-moderate atopic dermatitis","volume":"12","author":"Stein-Gold","year":"2014","journal-title":"Journal of the German Society of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD015064.pub2-BIB0536|cit536","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-4362.1981.tb00847.x","article-title":"A comparison of single and multiple applications of halcinonide cream","volume":"20","author":"Sudilovsky","year":"1981","journal-title":"International Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0537|cit537","doi-asserted-by":"crossref","first-page":"144","DOI":"10.5021\/ad.2012.24.2.144","article-title":"A randomized, open-label, multicenter trial of topical tacrolimus for the treatment of pruritis in patients with atopic dermatitis","volume":"24","author":"Takeuchi","year":"2012","journal-title":"Annals of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0538|cit538","first-page":"704","article-title":"A randomized, multicenter trial of topical tacrolimus for treatment of pruritus in patients with atopic dermatitis","volume":"89","author":"Takeuchi","year":"2009","journal-title":"Acta Dermato-Venereologica"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0539|cit539","first-page":"218","article-title":"Treatment effects of 1% pimecrolimus ointment formulations in adult patients with atopic dermatitis","volume":"19","author":"Thaci","year":"2005","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0540|cit540","first-page":"19","article-title":"A comparison of twice-daily and once-daily administration of fluticasone propionate cream, 0.05%, in the treatment of eczema","volume":"57","author":"Tharp","year":"1996","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0541|cit541","first-page":"245","article-title":"Combination atopic dermatitis therapy reduces adverse effects","volume":"39","year":"2004","journal-title":"Formulary (Cleveland, Ohio)"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0542|cit542","first-page":"161","article-title":"Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis","volume":"72","author":"Torok","year":"2003","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0543|cit543","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/09546639709160281","article-title":"Hydrocortisone buteprate versus betamethasone valerate for once-daily treatment of atopic dermatitis","volume":"8","author":"Traulsen","year":"1997","journal-title":"Journal of Dermatological Treatment"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0544|cit544","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/09546639709160281","article-title":"Hydrocortisone buteprate versus betamethasone valerate for once-daily treatment of atopic dermatitis","volume":"8","author":"Traulsen","year":"1997","journal-title":"Journal of Dermatological Treatment"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0545|cit545","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1440-0960.1975.tb00715.x","article-title":"Clinical comparison of halacinonide and betamethasone valerate in common dermatoses","volume":"16","author":"Turnbull","year":"1975","journal-title":"Australasian Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0546|cit546","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1468-3083.2010.03845.x","article-title":"Comparative trial of moisturizer containing licochalcone A vs. hydrocortisone lotion in the treatment of childhood atopic dermatitis: a pilot study","volume":"25","author":"Udompataikul","year":"2011","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"36","key":"10.1002\/14651858.CD015064.pub2-BIB0547|cit547","first-page":"741","article-title":"Treatment of acute episodes of atopic dermatitis. Double-blind comparative study with 0.05% halometasone cream versus 0.25% prednicarbate cream","volume":"109","author":"Ulrich","year":"1991","journal-title":"Fortschritte der Medizin"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0548|cit548","first-page":"177","article-title":"Double-blind study on the efficacy and safety of alclomethasone cream in the treatment of atopic dermatitis","volume":"58","author":"Van Del Rey","year":"1983","journal-title":"Anais Brasileiros de Dermatologia"},{"issue":"7","key":"10.1002\/14651858.CD015064.pub2-BIB0549|cit549","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/00007611-197607000-00017","article-title":"Betamethasone dipropionate ointment in the treatment of psoriasis and atopic dermatitis: a double-blind study","volume":"69","author":"Vanderploeg","year":"1976","journal-title":"Southern Medical Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0550|cit550","doi-asserted-by":"crossref","first-page":"S197","DOI":"10.1016\/S0926-9959(98)95292-8","article-title":"Topical treatment with the ascomycin macrolactam SDZ ASM 981 is effective in atopic dermatitis","volume":"11","author":"Van Leent","year":"1998","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0551|cit551","first-page":"234","article-title":"Topical treatment with the macrolactam SDZ ASM 981 is effective in atopic dermatitis","volume":"38","author":"Van Leent","year":"1997","journal-title":"Australasian Journal of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD015064.pub2-BIB0552|cit552","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/archderm.134.7.805","article-title":"Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis","volume":"134","author":"Van Leent","year":"1998","journal-title":"Archives of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0553|cit553","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/030006058401200509","article-title":"Hydrocortisone 17-butyrate (Locoid) 0.1% cream versus hydrocortisone (Uniderm) 1% cream in the treatment of children suffering from atopic dermatitis","volume":"12","author":"Veien","year":"1984","journal-title":"Journal of International Medical Research"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0554|cit554","first-page":"P0279","article-title":"The cost effectiveness of pimecrolimus (SDZ ASM 981) topical cream 1% and corticosteroids in the treatment of atopic dermatitis","volume":"129","author":"Verboom","year":"2002","journal-title":"Annales de Dermatologie et de Venereologie"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0555|cit555","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/0190-9622(91)70092-G","article-title":"Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis","volume":"24","author":"Vernon","year":"1991","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0556|cit556","unstructured":"Double-blind, randomised, active and placebo controlled study to assess the clinical efficacy, skin tolerability and pharmacological activity of a new topical compound (UR-1505 0.5%, 1% and 2%) in patients with mild to moderate atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2007-002550-27-FR"},{"issue":"9","key":"10.1002\/14651858.CD015064.pub2-BIB0557|cit557","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.clinthera.2015.06.005","article-title":"Safety and activity of UR-1505 in atopic dermatitis: a randomized, double=blind phase II exploratory trial","volume":"37","author":"Vives","year":"2015","journal-title":"Clinical Therapeutics"},{"issue":"Suppl s2","key":"10.1002\/14651858.CD015064.pub2-BIB0558|cit558","first-page":"110","article-title":"Pimecrolimus (Elidel\u00ae, SDZ ASM 981) cream 1% reduces the need for topical corticosteroids to treat atopic eczema in children","volume":"15","author":"De Prost","year":"2001","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0559|cit559","doi-asserted-by":"crossref","first-page":"133-9","DOI":"10.2165\/00128071-200607020-00006","article-title":"Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age","volume":"7","author":"Ellis","year":"2006","journal-title":"American Journal of Clinical Dermatology"},{"issue":"Suppl 1 Pt 2","key":"10.1002\/14651858.CD015064.pub2-BIB0560|cit560","first-page":"1S410","article-title":"Pimecrolimus (SDZ ASM 981) cream 1% can be safely used in conjunction with topical corticosteroids: results of a long term paediatric study","volume":"129","author":"Goodfield","year":"2002","journal-title":"Annales de Dermatologie et de Venereologie"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0561|cit561","doi-asserted-by":"crossref","first-page":"248-54","DOI":"10.1111\/j.1468-3083.2006.01383.x","article-title":"Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel\u00ae, SDZ ASM 981): impact on quality of life and health-related quality of life","volume":"20","author":"McKenna","year":"2006","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"12","key":"10.1002\/14651858.CD015064.pub2-BIB0562|cit562","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1365-4632.2004.02121.x","article-title":"Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis","volume":"43","author":"Papp","year":"2004","journal-title":"International Journal of Dermatology"},{"issue":"1 Pt 1","key":"10.1002\/14651858.CD015064.pub2-BIB0563|cit563","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1542\/peds.110.1.e2","article-title":"Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children","volume":"110","author":"Wahn","year":"2002","journal-title":"Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0564|cit564","first-page":"533","article-title":"SDZ ASM 981 cream 1%: a new approach to long-term management of atopic dermatitis","volume":"117","author":"Wahn","year":"2001","journal-title":"Journal of Investigative Dermatology"},{"issue":"Suppl 96","key":"10.1002\/14651858.CD015064.pub2-BIB0565|cit565","first-page":"634","article-title":"Comparison study of moisturiser containing licochalcone A and 1% hydrocortisone in the treatment of childhood atopic dermatitis","volume":"67","author":"Wananukul","year":"2012","journal-title":"Allergy"},{"issue":"9","key":"10.1002\/14651858.CD015064.pub2-BIB0566|cit566","first-page":"1135","article-title":"Randomized, double-blind, split-side, comparison study of moisturizer containing licochalcone A and 1% hydrocortisone in the treatment of childhood atopic dermatitis","volume":"96","author":"Wananukul","year":"2013","journal-title":"Chotmaihet Thangphaet [Journal of the Medical Association of Thailand]"},{"issue":"Suppl 1 Pt 2","key":"10.1002\/14651858.CD015064.pub2-BIB0567|cit567","first-page":"1S426","article-title":"Pimecrolimus (SDZ ASM 981) in the treatment of paediatric atopic eczema: benefit to quality of life and health-related quality of life","volume":"129","author":"Whalley","year":"2002","journal-title":"Annales de Dermatologie et de Venereologie"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0568|cit568","unstructured":"Whalley D Pimecrolimus (SDZ ASM 981) in the treatment of atopic eczema: benefit to quality of life among infants 20th World Congress of Dermatology 2002 P0283"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0569|cit569","unstructured":"Whalley D Pimecrolimus (SDZ ASM 981) in the treatment of paediatric atopic eczema: benefit to quality of life and health-related quality of life 20th World Congress of Dermatology 2002 P0284"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD015064.pub2-BIB0570|cit570","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0190-9622(98)70080-5","article-title":"Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis","volume":"39","author":"Wolkerstorfer","year":"1998","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0571|cit571","unstructured":"VANOS cream and skin barrier function clinicaltrials.gov\/ct2\/show\/NCT00819507"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0572|cit572","first-page":"171","article-title":"Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis","volume":"10","author":"Woods","year":"2011","journal-title":"Journal of Drugs in Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0573|cit573","first-page":"23","article-title":"A new corticosteroid for moderate\/severe dermatoses","volume":"82","author":"Wortzel","year":"1975","journal-title":"Clinical Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0574|cit574","first-page":"23","article-title":"A new corticosteroid for moderate\/severe dermatoses","volume":"82","author":"Wortzel","year":"1975","journal-title":"Clinical Medicine"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0575|cit575","first-page":"23","article-title":"A new corticosteroid for moderate\/severe dermatoses","volume":"82","author":"Wortzel","year":"1975","journal-title":"Clinical Medicine"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0576|cit576","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2133.2012.11177.x","article-title":"Efficacy and safety of 15(R\/S)-methyl-lipoxin A4 in topical treatment of infantile eczema","volume":"168","author":"Wu","year":"2013","journal-title":"British Journal of Dermatology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0577|cit577","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000257893","article-title":"Clinical experiences with hydrocortisone 17-butyrate","volume":"152","author":"Yasuda","year":"1976","journal-title":"Dermatologica"},{"issue":"6 Pt 2","key":"10.1002\/14651858.CD015064.pub2-BIB0578|cit578","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/0190-9622(91)70318-V","article-title":"Double-blind, comparative clinical trials with halobetasol propionate cream in patients with atopic dermatitis","volume":"25","author":"Yawalkar","year":"1991","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"10","key":"10.1002\/14651858.CD015064.pub2-BIB0579|cit579","first-page":"1108-12","article-title":"Crisaborole topical ointment, 2% in adults with atopic dermatitis: a phase 2a, vehicle-controlled, proof-of-concept study","volume":"14","author":"Murrell","year":"2015","journal-title":"Journal of Drugs in Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0580|cit580","unstructured":"Efficacy and safety of AN2898 and AN2728 topical ointments to treat mild-to-moderate atopic dermatitis clinicaltrials.gov\/show\/NCT01301508"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0581|cit581","article-title":"Crisaborole ointment improves global atopic dermatitis severity and provides early relief in pruritus: pooled results from two phase 3 clinical trials","volume":"57","author":"Paller","year":"2017","journal-title":"Journal of the American Pharmacists Association"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0582|cit582","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/j.jdermsci.2012.11.402","article-title":"AN2728 and AN2898 ointments demonstrate safety and efficacy in a bilateral study of atopic dermatitis","volume":"69","author":"Zane","year":"2013","journal-title":"Journal of Dermatological Science"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0583|cit583","first-page":"A69","article-title":"Boron-based AN2728 and AN2898 ointments demonstrate safety and efficacy in a phase 2A bilateral study of mild-to-moderate atopic dermatitis","volume":"20","author":"Zane","year":"2012","journal-title":"Wound Repair and Regeneration"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0584|cit584","first-page":"S90","article-title":"Safety and efficacy of AN2728 and AN2898 ointments in a phase 2a bilateral study of mild to-moderate atopic dermatitis","volume":"132","author":"Zane","year":"2012","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0585|cit585","unstructured":"A 24-week, randomized, multicenter, parallel-group, double-blind, vehicle-controlled study on pimecrolimus cream 1% assessing the steroid-sparing effect in the long term management of pediatric patients with severe atopic dermatitis www.novctrd.com\/ctrdweb\/trialresult\/trialresults\/pdf?trialResultId=1956"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0586|cit586","unstructured":"Steroid-sparing effect with pimecrolimus in pediatric patients with atopic dermatitis clinicaltrials.gov\/show\/NCT00351052"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0587|cit587","doi-asserted-by":"crossref","first-page":"718-21","DOI":"10.1111\/j.1468-3083.2008.02586.x","article-title":"Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease","volume":"22","author":"Zuberbier","year":"2008","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0588|cit588","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1159\/000107627","article-title":"Steroid-sparing effect of pimecrolimus cream 1% in children with severe atopic dermatitis","volume":"215","author":"Zuberbier","year":"2007","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0589|cit589","first-page":"1","article-title":"Pimecrolimus cream 1% in the long term management of severe pediatric atopic eczema","volume":"19","author":"Zuberbier","year":"2005","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0590|cit590","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/030006057600400404","article-title":"A double-blind comparison of a new combination (halcinonide neomycin amphotericin) and active controls in cutaneous candidiasis and steroid responsive dermatoses","volume":"4","author":"Abdel-Aal","year":"1976","journal-title":"Journal of International Medical Research"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0591|cit591","doi-asserted-by":"crossref","first-page":"426-8","DOI":"10.1111\/j.1365-2133.2012.11052.x","article-title":"The effect of pimecrolimus on innate immunity in subjects with atopic dermatitis: a double-blind, randomized, vehicle-controlled study","volume":"168","author":"Afshar","year":"2013","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0592|cit592","first-page":"36-42","article-title":"Comparative double blind study of two anti-eczema creams","volume":"9","author":"Padilla","year":"1982","journal-title":"Investigacion Medica Internacional"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0593|cit593","doi-asserted-by":"crossref","first-page":"AB120","DOI":"10.1016\/j.jaad.2018.05.505","article-title":"Efficacy and safety of HAT1, a novel topical therapeutic: results from randomized, double-blind, placebo-controlled clinical trials in psoriasis and atopic dermatitis","volume":"79","author":"Alex","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0594|cit594","first-page":"177","article-title":"A preliminary clinical trial of hydrocortisone-17-butyrate","volume":"27","author":"Alexander","year":"1973","journal-title":"British Journal of Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0595|cit595","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/pde.15117","article-title":"A randomized, observer-blind, vehicle-control, multi-center clinical investigation for assessing the efficacy and tolerability of a 1% ectoine and hyaluronic acid 0.1%-containing medical device in pediatric patients with mild-to-moderate atopic dermatitis","volume":"40","author":"Alexopoulos","year":"2023","journal-title":"Pediatric Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0596|cit596","first-page":"255-60","article-title":"Mometasone furoate 0.1% once a day in allergic contact dermatitis and in atopic dermatitis: controlled study versus betamethasone valerate","volume":"18","author":"Amerio","year":"1998","journal-title":"Dermatologia Clinica"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0597|cit597","doi-asserted-by":"crossref","unstructured":"Abstractband der DDG kompakt und praxisnah Journal of the German Society of Dermatology (Conference: DDG KOMPAKT und PRAXISNAH, 2018) 2018 16 Supplement 1","DOI":"10.1055\/s-0043-119913"},{"issue":"10","key":"10.1002\/14651858.CD015064.pub2-BIB0598|cit598","first-page":"585","article-title":"A new topical corticosteroid: controlled clinical study in dermatological patients","volume":"111","author":"Arico","year":"1976","journal-title":"Giornale Italiano di Dermatologia\/Minerva Dermatologica"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0599|cit599","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2230.2006.02313.x","article-title":"Blinded side-to-side comparison of topical corticosteroid and tacrolimus ointment in children with moderate to severe atopic dermatitis","volume":"32","author":"Arkwright","year":"2007","journal-title":"Clinical and Experimental Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0600|cit600","unstructured":"Side by side comparison of 0.03% tacrolimus ointment (Protopic) versus usual topical steroid treatment in children with atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=ISRCTN65507338"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0601|cit601","first-page":"824","article-title":"A well-controlled comparative study for the clinical evaluation of new topical corticosteroid difluprednate (DFBA, MYSER) and dexamethasone dipropionate (DDP, METHADERM)","volume":"32","author":"Asada","year":"1990","journal-title":"Skin Research"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0602|cit602","first-page":"45","article-title":"Beclomethasone dipropionate compared with betamethasone-17-valerate in the treatment of inflammatory dermatoses","volume":"24","author":"Ashurst","year":"1970","journal-title":"British Journal of Clinical Practice"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0603|cit603","first-page":"263","article-title":"Hydrocortisone 17-butyrate, a new synthetic topical corticosteroid","volume":"26","author":"Ashurst","year":"1972","journal-title":"British Journal of Clinical Practice"},{"issue":"10","key":"10.1002\/14651858.CD015064.pub2-BIB0604|cit604","first-page":"383","article-title":"A test of the half-side comparative design in the clinical evaluation of topical steroids, using diflucortolone and betamethasone creams","volume":"39","author":"August","year":"1985","journal-title":"British Journal of Clinical Practice"},{"issue":"12","key":"10.1002\/14651858.CD015064.pub2-BIB0605|cit605","first-page":"2075","article-title":"A trial comparing two corticoid preparations for the treatment of eczematous skin disorders","volume":"22","author":"Aussems","year":"1972","journal-title":"Arzneimittel-Forschung"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0606|cit606","first-page":"351","article-title":"Clinical trial of an ointment containing corticosteroids associated with nitrofurazone and vitamins A and D","volume":"65","author":"Belliboni","year":"1964","journal-title":"Hospital"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0607|cit607","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1046\/j.1365-4362.1999.00505.x","article-title":"The addition of topical doxepin to corticosteroid therapy: an improved treatment regimen for atopic dermatitis","volume":"38","author":"Berberian","year":"1999","journal-title":"International Journal of Dermatology"},{"issue":"36","key":"10.1002\/14651858.CD015064.pub2-BIB0608|cit608","first-page":"4477","article-title":"Double-blind comparison of hydrocortisone butyrate and halcinonide","volume":"89","author":"Bergoend","year":"1982","journal-title":"Gazette Medicale de France"},{"issue":"7403","key":"10.1002\/14651858.CD015064.pub2-BIB0609|cit609","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1136\/bmj.326.7403.1367","article-title":"Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double-blind, parallel group study","volume":"326","author":"Berth-Jones","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"Suppl 221","key":"10.1002\/14651858.CD015064.pub2-BIB0610|cit610","first-page":"63","article-title":"Efficacy and safety of baricitinib in combination with topical corticosteroids in moderate-to-severe atopic dermatitis patients with cyclosporine failure, intolerance, or contraindication: 52-week results from the Breeze-Ad 4 trial","volume":"101","author":"Bieber","year":"2021","journal-title":"Acta Dermato-Venereologica"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0611|cit611","first-page":"35","article-title":"Comparison of fluocinonide in a double-blind study with betamethasone valerate","volume":"14","author":"Binder","year":"1972","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0612|cit612","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1046\/j.1365-2133.2002.46296.x","article-title":"Stealth triamcinolone acetonide in a phytocosmetic cream","volume":"146","author":"Bircher","year":"2002","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0613|cit613","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1365-2133.1995.tb02711.x","article-title":"Fluticasone propionate 0.05% cream in the treatment of atopic eczema: a multicentre study comparing once-daily treatment and once-daily vehicle cream application versus twice-daily treatment","volume":"133","author":"Bleehen","year":"1995","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0614|cit614","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40257-022-00734-8","article-title":"Impact of ruxolitinib cream on work productivity and activity impairment and associated indirect costs in patients with atopic dermatitis: pooled results from two phase III studies","volume":"24","author":"Bloudek","year":"2023","journal-title":"American Journal of Clinical Dermatology"},{"issue":"10 A Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0615|cit615","first-page":"S97","article-title":"Effects of ruxolitinib cream on work productivity and activity impairment in patients with atopic dermatitis: 52-week pooled results from two phase 3 studies","volume":"28","author":"Eichenfield","year":"2022","journal-title":"Journal of Managed Care and Speciality Pharmacy"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0616|cit616","first-page":"e126","article-title":"Effects of ruxolitinib cream on work productivity and activity impairment in patients with atopic dermatitis: 52-week pooled results from two phase III studies","volume":"187","author":"Eichenfield","year":"2022","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0617|cit617","doi-asserted-by":"crossref","first-page":"AB69","DOI":"10.1016\/j.jaad.2006.10.336","article-title":"A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP nonsteroidal cream in the management of mild to moderate atopic dermatitis in infants and children","volume":"56","author":"Boguniewicz","year":"2007","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0618|cit618","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jpeds.2007.11.031","article-title":"MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled study","volume":"152","author":"Boguniewicz","year":"2008","journal-title":"Journal of Pediatrics"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0619|cit619","first-page":"AB88","article-title":"Tacrolimus ointment with and without topical steroids in patients with moderate to severe atopic dermatitis","volume":"54","author":"Breneman","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0620|cit620","first-page":"45","article-title":"Double-blind comparative trial of betamethasone 17-valerate and fluocinolone acetonide ointments","volume":"55","author":"Buckley","year":"1964","journal-title":"Journal of the Irish Medical Association"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0621|cit621","first-page":"330","article-title":"Trial of treatment of several dermatoses with betamethasone","volume":"70","author":"Barriere","year":"1963","journal-title":"Bulletin de la Societe Francaise de Dermatologie et de Syphiligraphie"},{"issue":"1-2","key":"10.1002\/14651858.CD015064.pub2-BIB0622|cit622","first-page":"59","article-title":"A comparative intraindividual double-blind assay between prednicarbate and fluocortolone in the management of atopic dermatitis (Spanish)","volume":"87","author":"Camacho","year":"1996","journal-title":"Actas Dermo-Sifiliograficas"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0623|cit623","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1365-2230.2006.02214.x","article-title":"Expression of adhesion molecules in atopic dermatitis is reduced by tacrolimus, but not by hydrocortisone butyrate: a randomized immunohistochemical study","volume":"31","author":"Caproni","year":"2006","journal-title":"Clinical and Experimental Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0624|cit624","article-title":"Results of the use of diflorasone diacetate ointment in dermatology","volume":"117","author":"Chiarenza","year":"1982","journal-title":"Giornale Italiano di Dermatologia e Venereologia"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0625|cit625","unstructured":"Clinical study of CAPCS gel in the treatment of atopic dermatitis http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR2000030216"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0626|cit626","unstructured":"Clinical research of treatment of atopic dermatitis with FuRui moisturizing cream combining with glucocorticoid topical http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR2000030246"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0627|cit627","unstructured":"Colpas PT Miyashiro CA Schalka S Neto AG Comparative study of non-inferiority of a moisturizer cream versus 1% hydrocortisone cream in children with atopic dermatitis 24th World Congress of Dermatology, conference abstract (https:\/\/www.wcd2019milan-dl.org\/abstract-book\/assets\/html\/abstracts\/05-atopic-eczema-dermatitis.html)"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0628|cit628","first-page":"AB84","article-title":"Vaccination response is equivalent in children with atopic dermatitis treated with 0.03% tacrolimus ointment or a hydrocortisone ointment regimen","volume":"54","author":"Cranswick","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0629|cit629","first-page":"57","article-title":"The effect of a complex emollient cream containing 5% urea, ceramide 3 and lactic acid, compared with a simple emollient, on the skin barrier in older people with dry skin","volume":"1","author":"Danby","year":"2014","journal-title":"British Journal of Dermatology"},{"issue":"9 Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0630|cit630","first-page":"743","article-title":"Clinical and biological trial of difluprednate in cream and gel forms in pediatric dermatology","volume":"22","author":"Desmons","year":"1977","journal-title":"Lille Medical"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0631|cit631","first-page":"471","article-title":"Non steroid treatment for eczema: results from a controlled and randomized study","volume":"148","author":"De Waure","year":"2013","journal-title":"Giornale Italiano di Dermatologia e Venereologia"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0632|cit632","first-page":"58-60","article-title":"Evaluation of the efficacy of topical doxepin, alone or in combination with topical corticosteroid, in the management of atopic dermatitis","volume":"44","author":"Dhar Smalakar","year":"1999","journal-title":"Indian Journal of Dermatology"},{"issue":"1330","key":"10.1002\/14651858.CD015064.pub2-BIB0633|cit633","first-page":"561","article-title":"Treatment of chronic eczemas. The comparative efficacy of two creams","volume":"222","author":"Doherty","year":"1979","journal-title":"Practitioner"},{"issue":"2I (2 Pt 1)","key":"10.1002\/14651858.CD015064.pub2-BIB0634|cit634","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0190-9622(99)70051-4","article-title":"Pharmacokinetics of doxepin in subjects with pruritic atopic dermatitis","volume":"41","author":"Drake","year":"1999","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"56","key":"10.1002\/14651858.CD015064.pub2-BIB0635|cit635","first-page":"71","article-title":"Clinical trial of a mixture of neomycin, bacitracin, natamycin and dexamethasone","volume":"3","author":"Durand","year":"1975","journal-title":"Mediterranee Medicale"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0636|cit636","first-page":"344","article-title":"Multicenter comparison of fluocinolone acetonide in an emollient cream base with betamethasone valerate cream","volume":"22","author":"Elgart","year":"1978","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0637|cit637","unstructured":"Randomised, placebo-controlled, double-blind, efficacy study of the emollient V0034CR in addition to a moderately potent corticosteroid in the acute phase of treatment of atopic dermatitis in infants trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2005-002803-18-LV"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0638|cit638","unstructured":"A multicenter, randomized, intra-individual, double blind, vehicle-controlled study to evaluate the efficacy and safety of CD2027 ointment 9 \u00b5g\/g applied twice daily over 4 weeks in the treatment of target lesions in adults subjects with atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2009-010498-19-FR"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0639|cit639","unstructured":"A single-center, randomized, controlled, observer-blind, phase IV study to develop the atopic localized eczema regression test (ALERT) using marketed topical corticosteroid formulations of different strength and the calcineurin inhibitors pimecrolimus (Elidel\u00ae) in patients with a pre-disposition for atopic dermatitis - atopic localized eczema regression test (ALERT) trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2009-012194-35-DE"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0640|cit640","unstructured":"A phase II, single-center, randomized, controlled, double-blind study to assess effects on skin conditions and patient reported outcome of a topical formulation containing LAS41002 on lesional skin in patients with atopic eczema - AD trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2009-017407-28-DE"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0641|cit641","first-page":"14-9","article-title":"A multi-centre evaluation of locoid and celestona valerate creams in the treatment of patients suffering from non-infected eczema","volume":"31","author":"Gip","year":"1982","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"issue":"10","key":"10.1002\/14651858.CD015064.pub2-BIB0642|cit642","first-page":"505","article-title":"Treatment of eczemas and infected eczemas","volume":"21","author":"GP Medical Research Unit","year":"1967","journal-title":"British Journal of Clinical Practice"},{"issue":"1353","key":"10.1002\/14651858.CD015064.pub2-BIB0643|cit643","first-page":"410","article-title":"Topical corticosteroids in eczema. A comparative trial","volume":"225","author":"General Practitioner Research Group","year":"1981","journal-title":"Practitioner"},{"issue":"12","key":"10.1002\/14651858.CD015064.pub2-BIB0644|cit644","first-page":"1930","article-title":"Comparative trial of diflucortolon-21-valerate cream and hydrocortisone-17-butyrate cream in skin diseases","volume":"117","author":"Grejs","year":"1978","journal-title":"Therapie der Gegenwart"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0645|cit645","first-page":"179","article-title":"Comparative double-blind study between hydrocortisone 17-butyrate vs. betamethasone 17-valerate in the treatment of no infected dermatosis","volume":"33","author":"Guillot","year":"1983","journal-title":"Archivos Argentinos de Dermatologia"},{"issue":"8","key":"10.1002\/14651858.CD015064.pub2-BIB0646|cit646","first-page":"1015-6","article-title":"Crisaborole ointment provides early relief of pruritus in two phase 3 clinical trials in patients with mild or moderate atopic dermatitis","volume":"97","author":"Guttman-Yasky","year":"2017","journal-title":"Acta Dermato-Venereologica"},{"issue":"10 Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0647|cit647","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1016\/j.jid.2017.07.108","article-title":"Crisaborole ointment provides early relief of pruritus in two phase 3 clinical trials in patients with mild or moderate atopic dermatitis","volume":"137","author":"Guttman-Yassky","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"issue":"S1","key":"10.1002\/14651858.CD015064.pub2-BIB0648|cit648","first-page":"S33","article-title":"Crisaborole ointment provides early relief of pruritus in two phase 3 clinical trials in patients with mild or moderate atopic dermatitis","volume":"34","author":"Guttman-Yassky","year":"2017","journal-title":"Pediatric Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0649|cit649","doi-asserted-by":"crossref","first-page":"AB86","DOI":"10.1016\/j.jaad.2017.04.349","article-title":"Crisaborole ointment provides early relief of pruritus regardless of baseline disease severity in two phase 3 clinical trials in patients with mild or moderate AD","volume":"76","author":"Guttman-Yassky","year":"2017","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0650|cit650","first-page":"97","article-title":"Evaluation of the clinical effect of terfenadine in patients with atopic dermatitis. A comparison of strong corticosteroid therapy to mild topical corticosteroid combined with terfenadine administration therapy","volume":"38","author":"Hamada","year":"1996","journal-title":"Skin Research"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0651|cit651","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3109\/09546639209092767","article-title":"The treatment of atopic dermatitis with methylprednisolone aceponate (MPA), a new topical corticosteroid","volume":"3","author":"Haneke","year":"1992","journal-title":"Journal of Dermatological Treatment"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0652|cit652","first-page":"155","article-title":"Effect of herbal cream containing fumaria officinalis and silymarin for treatment of eczema: a randomized double-blind controlled clinical trial","volume":"12","author":"Iraji","year":"2022","journal-title":"Avicenna Journal of Phytomedicine"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0653|cit653","unstructured":"The impact of Althaea officinalis formulation on controlling the symptoms of atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=IRCT2016102323235N5"},{"issue":"21","key":"10.1002\/14651858.CD015064.pub2-BIB0654|cit654","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.3390\/jcm11216477","article-title":"Proactive versus rank-down topical corticosteroid therapy for maintenance of remission in pediatric atopic dermatitis: a randomized, open-label, active-controlled, parallel-group study (Anticipate study)","volume":"11","author":"Kamiya","year":"2022","journal-title":"Journal of Clinical Medicine"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0655|cit655","first-page":"324","article-title":"Fluocinide gel in atopic dermatitis","volume":"16","author":"Kanof","year":"1975","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"3 II","key":"10.1002\/14651858.CD015064.pub2-BIB0656|cit656","first-page":"446-50","article-title":"Local treatment of non-infected bilateral eczema with Locoid (TM) and Celestoderm (TM): a double-blind comparison","volume":"31","author":"Kassis","year":"1982","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"8","key":"10.1002\/14651858.CD015064.pub2-BIB0657|cit657","first-page":"463-8","article-title":"Therapeutic action of a new non-steroid drug (bufexamac) in the treatment of inflammatory dermatologic diseases. Double-blind clinical study","volume":"53","author":"Katsambas","year":"1973","journal-title":"Bruxelles Medical"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0658|cit658","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5021\/ad.2013.25.1.17","article-title":"The clinical efficacy of mometason furoate in multi-lamellar emulsion for eczema: a double-blinded crossover study","volume":"25","author":"Kim","year":"2013","journal-title":"Annals of Dermatology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB0659|cit659","first-page":"AB67","article-title":"Skin barrier function and hydration effects of hydrolipid cream alone and in combination in the treatment of mild to moderate atopic dermatitis: investigator-blinded, split-body, pilot study results","volume":"60","author":"Kircik","year":"2009","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0660|cit660","doi-asserted-by":"crossref","first-page":"558-64","DOI":"10.1080\/09546634.2018.1544407","article-title":"The effect of autophagy-enhancing peptide in moisturizer on atopic dermatitis: a randomized controlled trial","volume":"30","author":"Kwon","year":"2019","journal-title":"Journal of Dermatological Treatment"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD015064.pub2-BIB0661|cit661","first-page":"176","article-title":"Pharmacoeconomic evaluation of pimecrolimus in long-term management of atopic dermatitis in Belgium","volume":"17","author":"Lecomte","year":"2003","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"Suppl 221","key":"10.1002\/14651858.CD015064.pub2-BIB0662|cit662","first-page":"31","article-title":"Efficacy and safety of pac-14028 cream, a novel, topical, nonsteroidal, selective trpv1 antagonist in patients with mild to moderate atopic dermatitis: a phase iib randomized trial","volume":"101","author":"Lee","year":"2021","journal-title":"Acta Dermato-Venereologica"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0663|cit663","first-page":"18","article-title":"Treatment of psoriasis and other steroid responsive dermatoses. Trial of a new topical corticosteroid, betamethasone dipropionate (Diprosone)","volume":"11","author":"Leeming","year":"1974","journal-title":"Clinical Trials Journal"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0664|cit664","first-page":"247","article-title":"Evaluation of desoximetasone 0.25% emollient cream in atopic dermatitis","volume":"27","author":"Lessard","year":"1980","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0665|cit665","first-page":"104","article-title":"A randomised controlled trial of prednisone versus kenacomb compound cream in the treatment of dermatitis and eczema (Chinese)","volume":"29","author":"Liu","year":"2000","journal-title":"Journal of Clinical Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0666|cit666","first-page":"161-2","article-title":"Effect observation of eczema treated with combined traditional Chinese medicine for external use with cetirizine and hydrocortisone butyrate","volume":"15","author":"Liu","year":"2008","journal-title":"Southern China Journal of Dermato-Venereology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0667|cit667","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/09546634.2017.1401211","article-title":"A randomized, open-label study to evaluate an intermittent dosing regimen of fluticasone propionate 0.05% cream in combination with regular emollient skin care in reducing the risk of relapse in pediatric patients with stabilized atopic dermatitis","volume":"29","author":"Liu","year":"2018","journal-title":"Journal of Dermatological Treatment"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0668|cit668","doi-asserted-by":"crossref","first-page":"B27","DOI":"10.1016\/j.jid.2022.05.1015","article-title":"LB991 Clinical serum biomarker profiling in TRuE-AD1 and TRuE-AD2 studies after 8 weeks of treatment with ruxolitinib cream","volume":"142","author":"Liu","year":"2022","journal-title":"Journal of Investigative Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0669|cit669","first-page":"463","article-title":"Halcinonide-neomycin-nystatin in the treatment of dermatosis and cutaneous candidiasis","volume":"4","author":"Londono","year":"1976","journal-title":"Medicina Cutanea Ibero-Latino-Americana"},{"issue":"28","key":"10.1002\/14651858.CD015064.pub2-BIB0670|cit670","first-page":"1929-34","article-title":"On the treatment of eczema in practice. Combination therapy with econazole nitrate and triamcinolone acetonide","volume":"57","author":"Luderschmidt","year":"1981","journal-title":"Zeitschrift fur Allgemeinmedizin"},{"issue":"10","key":"10.1002\/14651858.CD015064.pub2-BIB0671|cit671","first-page":"463","article-title":"A new corticosteroid preparation tested in a double-blind trial","volume":"50","author":"Lundell","year":"1974","journal-title":"Zeitschrift fur Allgemeinmedizin"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0672|cit672","first-page":"17","article-title":"A double-blind trial of a new topical steroid formulation containing desoximetasone against fluocinolonacetonid cream","volume":"Suppl 2","author":"Lundell","year":"1975","journal-title":"Zeitschrift fur Hautkrankheiten"},{"issue":"8","key":"10.1002\/14651858.CD015064.pub2-BIB0673|cit673","first-page":"214","article-title":"A double-blind clinical study of bufexamac and fluocinolone acetonide in dermatitis","volume":"67","author":"Mackey","year":"1974","journal-title":"Journal of the Irish Medical Association"},{"issue":"7","key":"10.1002\/14651858.CD015064.pub2-BIB0674|cit674","first-page":"462-5","article-title":"Diflucortolone valerate and fluocinolone acetonide in eczema: a double-blind trial","volume":"1","author":"Mackey","year":"1977","journal-title":"Pharmatherapeutica"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0675|cit675","first-page":"581-3","article-title":"A double-blind trial with two corticoid preparations (skin salves) in eczematous skin complaints","volume":"69","author":"Manusov","year":"1974","journal-title":"Folha Medica"},{"issue":"1-2","key":"10.1002\/14651858.CD015064.pub2-BIB0676|cit676","first-page":"9-21","article-title":"Comparative study of mometasone furoate and betamethasone dipropionate in the treatment of atopic dermatitis","volume":"129","author":"Marchesi","year":"1994","journal-title":"Giornale Italiano di Dermatologia e Venereologia"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0677|cit677","first-page":"705-13","article-title":"Clinical effectiveness of topical 0.1% dexamethasone 17,21-dipropionate on lichenoid eczematous dermatitis. A comparison between 0.1% dexamethasone 17,21-dipropionate and 0.1% diflucortolone valerate under randomized comparative study","volume":"31","author":"Methaderm Study Group","year":"1989","journal-title":"Skin Research"},{"issue":"12","key":"10.1002\/14651858.CD015064.pub2-BIB0678|cit678","first-page":"5027-37","article-title":"Clinical study of methaderm cream on psoriasis, chronic eczema and atopic dermatitis: comparative study with 0.1% diflcortolone 21-valerate universal cream","volume":"18","author":"Miki","year":"1990","journal-title":"Yakuri to Chiryo (Japanese Pharmacology and Therapeutics)"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0679|cit679","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1185\/03007997609109308","article-title":"Clinical evaluation of clobetasone butyrate in the treatment of children with atopic eczema, and its effect on plasma corticosteroid levels","volume":"4","author":"Morley","year":"1976","journal-title":"Current Medical Research and Opinion"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0680|cit680","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1001\/archderm.1977.01640050059006","article-title":"Betamethasone valerate ointment compared with fluocinonide FAPG","volume":"113","author":"Munro","year":"1977","journal-title":"Archives of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0681|cit681","unstructured":"A multi-center study of short and long-term use of protopic ointment in patients with atopic dermatitis clinicaltrials.gov\/show\/NCT00106496"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0682|cit682","unstructured":"Efficacy and safety study of advantan for maintenance treatment of atopic dermatitis clinicaltrials.gov\/ct2\/show\/NCT00185510"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0683|cit683","unstructured":"Treatment and control of atopic dermatitis with 0.1% tacrolimus ointment clinicaltrials.gov\/show\/NCT00480610"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0684|cit684","unstructured":"A clinical study in children and adolescents with mild to moderate atopic dermatitis clinicaltrials.gov\/show\/NCT00568412"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0685|cit685","unstructured":"Epiceram\u2122 device versus mid-strength topical steroid (fluticasone propionate 0.05%) for treatment of atopic dermatitis clinicaltrials.gov\/show\/NCT00616538"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0686|cit686","unstructured":"Comparison of the efficacy and safety of two topical creams for pediatric atopic dermatitis clinicaltrials.gov\/show\/NCT00828412"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0687|cit687","unstructured":"Efficacy and safety study of CD2027 ointment 3 mcg\/g twice daily treatment for adults with at least moderate atopic dermatitis clinicaltrials.gov\/show\/NCT00919763"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0688|cit688","unstructured":"Study to investigate skin conditions and patient assessment of LAS 41002 in the treatment of atopic eczema clinicaltrials.gov\/ct2\/show\/NCT01119313"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0689|cit689","unstructured":"Effectiveness of polymyxin B sulphate + prednisolone + benzocaine + clioquinol in acute and sub-acute dermatitis eczematous clinicaltrials.gov\/show\/NCT01429701"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0690|cit690","unstructured":"Safety, tolerability and pharmacokinetics in AD subjects and healthy subjects of cutaneous application of LEO 39652 cream clinicaltrials.gov\/show\/NCT01850849"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0691|cit691","unstructured":"Safety and efficacy study of Q301 in moderate to severe atopic dermatitis patients clinicaltrials.gov\/show\/NCT02426359"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0692|cit692","unstructured":"A study of baricitinib (LY3009104) in participants with moderate-to-severe atopic dermatitis clinicaltrials.gov\/show\/NCT02576938"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0693|cit693","unstructured":"Effectiveness study of ketoconazole and betamethasone to treat fungal infection and dermatophytosis clinicaltrials.gov\/show\/NCT02582177"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0694|cit694","doi-asserted-by":"crossref","first-page":"AB120","DOI":"10.1016\/j.jaad.2018.05.505","article-title":"Efficacy and safety of HAT1, a novel topical therapeutic: results from randomized, double-blind, placebo-controlled clinical trials in psoriasis and atopic dermatitis","volume":"79","author":"Alex","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0695|cit695","unstructured":"Efficacy and tolerability of HAT1 in patients with moderate to severe atopic dermatitis clinicaltrials.gov\/show\/NCT03059693"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0696|cit696","unstructured":"Study to investigate efficacy and safety of PF-04965842 in subjects aged 12 years and over with moderate to severe atopic dermatitis with the option of rescue treatment in flaring subjects clinicaltrials.gov\/ct2\/show\/NCT03627767"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0697|cit697","unstructured":"JAK1 inhibitor with medicated topical therapy in adolescents with atopic dermatitis (JADE TEEN) clinicaltrials.gov\/ct2\/show\/NCT03796676"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0698|cit698","unstructured":"Study in subjects with moderate atopic dermatitis clinicaltrials.gov\/ct2\/show\/NCT03859986"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0699|cit699","unstructured":"A study of lebrikizumab in combination with topical corticosteroids in participants having atopic dermatitis (AD) that are not adequately controlled or non-eligible for cyclosporine https:\/\/www.clinicaltrials.gov\/study\/NCT05149313"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0700|cit700","unstructured":"B244 topical spray for the treatment of pruritus in adults with a history of atopic dermatitis https:\/\/clinicaltrials.gov\/study\/NCT04490109"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0701|cit701","unstructured":"Proof of concept study of rilzabrutinib in adult patients with moderate-to-severe atopic dermatitis https:\/\/clinicaltrials.gov\/show\/NCT05018806"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0702|cit702","unstructured":"Evaluation of an adapted formula on atopic dermatitis https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05318300"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0703|cit703","unstructured":"Clinical study of BSZY cream intervention to relieve atopic facial dermatitis https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05792826"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0704|cit704","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s13555-022-00766-2","article-title":"Efficacy of pseudo-ceramide-containing steroid lamellar cream in patients with mild to moderate atopic dermatitis: a randomized, double-blind study","volume":"12","author":"Okoshi","year":"2022","journal-title":"Dermatology and Therapy"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0705|cit705","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jaci.2021.09.024","article-title":"Asivatrep, a TRPV1 antagonist, for the topical treatment of atopic dermatitis: phase 3, randomized, vehicle-controlled study (CAPTAIN-AD)","volume":"149","author":"Park","year":"2022","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0706|cit706","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000088504","article-title":"Low-dose triamcinolone acetonide in the phytocosmetic lichtena reduces inflammation in mild to moderate atopic dermatitis","volume":"211","author":"Pellanda","year":"2005","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0707|cit707","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1525-1470.1984.tb01124.x","article-title":"Efficacy versus systemic effects of six topical steroids in the treatment of atopic dermatitis of childhood","volume":"1","author":"Queille","year":"1984","journal-title":"Pediatric Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0708|cit708","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/09546639609089535","article-title":"Betamethasone valerate versus mometasone furoate cream once daily in atopic dermatitis","volume":"7","author":"Reidhav","year":"1996","journal-title":"Journal of Dermatological Treatment"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0709|cit709","first-page":"33","article-title":"Topical treatment of inflammatory dermatoses and cutaneous candidiasis with a new corticosteroid antibiotic combination: halcinonide neomycin amphotericin","volume":"31","author":"Reyes","year":"1977","journal-title":"British Journal of Clinical Practice"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0710|cit710","first-page":"183","article-title":"Topical treatment of eczema with flupamesone (Flutenal): a double blind comparison with betamethasone 17 valerate (method of simultaneous symmetrical paired comparisons)","volume":"21","author":"Rodriguez Moreno","year":"1977","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0711|cit711","doi-asserted-by":"crossref","first-page":"e068395","DOI":"10.1136\/bmjopen-2022-068395","article-title":"Defining the temporal relationship between the skin microbiome, immune response and skin barrier function during flare and resolution of atopic dermatitis: protocol of a Danish intervention study","volume":"13","author":"Ronnstad","year":"2023","journal-title":"BMJ Open"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0712|cit712","first-page":"237","article-title":"Atopic dermatitis: treatment with a urea-corticosteroid cream","volume":"11","author":"Roth","year":"1973","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0713|cit713","first-page":"16","article-title":"Double blind trial of fluocinonide cream in psoriasis and atopic dermatitis","volume":"80","author":"Roth","year":"1973b","journal-title":"Clinical Medicine"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0714|cit714","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2340\/00015555-0096","article-title":"Treatment of atopic dermatitis with 1% hydrocortisone and 25% pentane-1,5-diol: effect on Staphylococcus aureus","volume":"86","author":"Sandstrom Falk","year":"2006","journal-title":"Acta Dermato-Venereologica"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0715|cit715","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000248813","article-title":"Domoprednate, a new nonhalogenated topical steroid: comparison to hydrocortisone butyrate","volume":"175","author":"Schmidt","year":"1987","journal-title":"Dermatologica"},{"issue":"47","key":"10.1002\/14651858.CD015064.pub2-BIB0716|cit716","first-page":"8610","article-title":"Double blind trial of an ointment containing fluprednylidene acetate plus salicylic acid against salicylic acid alone","volume":"27","author":"Schneider","year":"1977","journal-title":"Die Therapiewoche"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD015064.pub2-BIB0717|cit717","first-page":"155-6","article-title":"The addition of tetracyclin to triamcinolon ointment in atopic dermatitis: a randomized controlled trial","volume":"17","author":"Schuttelaar","year":"2003","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"2 I","key":"10.1002\/14651858.CD015064.pub2-BIB0718|cit718","first-page":"341-4","article-title":"Comparative efficacy of hydrocortisone valerate 0.2% cream and triamcinolone acetonide 0.1% cream in the treatment of atopic dermatitis","volume":"34","author":"Sefton","year":"1983","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"10","key":"10.1002\/14651858.CD015064.pub2-BIB0719|cit719","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.36849\/JDD.6280","article-title":"Measuring and improving adherence to crisaborole 2% ointment in patients with atopic dermatitis","volume":"21","author":"Snyder","year":"2022","journal-title":"Journal of Drugs in Dermatology"},{"issue":"10","key":"10.1002\/14651858.CD015064.pub2-BIB0720|cit720","doi-asserted-by":"crossref","first-page":"418","DOI":"10.5694\/j.1326-5377.1965.tb18863.x","article-title":"Comparison of topical fluocinolone and tumenol prednisolone: a double-blind trial","volume":"2","author":"Stahle","year":"1965","journal-title":"Medical Journal of Australia"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0721|cit721","first-page":"142","article-title":"A comparative trial of full and half strength betamethasone 17-valerate cream","volume":"8","author":"Stahle","year":"1965","journal-title":"Australian Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0722|cit722","first-page":"579","article-title":"Comparison of two active topical preparations in psoriasis and atopic dermatitis","volume":"16","author":"Strick","year":"1975","journal-title":"Cutis; Cutaneous Medicine for the Practitioner"},{"issue":"11-12","key":"10.1002\/14651858.CD015064.pub2-BIB0723|cit723","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/j.1552-4604.1975.tb02342.x","article-title":"Comparative efficacy of halcinonide and fluocinonide creams in psoriasis and eszematous dermatoses","volume":"15","author":"Sudilovsky","year":"1975","journal-title":"Journal of Clinical Pharmacology"},{"issue":"10 Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0724|cit724","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1016\/j.jid.2017.07.141","article-title":"A comparative study of safety and efficacy of tacrolimus topical ointment (biocon's formulation) versus protopic topical ointment (astellas pharma) in children and adults with atopic dermatitis","volume":"137","author":"Suresh","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"issue":"10","key":"10.1002\/14651858.CD015064.pub2-BIB0725|cit725","first-page":"3203-10","article-title":"Clinical study of methaderm ointment on atopic dermatitis: comparative study with 0.1% diflucortone valerate ointment","volume":"22","author":"Takemura","year":"1988","journal-title":"Kiso to Rinsho (the Clinical Report)"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0726|cit726","unstructured":"A study of therapeutic equivalence of mometasone cream and elomet cream in eczema https:\/\/www.thaiclinicaltrials.org\/show\/TCTR20220210004"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0727|cit727","unstructured":"The effectiveness of tiptajo cream for treatment of mild to moderate dermatitis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=TCTR20220313002"},{"issue":"9","key":"10.1002\/14651858.CD015064.pub2-BIB0728|cit728","doi-asserted-by":"crossref","first-page":"1040-6","DOI":"10.1111\/j.1468-3083.2010.03577.x","article-title":"Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months","volume":"24","author":"Thaci","year":"2010","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0729|cit729","first-page":"983","article-title":"Clinical study of new moco KOWA ointment in eczematous skin diseases: well controlled study in comparison with 0.06% betamethasone 17-valerate ointment","volume":"11","author":"Toda","year":"1983","journal-title":"Yakuri to Chiryo (Japanese Pharmacology and Therapeutics)"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0730|cit730","first-page":"248","article-title":"Well-controlled comparative study and open clinical study of 0.05% hydrocortisone-17-butyrate ointment (TS-1020)","volume":"31","author":"Ueda","year":"1989","journal-title":"Skin Research"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015064.pub2-BIB0731|cit731","first-page":"235","article-title":"Efficacy and safety of fluticasone propionate ointment in the long-term treatment of atopic dermatitis","volume":"38","author":"Van der Meer","year":"1997","journal-title":"Australasian Journal of Dermatology"},{"issue":"Suppl 111","key":"10.1002\/14651858.CD015064.pub2-BIB0732|cit732","first-page":"375","article-title":"Atopic dermatitis in children in primary care: baseline characteristics, medication use and severity measures in the Rotterdam Eczema Study","volume":"78","author":"Van Halewijn","year":"2023","journal-title":"Allergy"},{"issue":"8","key":"10.1002\/14651858.CD015064.pub2-BIB0733|cit733","first-page":"1248","article-title":"Diflucortolone valerianate and fluocinolone acetonide in eczema and dermatitis. Interindividual randomized double-blind study with 124 patients","volume":"117","author":"Van Zuiden","year":"1978","journal-title":"Therapie der Gegenwart"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0734|cit734","first-page":"932","article-title":"Controlled clinical trial of a topical formulation of fluocortolone (as privalate and caproate esters) plus chlorquinaldol","volume":"21","author":"Venier","year":"1982","journal-title":"Clinica Europea"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0735|cit735","first-page":"128","article-title":"Clinical observation on the efficacy of fluticasone propionate cream and ointment in the treatment of eczema","volume":"28","author":"Wang","year":"1995","journal-title":"Chinese Journal of Dermatology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD015064.pub2-BIB0736|cit736","first-page":"347","article-title":"Hydrocortisone aceponate lipophilic cream has similar efficacy and safety to hydrocortisone butyrate lipocream in the treatment of endogenous eczema","volume":"17","author":"Wang","year":"2003","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"14","key":"10.1002\/14651858.CD015064.pub2-BIB0737|cit737","first-page":"196-8","article-title":"Experiences with a dexamethasone-nandrolonedekanoate creme","volume":"122","author":"Weitgasser","year":"1972","journal-title":"Wiener Medizinische Wochenschrift (1946)"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0738|cit738","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1185\/03007997309111672","article-title":"Betamethasone 17-valerate ointment in a lanolin-free base","volume":"1","author":"Wilson","year":"1973","journal-title":"Current Medical Research and Opinion"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0739|cit739","doi-asserted-by":"crossref","first-page":"328-32","DOI":"10.1159\/000100884","article-title":"Comparative effect of tacrolimus and betamethasone valerate on the passive sustainable hydration of the stratum corneum in atopic dermatitis","volume":"214","author":"Xhauflaire-Uhoda","year":"2007","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0740|cit740","first-page":"243-7","article-title":"Anti-pruritis efficacy of itch relift lotion and cream in patients with atopic history: comparison with hydroxortisone cream","volume":"16","author":"Zirwas","year":"2017","journal-title":"Journal of Drugs in Dermatology"},{"issue":"Suppl 1 Pt 2","key":"10.1002\/14651858.CD015064.pub2-BIB0741|cit741","first-page":"1S408","article-title":"Tacrolimus ointment (protopic) 0.03% twice daily as the therapy of choice in young paediatric patients (2-6 years) with moderate to severe AD","volume":"129","author":"Bos","year":"2002","journal-title":"Annales de Dermatologie et de Venereologie"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0742|cit742","unstructured":"The role and application of skin microbiota and its metabolites in atopic dermatitis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2100043963"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0743|cit743","unstructured":"Experimental study on the effect of taxisan on colonization of Staphylococcus aureus in skin lesions of atopic dermatitis in vivo and in vitro https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2100044339"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0744|cit744","unstructured":"A single-center, randomized, blinded, desonide cream-controlled phase IV to evaluate the safety and efficacy of 2% cliborrol ointment combined with desonide cream for sequential use in patients with mild to moderate atopic dermatitis clinical research https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2100053644"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0745|cit745","unstructured":"Short-term growth in children with atopic dermatitis treated with tacrolimus and hydrocortisone-17-butyrate trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2004-004052-39-DK"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0746|cit746","unstructured":"A phase II, single-centre, investigator-blind, parallel group clinical trial to investigate the efficacy and safety of 1% ciclopirox olamine (Batrafen\u00ae cream), compared to 1% hydrocortisone acetate (HC45\u00ae cream), compared to a topical emollient (E45\u00ae cream), in the treatment of patients with mild to moderate atopic eczema trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2005-002471-32-GB"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0747|cit747","unstructured":"A single center, single-blind, parallel group clinical trial to investigate the efficacy and safety of W0153 vs. standard moisturizer in the maintenance of patients with atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2007-002182-12-GB"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0748|cit748","unstructured":"Efficacy and safety comparison of CD4802 0.1% ointment versus vehicle in the treatment of target lesions in adults with atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2007-007789-39-FR"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0749|cit749","unstructured":"CBPR277X2101 A first-in-human study to evaluate safety and tolerability of repeated topical administrations of BPR277 ointment in healthy volunteers, and safety, tolerability, and preliminary efficacy of multiple topical administrations of BPR277 in patients with atopic dermatitis and Netherton syndrome trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2011-000917-38-DE"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0750|cit750","unstructured":"A study evaluating the safety and efficacy of topical BPR277 for the treatment of atopic dermatitis and netherton syndrome https:\/\/clinicaltrials.gov\/show\/NCT01428297"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0751|cit751","first-page":"109","article-title":"A clinical controlled trial of laikede cream versus 0.1% eloson cream in the treatment of dermatitis and eczema","volume":"29","author":"Guo","year":"2000","journal-title":"Journal of Clinical Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0752|cit752","first-page":"681","article-title":"Double-blind hydrocortisone-controlled tacrolimus ointment for atopic dermatitis","volume":"110","author":"Gutgesell","year":"1998","journal-title":"Journal of Investigative Dermatology"},{"issue":"Suppl 1 Pt 2","key":"10.1002\/14651858.CD015064.pub2-BIB0753|cit753","first-page":"1S411","article-title":"Pimecrolimus (SDZ ASM 981) cream: good tolerability in paediatric patients","volume":"129","author":"Hanifin","year":"2002","journal-title":"Annales de Dermatologie et de Venereologie"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0754|cit754","unstructured":"A pharmacological study of tacrolimus ointment trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-JapicCTI-205315"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0755|cit755","unstructured":"A pharmacological study of M1151C2 trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-jRCT2031210012"},{"issue":"Supplement 2","key":"10.1002\/14651858.CD015064.pub2-BIB0756|cit756","first-page":"892023","article-title":"Phase 2 trial of novel topical drug AB-101a for treatment of mild to moderate atopic dermatitis in children and adults","volume":"40","author":"Koller","year":"2023","journal-title":"Pediatric Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0757|cit757","first-page":"10","article-title":"Intermittent proactive maintenance treatment with 0.03% tacrolimus ointment in pediatric patients with moderate to severe atopic dermatitis: results from a multicenter, open-label, randomized, controlled study","volume":"41","author":"Liu","year":"2014","journal-title":"Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0758|cit758","unstructured":"LEO19123 cream in the treatment of atopic dermatitis. A phase II, proof of concept study, testing once daily use of two dose-combinations of LEO19123 cream (calcipotriol and LEO80122) in the treatment of atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2006-001472-20-DK"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0759|cit759","unstructured":"Clinical Study Report: LEO 19123 cream in the treatment of atopic dermatitis https:\/\/clinicaltrials.gov\/study\/NCT00392067"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0760|cit760","unstructured":"LEO19123 cream in the treatment of atopic dermatitis clinicaltrials.gov\/show\/NCT00392067"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0761|cit761","unstructured":"A study to determine the safety, tolerability and efficacy of KP-413 in subjects with atopic dermatitis (AD) clinicaltrials.gov\/ct2\/show\/NCT00932074"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0762|cit762","unstructured":"Efficacy of KAM2904 face cream and KAM3008 body lotion treatment in children with atopic dermatitis (AD) clinicaltrials.gov\/show\/NCT01781663"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0763|cit763","unstructured":"To evaluate the effectiveness of MetaDerm HAT01H cream in atopic dermatitis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2017\/05\/008636"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0764|cit764","unstructured":"A study to evaluate the efficacy and safety of HAT01H in atopic dermatitis clinicaltrials.gov\/show\/NCT03089229"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0765|cit765","unstructured":"Study to evaluate the efficacy and safety of ZL-3101 in subjects with subacute eczema clinicaltrials.gov\/ct2\/show\/NCT03134352"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0766|cit766","unstructured":"Study of TER-101 topical ointment in subjects with atopic dermatitis clinicaltrials.gov\/show\/NCT04753034"},{"issue":"Suppl 1 Pt 2","key":"10.1002\/14651858.CD015064.pub2-BIB0767|cit767","first-page":"1S421","article-title":"Paediatric patients with moderate to severe atopic dermatitis treated with tacrolimus ointment 0.03% show minimal systemic exposure","volume":"129","author":"Ruzicka","year":"2002","journal-title":"Annales de Dermatologie et de Venereologie"},{"issue":"Suppl s1","key":"10.1002\/14651858.CD015064.pub2-BIB0768|cit768","first-page":"132","article-title":"Pentoxifylline therapy of acute atopic dermatitis","volume":"16","author":"Szybejko-Machaj","year":"2002","journal-title":"Journal of the European Academy of Dermatology and Venereology: JEADV"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0769|cit769","first-page":"179","article-title":"Clinical observation of calcipotriol betamethasone ointment in the treatment of chronic eczema","volume":"43","author":"Wang","year":"2014","journal-title":"Journal of Clinical Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0770|cit770","unstructured":"A phase I, safety, tolerability and efficacy study of topical AKP-11 administration to participants with atopic dermatitis https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=370241"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0771|cit771","unstructured":"A phase II, safety, tolerability and efficacy study of topical AKP-11 administration to participants with atopic dermatitis https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=372955"},{"issue":"Suppl 57","key":"10.1002\/14651858.CD015064.pub2-BIB0772|cit772","first-page":"34","article-title":"Long-term safety and efficacy of SDZ ASM 981 cream in adult patients with atopic dermatitis","volume":"143","author":"Bos","year":"2000","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0773|cit773","unstructured":"Comparative study on the efficacy and safety of 0.03% tacrolimus ointment and 2% criborol ointment in the treatment of moderate atopic dermatitis in children https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2100054661"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0774|cit774","unstructured":"Phase III Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Atopic Dermatitis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR2200059419"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0775|cit775","unstructured":"A randomized controlled study comparing the efficacy and safety of 2% crisaborole ointment versus 1% pimemollimus cream in the treatment of mild to moderate atopic dermatitis in children aged 2 years and older https:\/\/www.chictr.org.cn\/showprojEN.html?proj=164592"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0776|cit776","unstructured":"Efficacy and safety of calcineurin inhibitors compared with that of glucocorticoid for the treatment of atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR-IPR-17013807"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0777|cit777","unstructured":"A clinical trial of tacrolimus as a therapeutic agent for atopic dermatitis in Chinese children: objective assessment of clinical efficacy in itch reduction and immunomodulatory effects trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR-TRC-09000738"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0778|cit778","unstructured":"0.03% Tacrolimus ointment long-term intermittent maintain treatment of children with moderate to severe atopic dermatitis multicenter, open, randomized, controlled study trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR-TRC-12002479"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0779|cit779","unstructured":"Optimization of light, moderate to severe atopic dermatitis treatment strategies of the stabilization period: multicenter, open, randomized controlled study trialsearch.who.int\/Trial2.aspx?TrialID=ChiCTR-TRC-12002591"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0780|cit780","unstructured":"A study to evaluate effectiveness of tacrolimus 0.1% topical ointment in the patients of the allergic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2012\/05\/002636"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0781|cit781","unstructured":"A randomized, double-blind, placebo-controlled, three arms, parallel-group, multiple-site bioequivalence study with clinical endpoints trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2018\/11\/016407"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0782|cit782","unstructured":"A clinical trial to study the effects of two drugs, tofacitinib 2% w\/w ointment and 0.1% hydrocortisone butyrate ointment in patients suffering from dermatitis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2022\/07\/043740"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0783|cit783","unstructured":"Effect of tofacitinib ointment 2% w\/w compared to pimecrolimus cream 1% w\/w in patients with mild to moderate atopic dermatitis (AD) https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2022\/07\/044136"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0784|cit784","unstructured":"A randomized, double-blind, vehicle-controlled, three arm, parallel group, multi-centric, clinical study to establish the therapeutic equivalence of tacrolimus 0.03% topical ointment of Intas Pharmaceuticals Limited with protopic\u00c2\u00ae 0.03% topical ointment in patients with moderate to severe atopic dermatitis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2022\/08\/045019"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0785|cit785","unstructured":"A study to establish the therapeutic equivalence of tacrolimus 0.1 % topical ointment in adult patients with moderate to severe atopic dermatitis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2022\/08\/045020"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0786|cit786","unstructured":"An investigator initiated, randomized, placebo and active controlled, evaluator blinded study to assess the efficacy and tolerability of pimecrolimus lotion 0.8% (ENZ001) in the treatment of target lesions in patients with moderate atopic dermatitis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2022\/12\/047916"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0787|cit787","unstructured":"A double-blind, randomized, placebo-controlled, three-arm, parallel-group, multi-centre clinical study to evaluate the safety and clinical endpoint bioequivalence of tacrolimus ointment 0.1% w\/w of JAMP Pharma Corporation, Canada and protopic\u00ae tacrolimus ointment, 0.1% (w\/w) of LEO Pharma Inc., Thornhill, Ontario, L3T 7W8 and compare both active treatments to a placebo control in the treatment of non-immunocompromised patients with moderate to severe atopic dermatitis https:\/\/ctri.nic.in\/Clinicaltrials\/advsearch.php"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0788|cit788","unstructured":"Study to evaluate safety, efficacy of topical 1% AKP-11 in atopic dermatitis participants https:\/\/ctri.nic.in\/Clinicaltrials\/pubview2.php"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0789|cit789","unstructured":"Clinical study on tacrolimus ointment over the long-term \u201cControl Study - Children\u201d Revised version of FG-506-06-39 - Control Study - Children trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2004-001644-80-HU"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0790|cit790","unstructured":"Comparative, multicentre, randomised, double-blind study to assess the efficacy of tacrolimus 0.1% ointment versus fluticasone 0.005% ointment in adult patients suffering from moderate to severe atopic dermatitis and presenting with so-called \"red face\" lesions of the head and neck trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2004-002477-23-BE"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0791|cit791","unstructured":"Comparative, multicentre, randomised, double-blind study to assess the efficacy of tacrolimus 0.03% ointment versus fluticasone 0.005% ointment in children aged 2 years or over suffering from moderate to severe atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2004-002478-47-BE"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0792|cit792","unstructured":"Role for pimecrolimus in restoring skin barrier function and normalizing epidermal lipid content and differentiation in atopic epidermis: a randomized, intra-patient, double-blind (right\/left arm) study in adults with atopic dermatitis treated with 1% pimecrolimus cream and 0.1 % betamethasone cream as treatment control twice daily for 3 weeks trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2004-004824-11-DE"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0793|cit793","unstructured":"A randomized, double-blind, placebo-controlled, three-arm, parallel assignment, multi-centre, therapeutic equivalence study of two tacrolimus 0.1% topical ointment formulations in adult patients with moderate to severe atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2011-006236-23-PL"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0794|cit794","unstructured":"Comparison of defined skin parameters in two comparable lesional skin areas after topical treatment with Soventol HydroCort 1% cream or vehicle trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2013-000715-25-DE"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0795|cit795","unstructured":"Diacerein for the treatment of atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2014-005593-11-AT"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0796|cit796","unstructured":"Avexxin (AVX001) 3% ointment (NG) in atopic dermatitis - safety and efficacy study trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2016-003013-96-DK"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0797|cit797","unstructured":"The effects of topical corticosteroid use on insulin sensitivity and bone turnover trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2018-004370-96-DK"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0798|cit798","unstructured":"Clinical study to compare two cutaneous ointments with the active substance methylprednisolone aceponate 0.1% and one cutaneous ointment without active substance for patients with atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2019-002686-35-DE"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0799|cit799","first-page":"AB4","article-title":"A novel topical nuclear factor kappa-B decoy: results from a phase I\/II trial in atopic dermatitis","volume":"54","author":"Hanifin","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0800|cit800","unstructured":"Comparison of efficacy of tacrolimus 0.03% ointment with mometason ointment in treatment of pediatric atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=IRCT20091012002581N6"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0801|cit801","unstructured":"A randomised double-blinded cross-over trial comparing betamethasone valerate and tacrolimus ointment for the treatment of moderate to severe atopic eczema trialsearch.who.int\/Trial2.aspx?TrialID=ISRCTN27411543"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0802|cit802","unstructured":"A phase 2a study of M520102 in atopic dermatitis patients trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-JapicCTI-121946"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0803|cit803","unstructured":"A multicenter, randomized, double-blind, vehicle-controlled, parallel-group trial to assess the safety and efficacy of 0.3% and 1% OPA-15406 ointments when administered for 4 weeks in pediatric patients with atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-JapicCTI-173484"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0804|cit804","unstructured":"Phase 3 clinical study of JTE-061 cream - randomized vehicle-controlled study (Part 1) and extension study (Part 2) in patients with atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-jRCT2031210255"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0805|cit805","unstructured":"The effect of proactive therapy with tacrolimus and betamethasone butyrate on atopic dermatitis: randomized placebo-controlled study trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-UMIN000006955"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0806|cit806","unstructured":"A clinical trial of the effects of topical steroid cream (PVA-N11) on atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-UMIN000022212"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0807|cit807","unstructured":"Quality of life study in adults with facial eczema clinicaltrials.gov\/show\/NCT00120302"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0808|cit808","unstructured":"Pimecrolimus cream 1% plus topical corticosteroid in patients (2-17 years of age) with severe atopic dermatitis clinicaltrials.gov\/show\/NCT00121381"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0809|cit809","unstructured":"Topical NF-kappaB decoy in the treatment of atopic dermatitis clinicaltrials.gov\/show\/NCT00125333"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0810|cit810","unstructured":"Randomised, double-blind, placebo-controlled study of topical GW842470X formulation in adult patients with moderate atopic dermatitis trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2005-005430-12-GB"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0811|cit811","unstructured":"Topical GW842470X in adults patients with moderate atopic dermatitis clinicaltrials.gov\/show\/NCT00354510"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0812|cit812","unstructured":"Study of single and ten day repeat atopical applications of GW842470X cream on the skin of patients with atopic dermatitis clinicaltrials.gov\/show\/NCT00356642"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0813|cit813","unstructured":"Assessment of pruritus improvement with pimecrolimus treatment on the areas affected by mild-to-moderate AD, in patients 2- to 11- year-old clinicaltrials.gov\/show\/NCT00510003"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0814|cit814","unstructured":"Protopic ointment in children [with] atopic eczema clinicaltrials.gov\/show\/NCT00689832"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0815|cit815","unstructured":"Protopic ointment in adult atopic eczema of the face clinicaltrials.gov\/show\/NCT00690105"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0816|cit816","unstructured":"Bioequivalence of two tacrolimus 0.1% topical ointment formulations in patients with atopic dermatitis clinicaltrials.gov\/show\/NCT00833079"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0817|cit817","unstructured":"Dose escalation of different concentrations of ZK 245186 in atopic dermatitis clinicaltrials.gov\/show\/NCT00944632"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0818|cit818","unstructured":"Effect of pimecrolimus cream on cathelicidin levels in subjects with eczema clinicaltrials.gov\/show\/NCT00946478"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0819|cit819","unstructured":"Sinecort pilot efficacy study clinicaltrials.gov\/show\/NCT00980135"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0820|cit820","unstructured":"Efficacy and safety of different concentrations of ZK245186 in atopic dermatitis (AD) clinicaltrials.gov\/ct2\/show\/NCT01228513"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0821|cit821","unstructured":"Efficacy and safety of different concentrations of mapracorat ointment over 4 weeks in atopic dermatitis (AD) clinicaltrials.gov\/show\/NCT01359787"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0822|cit822","unstructured":"Randomised, double-blind, placebo-controlled study of topical clobetasone butyrate 0.05% cream in subjects with eczema for two weeks to evaluate the efficacy and safety clinicaltrials.gov\/show\/NCT01567995"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0823|cit823","unstructured":"A safety and efficacy of DRM02 in subjects with atopic dermatitis clinicaltrials.gov\/ct2\/show\/NCT01993420"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0824|cit824","unstructured":"Efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics study of the topical formulation SB011 applied to lesional skin in patients with atopic eczema clinicaltrials.gov\/show\/NCT02079688"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0825|cit825","unstructured":"Effect of LEO 39652 cream in adults with mild to moderate atopic dermatitis (AD) clinicaltrials.gov\/show\/NCT02219633"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0826|cit826","unstructured":"An explorative trial evaluating the effect of LEO 32731 cream in adults with mild to moderate atopic dermatitis clinicaltrials.gov\/show\/NCT02496546"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0827|cit827","unstructured":"To study generic tacrolimus ointment, 0.1% in the treatment of moderate to severe atopic dermatitis (inflammation of skin: itchy, red, swollen, and cracked skin) clinicaltrials.gov\/show\/NCT02601703"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0828|cit828","unstructured":"Efficacy and tolerability of new topical formulations in subjects with atopic dermatitis clinicaltrials.gov\/show\/NCT02732314"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0829|cit829","unstructured":"Topical solution for the treatment of atopic dermatitis (CYCLATOP) clinicaltrials.gov\/ct2\/show\/NCT02865356"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0830|cit830","unstructured":"DMT210 topical gel in the treatment of atopic dermatitis clinicaltrials.gov\/show\/nct02949960"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0831|cit831","unstructured":"Efficacy and safety of IDP-124 lotion clinicaltrials.gov\/show\/NCT03002571"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0832|cit832","unstructured":"Efficacy and safety of IDP-124 lotion for the treatment of moderate to severe atopic dermatitis in pediatric and adult subjects clinicaltrials.gov\/show\/NCT03058783"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0833|cit833","unstructured":"Study of RVT-501 topical ointment in pediatric patients with atopic dermatitis clinicaltrials.gov\/show\/NCT03394677"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0834|cit834","unstructured":"Steroid-reducing effects of crisaborole clinicaltrials.gov\/show\/NCT03832010"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0835|cit835","unstructured":"Different application rates of crisaborole ointment 2% in adults with mild to moderate atopic dermatitis clinicaltrials.gov\/ct2\/show\/NCT03868098"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0836|cit836","unstructured":"Improvement of short term outcome of mild to moderate atopic dermatitis using a combination of crisaborole and a concomitant topical corticosteroid over a 8 week period clinicaltrials.gov\/show\/NCT04008784"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0837|cit837","unstructured":"Skin bioMARkers for atopic eczema therapy evaluation (SMART) clinicaltrials.gov\/show\/NCT04194814"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0838|cit838","unstructured":"Topically applied AMTX-100 CF for adult patients with mild to moderate atopic dermatitis clinicaltrials.gov\/show\/NCT04313400"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0839|cit839","unstructured":"Jaktinib hydrochloride cream for atopic dermatitis clinicaltrials.gov\/show\/NCT04435392"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0840|cit840","unstructured":"Study of ATI-1777 in adult patients with moderate or severe atopic dermatitis clinicaltrials.gov\/ct2\/show\/NCT04598269"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0841|cit841","unstructured":"Topical cream SNG100 for treatment in moderate atopic dermatitis subjects clinicaltrials.gov\/show\/NCT04615962"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0842|cit842","unstructured":"Evaluate the efficacy and safety of topical SHR0302 ointment in patients with mild-to-moderate atopic dermatitis clinicaltrials.gov\/show\/NCT04717310"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0843|cit843","unstructured":"A first-in-human trial to investigate how safe, tolerable, effective and how the body handles BEN2293 in patients who have mild to moderate eczema trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2020-003143-28-GB"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0844|cit844","unstructured":"A first-in-human PoC study with BEN2293 in patients with mild to moderate atopic dermatitis clinicaltrials.gov\/ct2\/show\/NCT04737304"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0845|cit845","unstructured":"A phase 3, 4-week, parallel group, double blind, vehicle-controlled study of the safety and efficacy of ARQ-151 cream 0.05% administered QD in subjects with atopic dermatitis https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2021-006903-14-PL"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0846|cit846","unstructured":"Trial of PDE4 inhibition with roflumilast for the management of atopic dermatitis (integument-PED) clinicaltrials.gov\/show\/NCT04845620"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0847|cit847","unstructured":"A study to assess the efficacy and safety of ruxolitinib cream in children with atopic dermatitis (TRuE-AD3) clinicaltrials.gov\/show\/NCT04921969"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0848|cit848","unstructured":"Phase 2a study of the safety, tolerability, and pharmacokinetics of topically administered PRN473 (SAR444727) in patients with mild to moderate atopic dermatitis clinicaltrials.gov\/ct2\/show\/NCT04992546"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0849|cit849","unstructured":"Ruxolitinib cream in participants with facial and\/or neck atopic dermatitis involvement clinicaltrials.gov\/show\/NCT05127421"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0850|cit850","unstructured":"Improvement In scratch behavior and sleep in patients with atopic dermatitis clinicaltrials.gov\/show\/NCT05200403"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0851|cit851","unstructured":"Tacrolimus versus hydrocortisone in atopic dermatitis https:\/\/clinicaltrials.gov\/study\/NCT05324618"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0852|cit852","unstructured":"Phase III clinical study of benvitimod cream in the treatment of mild to moderate atopic dermatitis https:\/\/clinicaltrials.gov\/study\/NCT05326672"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0853|cit853","unstructured":"A study to learn about the study medicine (PF-07038124) in patients with mild to moderate atopic dermatitis or mild to severe plaque psoriasis https:\/\/clinicaltrials.gov\/study\/NCT05375955"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0854|cit854","unstructured":"Study of ATI-1777 in patients 12 to 65 years old with mild to severe atopic dermatitis https:\/\/clinicaltrials.gov\/study\/NCT05432596"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0855|cit855","unstructured":"Tolerability and effectiveness of CGB-500 topical ointment, 1% tofacitinib, for the treatment of atopic dermatitis https:\/\/clinicaltrials.gov\/study\/NCT05487963"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0856|cit856","unstructured":"Safety and efficacy study of EVO101 topical cream in atopic dermatitis https:\/\/clinicaltrials.gov\/study\/NCT05579899"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0857|cit857","unstructured":"A comparative clinical trial evaluating the effect and safety of tacrolimus versus hydrocortisone https:\/\/clinicaltrials.gov\/study\/NCT05607901"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0858|cit858","unstructured":"A phase 3, randomized, double-blind, vehicle-controlled, multicenter study to assess the efficacy and safety of difamilast ointment 1% in children, adolescents, and adults with mild to moderate atopic dermatitis https:\/\/clinicaltrials.gov\/study\/NCT05608343"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0859|cit859","unstructured":"To demonstrate the superiority of IMP (0.3% and 1% OPA-15406 ointment) versus the vehicle in pediatric patients with AD https:\/\/clinicaltrials.gov\/study\/NCT05650320"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0860|cit860","unstructured":"To demonstrate the superiority of IMP (1% OPA-15406 ointment) to the vehicle in adult patients with AD https:\/\/clinicaltrials.gov\/study\/NCT05667623"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0861|cit861","unstructured":"A study to evaluate the safety, tolerability and pharmacokinetic properties of IN-A002 ointment in healthy adult male volunteers and mild to moderate atopic dermatitis patients https:\/\/clinicaltrials.gov\/study\/NCT05729074"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0862|cit862","unstructured":"A first-in-human study of QY211 gel in adult subjects https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05843422"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0863|cit863","unstructured":"A study to evaluate the anti-pruritic effectiveness of ASN008 in adults with mild to moderate atopic dermatitis https:\/\/ichgcp.net\/clinical-trials-registry\/NCT05870865"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0864|cit864","first-page":"44-5","article-title":"Cerdulatinib (DMVT-502), a novel, topical dual Janus kinase\/spleen tyrosine kinase inhibitor, improves the cellular and molecular cutaneous signature in patients with atopic dermatitis","volume":"27","author":"Piscitelli","year":"2018","journal-title":"Experimental Dermatology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD015064.pub2-BIB0865|cit865","first-page":"AB210","article-title":"A double-blind, placebo-controlled study of a natural topical anti-inflammatory for treatment of atopic dermatitis and psoriasis","volume":"54","author":"Rhemus","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0866|cit866","doi-asserted-by":"crossref","first-page":"AB211","DOI":"10.1016\/j.jaad.2020.06.932","article-title":"Improvement of short-term outcome of mild to moderate atopic dermatitis using a combination treatment of crisaborole ointment 2% and a concomitant topical cortiscosteroid over a 8 week period","volume":"83","author":"Schlesinger","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0867|cit867","unstructured":"Effectiveness of different strengths of hormone cream: providing evidence for a better treatment strategy in children with eczema in general practice trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2017-001525-40-NL"},{"issue":"Supplement 111","key":"10.1002\/14651858.CD015064.pub2-BIB0868|cit868","first-page":"375","article-title":"Atopic dermatitis in children in the general population: baseline characteristics, medication use, and severity measures in the Rotterdam Eczema study","volume":"78","author":"Halewijn","year":"2023","journal-title":"Allergy"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0869|cit869","unstructured":"Effectiveness of different strengths of topical steroids in children with eczema in general practice trialsearch.who.int\/Trial2.aspx?TrialID=NTR6679"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0870|cit870","first-page":"e55","article-title":"Different potencies of topical steroids for children with eczema: protocol for an observational cohort study with embedded randomized controlled trial","volume":"179","author":"Van Halewijn","year":"2018","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0871|cit871","doi-asserted-by":"crossref","first-page":"e027239","DOI":"10.1136\/bmjopen-2018-027239","article-title":"Different potencies of topical corticosteroids for a better treatment strategy in children with atopic dermatitis (the Rotterdam Eczema study): protocol for an observational cohort study with an embedded randomised open-label controlled trial","volume":"9","author":"Van Halewijn","year":"2019","journal-title":"BMJ Open"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0872|cit872","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.anai.2023.11.009","article-title":"Atopic dermatitis (eczema) guidelines: 2023 american academy of allergy, asthma and immunology\/american college of allergy, asthma and immunology joint task force on practice parameters: GRADE- and institute of medicine-based recommendations","volume":"132","author":"Chu","year":"2024","journal-title":"Annals of Allergy, Asthma and Immunology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0873|cit873","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/all.13320","article-title":"The prevalence of atopic dermatitis beyond childhood: a systematic review and meta-analysis of longitudinal studies","volume":"73","author":"Abuabara","year":"2018","journal-title":"Allergy"},{"issue":"11","key":"10.1002\/14651858.CD015064.pub2-BIB0874|cit874","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1016\/j.jaip.2022.06.017","article-title":"Trustworthy patient-centered guidelines: insights from atopic dermatitis and a proposal for the future","volume":"10","author":"Agarwal","year":"2022","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0875|cit875","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/09629359891126","article-title":"Topical glucocorticoids and the skin - mechanisms of action: an update","volume":"7","author":"Ahluwalia","year":"1998","journal-title":"Mediators Inflammation"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0876|cit876","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1152\/ajplegacy.1966.211.6.1393","article-title":"Role of glucocorticoids in local regulation of blood flow","volume":"211","author":"Altura","year":"1966","journal-title":"American Journal of Physiology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0877|cit877","doi-asserted-by":"crossref","first-page":"e13685","DOI":"10.1111\/dth.13685","article-title":"The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: a systematic review and meta-analysis","volume":"33","author":"Arora","year":"2020","journal-title":"Dermatologic Therapy"},{"issue":"10","key":"10.1002\/14651858.CD015064.pub2-BIB0878|cit878","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamadermatol.2020.2240","article-title":"Association between topical calcineurin inhibitor use and keratinocyte carcinoma risk among adults with atopic dermatitis","volume":"156","author":"Asgari","year":"2020","journal-title":"JAMA Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0879|cit879","unstructured":"Australian Goverment Department of Health Pharmaceutical Benefits Scheme www.pbs.gov.au\/browse\/body-system?depth=4&codes=d07aa#d07aa"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0880|cit880","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2133.2006.07185.x","article-title":"A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases","volume":"155","author":"Beattie","year":"2006","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0881|cit881","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0882|cit882","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/pde.13698","article-title":"Corticosteroid phobia (corticophobia) in parents of young children with atopic dermatitis and their health care providers","volume":"36","author":"Bos","year":"2019","journal-title":"Pediatric Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD015064.pub2-BIB0883|cit883","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/jamadermatol.2022.1706","article-title":"Agreement and correlation between different topical corticosteroid potency classification systems","volume":"158","author":"Bowie","year":"2022","journal-title":"JAMA Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0884|cit884","doi-asserted-by":"publisher","first-page":"m3900","DOI":"10.1136\/bmj.m3900","article-title":"GRADE approach to drawing conclusions from a network meta-analysis using a minimally contextualised framework","volume":"371","author":"Brignardello-Petersen","year":"2020","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0885|cit885","unstructured":"British Association of Dermatologists British Association of Dermatologists\u2019 information on topical corticosteroids \u2013 established and alternative proprietary names, potency, and discontinuation 2015 www.bad.org.uk"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0886|cit886","unstructured":"BMJ Group & Pharmaceutical Press British National Formulary bnf.nice.org.uk\/"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0887|cit887","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jaad.2016.02.1228","article-title":"Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: a 15-year experience","volume":"75","author":"Broeders","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"9","key":"10.1002\/14651858.CD015064.pub2-BIB0888|cit888","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1093\/ced\/llad161","article-title":"Topical steroid withdrawal: an emerging clinical problem","volume":"48","author":"Brookes","year":"2023","journal-title":"Clinical and Experimental Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0889|cit889","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1525-1470.2005.22303.x","article-title":"The burden of atopic dermatitis: impact on the patient, family, and society","volume":"22","author":"Carroll","year":"2005","journal-title":"Pediatric Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0890|cit890","unstructured":"Celsus enrols first patient in MRX-6 Phase II trial for paediatric atopic dermatitis https:\/\/www.clinicaltrialsarena.com\/news\/newscelsus-enrols-first-patient-in-mrx-6-phase-ii-trial-for-paediatric-atopic-dermatitis-4338741\/"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0891|cit891","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PloS One"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0892|cit892","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1542\/peds.2004-0374","article-title":"Effects of atopic dermatitis on young American children and their families","volume":"114","author":"Chamlin","year":"2004","journal-title":"Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0893|cit893","first-page":"162","article-title":"Grades of severity and the validation of an atopic dermatitis assessment measure (ADAM)","volume":"3","author":"Charman","year":"1999","journal-title":"Journal of Outcome Measures"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0894|cit894","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1046\/j.1365-2133.2000.03473.x","article-title":"Topical corticosteroid phobia in patients with atopic eczema","volume":"142","author":"Charman","year":"2000","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0895|cit895","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1046\/j.1365-2133.2002.04644.x","article-title":"Reliability testing of the six area, six sign atopic dermatitis severity score","volume":"146","author":"Charman","year":"2002","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0896|cit896","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/s0738-081x(02)00368-1","article-title":"The use of corticosteroids and corticosteroid phobia in atopic dermatitis","volume":"21","author":"Charman","year":"2003","journal-title":"Clinical Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0897|cit897","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.jaci.2017.04.052","article-title":"Relationship between EASI and SCORAD severity assessments for atopic dermatitis","volume":"140","author":"Chopra","year":"2017","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0898|cit898","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.det.2011.11.003","article-title":"The Skindex instruments to measure the effects of skin disease on quality of life","volume":"30","author":"Chren","year":"2012","journal-title":"Dermatology Clinics"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0899|cit899","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jaci.2023.08.030","article-title":"Topical treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials","volume":"152","author":"Chu","year":"2023","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0900|cit900","unstructured":"Searching: Conducting: Screen4Me community.cochrane.org\/organizational-info\/resources\/resources-groups\/information-specialists-portal\/searching-conducting"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0901|cit901","unstructured":"More about the Cochrane Skin Specialised Register skin.cochrane.org\/search-methods"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0902|cit902","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/bjd.21770","article-title":"Topical steroid withdrawal syndrome: time to bridge the gap","volume":"187","author":"Cotter","year":"2022","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0903|cit903","unstructured":"Covidence Veritas Health Innovation 2023"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0904|cit904","doi-asserted-by":"crossref","first-page":"e065557","DOI":"10.1136\/bmjopen-2022-065557","article-title":"Can co-created knowledge mobilisation interventions alter and enhance mindlines to improve childhood eczema care? A UK-based Social Impact Framework evaluation","volume":"13","author":"Cowdell","year":"2023","journal-title":"BMJ Open"},{"issue":"7","key":"10.1002\/14651858.CD015064.pub2-BIB0905|cit905","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009864.pub2","article-title":"Topical tacrolimus for atopic dermatitis","author":"Cury Martins","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0906|cit906","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/cea.13784","article-title":"The epidemiology of eczema in children and adults in England: a population-based study using primary care data","volume":"51","author":"De Lusignan","year":"2021","journal-title":"Clinical and Experimental Allergy"},{"issue":"6408","key":"10.1002\/14651858.CD015064.pub2-BIB0907|cit907","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1126\/science.361.6408.1184","article-title":"The metawars","volume":"361","author":"De Vrieze","year":"2018","journal-title":"Science"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0908|cit908","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0909|cit909","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0910|cit910","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S2352-4642(22)00283-8","article-title":"Cancer risk with topical calcineurin inhibitors, pimecrolimus and tacrolimus, for atopic dermatitis: a systematic review and meta-analysis","volume":"7","author":"Devasenapathy","year":"2023","journal-title":"Lancet Child Adolescent Health"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0911|cit911","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40265-020-01291-2","article-title":"Delgocitinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0912|cit912","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The burden of atopic dermatitis: summary of a report for the National Eczema Association","volume":"137","author":"Drucker","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"issue":"10","key":"10.1002\/14651858.CD015064.pub2-BIB0913|cit913","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1001\/jamadermatol.2020.2239","article-title":"Topical calcineurin inhibitors and skin cancer - another piece of the puzzle","volume":"156","author":"Drucker","year":"2020","journal-title":"JAMA Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0914|cit914","unstructured":"Vtama Prices, Coupons and Patient Assistance Programs https:\/\/www.drugs.com\/price-guide\/vtama#"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0915|cit915","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0916|cit916","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0917|cit917","unstructured":"European Directorate for the Quality of Medicines committee of experts CD-P-PH\/PHO - Classification of Medicines as Regards their Supply https:\/\/www.edqm.eu\/en\/classification-of-medicines-as-regards-their-supply"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0918|cit918","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3109\/09546634.2010.512950","article-title":"Balneotherapy for atopic dermatitis in children at Comano spa in Trentino, Italy","volume":"22","author":"Farina","year":"2011","journal-title":"Journal of Dermatological Treatment"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0919|cit919","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1007\/s12325-022-02071-y","article-title":"Prescription market share and treatment patterns in atopic dermatitis: a retrospective observational study using US insurance claims","volume":"39","author":"Fenske","year":"2022","journal-title":"Advances in Therapy"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0920|cit920","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clinical and Experimental Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0921|cit921","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2133.1981.tb01712.x","article-title":"The Duhring chamber assay for corticosteroid atrophy","volume":"104","author":"Frosch","year":"1981","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0922|cit922","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jaad.2015.09.062","article-title":"A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards","volume":"74","author":"Futamura","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0923|cit923","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjd.20908","article-title":"Overlapping network meta-analyses on psoriasis systemic treatments, an overview: quantity does not make quality","volume":"187","author":"Guelimi","year":"2022","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0924|cit924","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.burns.2011.04.007","article-title":"Measurement of itching: validation of the Leuven Itch Scale","volume":"37","author":"Haest","year":"2011","journal-title":"Burns"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0925|cit925","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jaad.2014.11.024","article-title":"A systematic review of topical corticosteroid withdrawal (\"steroid addiction\") in patients with atopic dermatitis and other dermatoses","volume":"72","author":"Hajar","year":"2015","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0926|cit926","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis","volume":"10","author":"Hanifin","year":"2001","journal-title":"Experimental Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0927|cit927","doi-asserted-by":"publisher","first-page":"e268","DOI":"10.1002\/ski2.268","article-title":"The long-term safety of topical corticosteroids in atopic dermatitis: a systematic review","volume":"3","author":"Harvey","year":"2023","journal-title":"Skin Health and Disease"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0928|cit928","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/jid.2013.446","article-title":"The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions","volume":"134","author":"Hay","year":"2014","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0929|cit929","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0930|cit930","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook\/archive\/v6.2"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0931|cit931","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1046\/j.1365-2133.2002.05031.x","article-title":"Use of the Self-Administered Eczema Area and Severity Index by parent caregivers: results of a validation study","volume":"147","author":"Housman","year":"2002","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0932|cit932","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus Kinase family in autoimmune skin diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Frontiers of Immunology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0933|cit933","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bjd.18780","article-title":"Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: recap of atopic eczema (RECAP)","volume":"183","author":"Howells","year":"2020","journal-title":"British Journal of Dermatology"},{"issue":"11","key":"10.1002\/14651858.CD015064.pub2-BIB0934|cit934","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Annals of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD015064.pub2-BIB0935|cit935","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1503\/cmaj.060410","article-title":"The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey","volume":"176","author":"Ioannidis","year":"2007","journal-title":"Canadian Medical Association Journal"},{"issue":"8","key":"10.1002\/14651858.CD015064.pub2-BIB0936|cit936","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1503\/cmaj.081086","article-title":"Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses","volume":"181","author":"Ioannidis","year":"2009","journal-title":"Canadian Medical Association Journal"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0937|cit937","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jaci.2003.12.591","article-title":"Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003","volume":"113","author":"Johansson","year":"2004","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0938|cit938","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jaad.2021.01.067","article-title":"The long-term risk of lymphoma and skin cancer did not increase after topical calcineurin inhibitor use and phototherapy in a cohort of 25,694 patients with vitiligo","volume":"84","author":"Ju","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0939|cit939","unstructured":"KEGG (Kyoto Encyclopedia of Genes and Genomes) MEDICUS: Drug information search https:\/\/www.kegg.jp\/kegg\/medicus\/"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0940|cit940","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00019053-200321020-00003","article-title":"Cost of illness of atopic dermatitis in children: a societal perspective","volume":"21","author":"Kemp","year":"2003","journal-title":"PharmacoEconomics"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0941|cit941","doi-asserted-by":"crossref","first-page":"563","DOI":"10.5021\/ad.2015.27.5.563","article-title":"Consensus Guidelines for the treatment of atopic dermatitis in Korea (Part 1): general management and topical treatment","volume":"27","author":"Kim","year":"2015","journal-title":"Annals of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0942|cit942","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000245677","article-title":"Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis","volume":"195","author":"Kunz","year":"1997","journal-title":"Dermatology (Basel, Switzerland)"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0943|cit943","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/jamadermatol.2021.0345","article-title":"Association between topical calcineurin inhibitor use and risk of cancer, including lymphoma, keratinocyte carcinoma, and melanoma: a systematic review and meta-analysis","volume":"157","author":"Lam","year":"2021","journal-title":"JAMA Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0944|cit944","doi-asserted-by":"crossref","first-page":"Article 3","DOI":"10.1111\/cea.14276","article-title":"Trends in eczema prevalence in children and adolescents: a Global Asthma Network Phase I study","volume":"53","author":"Langan","year":"2023","journal-title":"Clinical and Experimental Allergy"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0945|cit945","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013356.pub2","article-title":"Strategies for using topical corticosteroids in children and adults with eczema","author":"Lax","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD015064.pub2-BIB0946|cit946","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1742-1241.2006.01047.x","article-title":"Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema","volume":"60","author":"Lewis-Jones","year":"2006","journal-title":"International Journal of Clinical Practice"},{"issue":"10","key":"10.1002\/14651858.CD015064.pub2-BIB0947|cit947","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1001\/jamadermatol.2017.2437","article-title":"Topical corticosteroid phobia in atopic dermatitis: a systematic review","volume":"153","author":"Li","year":"2017","journal-title":"JAMA Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0948|cit948","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1136\/bmjebm-2019-111191","article-title":"The magnitude of small-study effects in the Cochrane Database of Systematic Reviews: an empirical study of nearly 30 000 meta-analyses","volume":"25","author":"Lin","year":"2020","journal-title":"BMJ Evidence-Based Medicine"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0949|cit949","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40272-021-00490-y","article-title":"Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years","volume":"24","author":"Luger","year":"2022","journal-title":"Paediatr Drugs"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0950|cit950","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1365-2133.2006.07736.x","article-title":"Itch Severity Scale: a self-report instrument for the measurement of pruritus severity","volume":"156","author":"Majeski","year":"2007","journal-title":"British Journal of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0951|cit951","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/jrsm.1287","article-title":"Machine learning for identifying randomized controlled trials: an evaluation and practitioner\u2019s guide","volume":"9","author":"MarshallI","year":"2018","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0952|cit952","doi-asserted-by":"crossref","first-page":"100679","DOI":"10.1016\/j.curtheres.2022.100679","article-title":"Safety profile and tolerability of topical phosphodiesterase 4 inhibitors for the treatment of atopic dermatitis: a systematic review and meta-analysis","volume":"96","author":"Mart\u00edn-Santiago","year":"2022","journal-title":"Current Therapeutic Research"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0953|cit953","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012167.pub2","article-title":"Oral H1 antihistamines as 'add-on' therapy to topical treatment for eczema","author":"Matterne","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0954|cit954","first-page":"f2914","article-title":"Demystifying trial networks and network meta-analysis","volume":"346","author":"Mills","year":"2013","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"10027","key":"10.1002\/14651858.CD015064.pub2-BIB0955|cit955","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/S0140-6736(15)00307-4","article-title":"Increasing value and reducing waste in biomedical research: who's listening?","volume":"387","author":"Moher","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0956|cit956","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/ced\/llad372","article-title":"Do people with eczema and their carers understand topical steroid potency? Results of two surveys","volume":"49","author":"Moss","year":"2023","journal-title":"Clinical and Experimental Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0957|cit957","unstructured":"National Psoriasis Foundation topical steroid potency chart www.psoriasis.org\/potency-chart"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0958|cit958","unstructured":"National Institute for Health and Care Excellence (NICE) Atopic eczema in under 12s: diagnosis and management [CG57] Available at www.nice.org.uk\/guidance\/cg57"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0959|cit959","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/pde.15269","article-title":"Steroid phobia on social media platforms","volume":"40","author":"Nickles","year":"2023","journal-title":"Pediatric Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0960|cit960","doi-asserted-by":"crossref","first-page":"e1003082","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0961|cit961","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jclinepi.2020.08.008","article-title":"Cochrane Centralised Search Service showed high sensitivity identifying randomized controlled trials: a retrospective analysis","volume":"127","author":"Noel-Storr","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0962|cit962","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jclinepi.2021.01.006","article-title":"An evaluation of Cochrane Crowd found that crowdsourcing produced accurate results in identifying randomized trials","volume":"133","author":"Noel-Storr","year":"2021","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2 Pt 1","key":"10.1002\/14651858.CD015064.pub2-BIB0963|cit963","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/s0190-9622(86)70164-3","article-title":"Topical clobetasol-17-propionate: review of its clinical efficacy and safety","volume":"15","author":"Olsen","year":"1986","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0964|cit964","unstructured":"Opzelura\u00ae (ruxolitinib) cream 1.5% https:\/\/www.opzelura.com\/atopic-dermatitis\/cost"},{"issue":"11","key":"10.1002\/14651858.CD015064.pub2-BIB0965|cit965","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1111\/ced.15322","article-title":"Atopic dermatitis on TikTok: a cross-sectional study","volume":"47","author":"Oulee","year":"2022","journal-title":"Clinical and Experimental Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0966|cit966","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB0967|cit967","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.jaad.2020.03.075","article-title":"No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis","volume":"83","author":"Paller","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0968|cit968","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaad.2020.05.135","article-title":"Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis","volume":"84","author":"Paller","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0969|cit969","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/03007995.2019.1699516","article-title":"Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT)","volume":"36","author":"Pariser","year":"2020","journal-title":"Current Medical Research Opinion"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB0970|cit970","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.jaip.2023.03.022","article-title":"A comparison of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis","volume":"11","author":"Pena","year":"2023","journal-title":"Journal of Allergy and Clinical Immunology in Practice"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0971|cit971","unstructured":"Canadian Agency for Drugs and Technologies in Health Pharmacoeconomic Review Report: Crisaborole ointment, 2% (Eucrisa): (Pfizer Canada Inc.): Indication: For topical treatment of mild-to-moderate atopic dermatitis in patients two years of age and older https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK542517\/ Appendix 1, Cost Comparison"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0972|cit972","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1365-2133.1972.tb02236.x","article-title":"Metosyn\u2019 in psoriasis and eczema","volume":"86","author":"Portney","year":"1972","journal-title":"British Journal of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB0973|cit973","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1111\/bjd.18180","article-title":"Prioritization of Cochrane systematic reviews","volume":"181","author":"Presley","year":"2019","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0974|cit974","unstructured":"Resource clinical topical corticosteroids potency classification www.resourceclinical.com\/clinical-tables\/topical-corticosteroids-potency-USA-classification.pdf"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0975|cit975","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2022"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0976|cit976","unstructured":"WebPlotDigitizer WebPlotDigitizer 2021"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0977|cit977","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.alit.2022.06.009","article-title":"Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021","volume":"71","author":"Saeki","year":"2022","journal-title":"Allergology International"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0978|cit978","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0979|cit979","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2222.1990.tb03137.x","article-title":"Pathogenesis of eczema","volume":"20","author":"Sampson","year":"1990","journal-title":"Clin Exp Allergy"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB0980|cit980","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatology and Therapy (Heidelb)"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0981|cit981","doi-asserted-by":"publisher","first-page":"e072007","DOI":"10.1136\/bmj-2022-072007","article-title":"Eczema Care Online behavioural interventions to support self-care for children and young people: two independent, pragmatic, randomised controlled trials","volume":"379","author":"Santer","year":"2022","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0982|cit982","volume-title":"Anti-Inflammatory Agents","author":"Scherrer","year":"1974"},{"issue":"9","key":"10.1002\/14651858.CD015064.pub2-BIB0983|cit983","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/j.1398-9995.2012.02874.x","article-title":"Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting","volume":"67","author":"Schmitt","year":"2012","journal-title":"Allergy"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0984|cit984","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaci.2014.07.043","article-title":"The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials","volume":"134","author":"Schmitt","year":"2014","journal-title":"Journal of Allergy and Clinical Immunology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0985|cit985","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1398-9995.2011.02719.x","article-title":"EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference","volume":"67","author":"Schram","year":"2012","journal-title":"Allergy"},{"issue":"12","key":"10.1002\/14651858.CD015064.pub2-BIB0986|cit986","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0987|cit987","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook\/archive\/v6.3"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB0988|cit988","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jaad.2022.12.029","article-title":"Guidelines of care for the management of atopic dermatitis in adults with topical therapies","volume":"89","author":"Sidbury","year":"2023","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0989|cit989","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1542\/peds.2014-1990","article-title":"Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial","volume":"135","author":"Sigurgeirsson","year":"2015","journal-title":"Pediatrics"},{"issue":"10","key":"10.1002\/14651858.CD015064.pub2-BIB0990|cit990","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans","volume":"137","author":"Smith","year":"2017","journal-title":"Journal of Investigative Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0991|cit991","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/bjd.15179","article-title":"Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement","volume":"176","author":"Spuls","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD015064.pub2-BIB0992|cit992","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1111\/j.1398-9995.2011.02577.x","article-title":"Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe","volume":"66","author":"Stalder","year":"2011","journal-title":"Allergy"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0993|cit993","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT pathway at twenty","volume":"36","author":"Stark","year":"2012","journal-title":"Immunity"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0994|cit994","first-page":"4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"9","key":"10.1002\/14651858.CD015064.pub2-BIB0995|cit995","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/sim.1761","article-title":"What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data","volume":"23","author":"Sweeting","year":"2004","journal-title":"Statistics in Medicine"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0996|cit996","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/bjd.19299","article-title":"Views and experiences of managing eczema: systematic review and thematic synthesis of qualitative studies","volume":"184","author":"Teasdale","year":"2021","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0997|cit997","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jclinepi.2020.11.003","article-title":"Machine learning reduced workload with minimal risk of missing studies: development and evaluation of a randomized controlled trial classifier for Cochrane Reviews","volume":"133","author":"Thomas","year":"2021","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB0998|cit998","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/jpm11040279","article-title":"Application of Janus kinase inhibitors in atopic dermatitis: an updated systematic review and meta-analysis of clinical trials","volume":"11","author":"Tsai","year":"2021","journal-title":"Journal of Personalized Medicine"},{"key":"10.1002\/14651858.CD015064.pub2-BIB0999|cit999","unstructured":"OPZELURA\u2122 (ruxolitinib) cream, for topical use https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215309s001lbl.pdf"},{"key":"10.1002\/14651858.CD015064.pub2-BIB1000|cit1000","unstructured":"FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB1001|cit1001","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/ije\/dys222","article-title":"Evaluation of inconsistency in networks of interventions","volume":"42","author":"Veroniki","year":"2013","journal-title":"International Journal of Epidemiology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB1002|cit1002","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/bjd\/ljac058","article-title":"The association between atopic dermatitis, cognitive function and school performance in children and young adults","volume":"188","author":"Vittrup","year":"2023","journal-title":"British Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD015064.pub2-BIB1003|cit1003","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/hex.12643","article-title":"Written action plans for children with long-term conditions: a systematic review and synthesis of qualitative data","volume":"21","author":"Waldecker","year":"2018","journal-title":"Health Expectations"},{"issue":"1","key":"10.1002\/14651858.CD015064.pub2-BIB1004|cit1004","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jid.2018.10.028","article-title":"Research techniques made simple: network meta-analysis","volume":"139","author":"Watt","year":"2019","journal-title":"Journal of Investigative Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015064.pub2-BIB1005|cit1005","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2133.2004.05783.x","article-title":"A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD)","volume":"150","author":"Whalley","year":"2004","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB1006|cit1006","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"Stata Journal"},{"key":"10.1002\/14651858.CD015064.pub2-BIB1007|cit1007","unstructured":"World Health Organization WHO model prescribing information: drugs used in skin diseases: classification of topical corticosteroids apps.who.int\/iris\/handle\/10665\/41975"},{"issue":"10","key":"10.1002\/14651858.CD015064.pub2-BIB1008|cit1008","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.jid.2016.05.104","article-title":"How clinically relevant are treatment comparisons of topical calcineurin inhibitor trials for atopic eczema?","volume":"136","author":"Wilkes","year":"2016","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB1009|cit1009","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2133.1994.tb08532.x","article-title":"The U.K.Working Party\u2019s Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation","volume":"131","author":"Williams","year":"1994","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1002\/14651858.CD015064.pub2-BIB1010|cit1010","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/archderm.140.9.1151","article-title":"Twice-weekly topical corticosteroid therapy may reduce atopic dermatitis relapses","volume":"140","author":"Williams","year":"2004","journal-title":"Archives of Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB1011|cit1011","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jaci.2007.11.004","article-title":"Is eczema really on the increase worldwide?","volume":"121","author":"Williams","year":"2008","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB1012|cit1012","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jaad.2021.06.002","article-title":"New topical treatments for atopic dermatitis: active comparators are needed","volume":"85","author":"Williams","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD015064.pub2-BIB1013|cit1013","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/j.jaci.2022.03.017","article-title":"The HOME Core outcome set for clinical trials of atopic dermatitis","volume":"149","author":"Williams","year":"2022","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"12","key":"10.1002\/14651858.CD015064.pub2-BIB1014|cit1014","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1111\/jdv.16892","article-title":"ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children","volume":"34","author":"Wollenberg","year":"2020","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"issue":"11","key":"10.1002\/14651858.CD015064.pub2-BIB1015|cit1015","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1111\/jdv.18429","article-title":"European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations","volume":"36","author":"Wollenberg","year":"2022","journal-title":"Journal of the European Academy of Dermatology and Venereology : JEADV"},{"key":"10.1002\/14651858.CD015064.pub2-BIB1016|cit1016","unstructured":"World Bank Group country classifications by income level for FY24 (July 1, 2023-June 30, 2024) https:\/\/blogs.worldbank.org\/opendata\/new-world-bank-group-country-classifications-income-level-fy24"},{"issue":"5","key":"10.1002\/14651858.CD015064.pub2-BIB1017|cit1017","doi-asserted-by":"crossref","first-page":"585\u201393","DOI":"10.1001\/jamadermatol.2019.0008","article-title":"Application of topical phosphodiesterase 4 inhibitors in mild to moderate atopic dermatitis: a systematic review and meta-analysis","volume":"155","author":"Yang","year":"2019","journal-title":"JAMA Dermatology"},{"key":"10.1002\/14651858.CD015064.pub2-BIB1018|cit1018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.04.018","article-title":"Development of the summary of findings table for network meta-analysis","volume":"115","author":"Yepes-Nunez","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD015064.pub2-BIB1019|cit1019","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.17744","article-title":"Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"British Journal of Dermatology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD015064.pub2-BIB1020|cit1020","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.jaad.2017.11.056","article-title":"Phosphodiesterase 4 inhibitors","volume":"78","author":"Zebda","year":"2018","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"7","key":"10.1002\/14651858.CD015064.pub2-BIB1021|cit1021","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015064","article-title":"Topical anti-inflammatory treatments for eczema: network meta-analysis","author":"Steele","year":"2022","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:12:02Z","timestamp":1765757522000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015064.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Skin Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":1021,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015064.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]}}}